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CHAPTER I 
 
 
INTRODUCTION AND OVERVIEW OF PHOSPHOLIPASE 
D SUPERFAMILY 
 
 
 
 
Phosphatidic acid (PA) is a critical phospholipid constituent in eukaryotic 
cell membranes, that accounts for 1-4 % of the total lipid [1]. This lipophilic 
glycerophospholipid has a phosphate head group, and as such serves not only a 
structural capacity in lipid bilayers, but also participates both as an intermediate 
in lipid metabolism and as a signaling molecule. Because of the small head 
group, PA facilitates changes in lipid bilayer curvature that are important for 
membrane fusion events, such as vesicular trafficking and endocytosis [2]. PA is 
also a precursor to other lipid signaling molecules including diacylglycerol (DAG) 
and lysophosphatidic acid (LPA). As a lipid second messenger, PA activates 
signaling proteins and acts as a node within the membrane to which signaling 
proteins translocate. Several signaling proteins, including Raf-1 [3], [4] and 
mTOR [5], directly bind PA to mediate translocation or activation, respectively. 
PA has been implicated in signaling cascades involving cell growth, proliferation, 
and survival. Aberrant PA signaling has been identified in multiple cancers [6], 
neurodegeneration [7], and platelet aggregation [8], which makes proteins that 
mediate cellular levels of PA attractive as potential therapeutic targets. 
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PA can be generated de novo [9], [10], [11] by sequential enzyme-
catalyzed acylations of glycerol-3-phosphate, or in response to cell signaling 
pathways (Figure 1). Every glycerophospholipid generated in eukaryotic 
membranes transitions through PA, a pathway characterized by Eugene 
Kennedy and his colleagues more than half a century ago [11], [12]. Signal 
generated PA is formed by enzymes that modify existing lipids. These enzymes 
include lysophosphatidic acid acyltransferase (LPAAT) which acylates LPA, DAG 
kinase which phosphorylates DAG at the sn-3 position, and phospholipase D 
(PLD) which hydrolyzes the headgroup of a phospholipid, generally 
phosphatidylcholine (PC), triggering the release of choline.   
PLD activity, enzyme catalyzed hydrolysis of a phosphodiester bond, was 
first described in plants [13], [14], [15], [16] and subsequently many enzymes 
from a range of viral, prokaryotic and eukaryotic organisms have been described 
as possessing PLD activity. To date, more than 4000 PLD enzymes have been 
entered in NCBI GenBank. The majority of these enzymes hydrolyze 
phosphodiester bonds within phospholipids such as PC (classified as EC 3.1.4.4 
[17]), but there are other enzymes ascribed to having PLD activity that hydrolyze 
neutral lipids and even polynucleotide backbone. A large subset of enzymes with 
PLD activity share a conserved HxKxxxxDx6GSxN motif (HKD motif) [18], or a 
variation thereof, that is responsible for catalytic activity. These enzymes are 
members of the PLD superfamily, and are proposed to follow a similar reaction 
mechanism in which a nucleophilic histidine residue initiates the reaction and 
generates a covalent intermediate, and a water or short alcohol completes the 
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Figure 1. A schematic of the various enzyme-catalyzed reactions that results in the 
formation of phosphatidic acid (PA) and some of the cellular functions mediated by PA  
(figure from [19]). 
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hydrolytic or transphosphatidylation reaction, respectively (pg. 18). Non-HKD 
enzymes exhibiting PLD activity are predicted to have divergent structures or 
have divergent sequences and catalytic mechanisms. Two non-HKD enzymes, 
scPLD and autotoxin, are discussed in this chapter as a means of comparison to 
enzymes in the PLD superfamily.  
This introduction serves as a brief survey of PLD enzymology with specific 
emphasis on the PLD superfamily and mammalian family members (a more in 
depth review was recently published ([19]).  This chapter concludes with a brief 
discussion of the history and recent advances in pharmacological intervention of 
mammalian PLD, and possible functional consequences of such an approach. 
This section provides the background necassary for interpretation of the 
dissertation research discussed herein in which a novel class of isoform-selective 
small molecules was identified (Chapter II) and mechanistically characterized 
(Chapter III). 
 
Enzymes with phospholipase D activity 
 Prior to sequencing technology or cloning of genes, enzymes were 
purified from the host organism and biochemically characterized. Enzymes with 
similar activities were described with similar nomenclature. Such is the case with 
PLD enzymes. Historically, many bacterial virulence factors that demonstrated 
the release of a choline headgroup were named PLDs for this function. 
Subsequent cloning and sequence analysis of these enzymes demonstrated that 
not all of these enzymes bear the conserved HxKxxxxD(x6GSxN) motif first 
 5 
 
described by Ponting and Kerr [18] and Koonin [20]. Therefore these enzymes 
named as PLDs are not classified as members of the PLD superfamily. At the 
same time, superfamily classification based on a conserved HKD motif 
characterized some enzymes as PLDs that were not previously considered as 
such solely based on biochemical analysis (e.g. some endonucleases). The PLD 
superfamily classification based on the conserved HKD catalytic motif is useful 
since these enzymes are proposed to hydrolyze phosphodiester bonds via a 
similar reaction mechanism. 
 
Non-HKD enzymes 
 Enzymes lacking a conserved HKD motif are referred to here as non-HKD 
PLDs. These enzymes exhibit PLD-like activity and are no less physiologically 
relevant than members of the PLD superfamily. Detailed description of this class 
is not the focus of this chapter. However, brief mention of a couple of these 
enzymes is necessary to clarify their distinction in mechanism and enzymology 
from the PLD superfamily (Table 1). 
 
Streptomyces chromofuscus PLD 
 S. chromofuscus secretes a 57 kDa phospholipase D, scPLD. This 
enzyme, first purified in the 1970‟s [21] and cloned in the early 1990‟s [22], is the 
best characterized non-HKD PLD [23]. scPLD exhibits both phosphodiesterase 
as well as phosphatase activities [24], and is proposed to be secreted by bacteria  
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Table 1: NON-HKD PLDs (table from [19]) 
SPECIES ENZYME ACTIVITY FUNCTION LOCALIZATION 
Streptomyces 
chromofuscius 
scPLD PLD 
(transphosphatidyl-
ation w/ M alcohol) 
virulence factor secreted into 
extracellular milieu 
  
Corynebacterium PLD sphingomyelinase 
(releases C1P)  
membrane 
remodeling 
secreted   
  
Sphingo-
myelinase D 
LPC → LPA (in 
plasma) 
vascular 
permeabilization 
Arcanobacterium PLD sphingomyelinase 
(releases Ceramide-1-
phosphate)  
bacterial 
adhesion 
secreted 
  
Sphingo-
myelinase D 
LPC → LPA escape from 
vacuole 
host cell necrosis 
Loxosceles reclusa lysoPLD SM → C1P hemolysis venom 
  Sphingo-
myelinase D 
LPC → LPA (in 
plasma) 
platelet 
aggregation 
inflammatory 
responses 
Mammalian Autotaxin LPC → LPA, cyclic LPA production of 
lysolipids in blood 
secreted into blood 
  
Mammalian cyp1A2 monooxygenase → 
drug metabolism 
hepatic microsomal, 
membrane-bound 
  cyp2E1 PLD (PC → PA) → 
unknown 
microsomes/ER 
Mammalian GPI-PLD GPI → IPG + PA, GPI-
protein → protein + 
PA 
signaling and 
membrane-
associated 
protein release 
secreted into 
serum 
  
Mammalian NAPE-PLD NAPE → NAE + PA endocannabinoid 
signaling 
microsomal, 
membrane-
associated 
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to scavenge for phosphate in the microenvironment [23]. Biochemical and 
mutagenesis analyses of scPLD demonstrate that this enzymeutilizes a metal-
coordinated reaction mechanism similar to the purple-acid phosphatase family 
(PAP) [24]. A Fe3+ cation is essential for the one-step classic acid-base catalyzed 
reaction mechanism, whereas a Mn2+ cation is thought to be necessary for 
proper substrate binding.   
 scPLD is also able to perform transphosphatidylation, but less efficiently 
than HKD PLD enzymes (8-10 M primary alcohol is necessary for scPLD, 
compared to >95 % transphosphatidylation with 1-2 M alcohol for HKD PLD) [25]. 
scPLD also does not exhibit interfacial activation. Known as the surface dilution 
effect, HKD enzyme activity is affected (pg. 24), whereas scPLD activity is not 
dependent on the surface mole fraction of substrate within a lipid micelle or 
vesicle, hence substrate presentation does not impact scPLD activity [26]. This is 
also referred to as the “hopping” versus “scooting” mode of activity (Figure 2). 
scPLD activity is dependent on whether the substrate is readily accessible, and 
therefore exhibits greater activity towards monomer and mixed micelle than 
substrate present in a lipid vesicle [27].   
 scPLD is also the only PLD known to be activated by PA, most likely 
allosterically [26], [28]. Calcium can activate PLD by two mechanisms: calcium 
can directly bind the enzyme with biphasic affinity (Kd1 and Kd2), but is also able 
to bind to PA and make the lipid more rigid triggering product release from the 
active site to allow new substrate to bind [26]. The allosteric PA binding domain 
is predicted to be in the C-terminal domain, as proteolytically cleaved scPLD42/20 
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does not exhibit PA activation to the extent that uncleaved scPLD57 responds 
[29]. This activation is believed to be elicited via an allosteric site secondary to 
the catalytic site because soluble PA can increase Vmax towards substrate 
present at an interface. 
 Despite the fact that scPLD is not a member of the PLD superfamily, many 
studies have used, and some still use, exogenous application of recombinant 
scPLD to rescue the deleterious effects of deletion of a HKD PLD. This is a 
legitimate approach as long as the results are clearly understood with regards to 
substrate-product relationships. Supplemental application of scPLD will hydrolyze 
a range of phospholipids generating PA and possibly perform phosphatase 
activities. Observation that scPLD rescues a phenotype following deletion of a 
HKD PLD enzyme suggests that PA may in fact be the functional consequence 
of that particular HKD PLD. However, this result or the possible lack of a “rescue” 
effect should not be over-interpreted. Recent studies of viral, prokaryotic, and 
eukaryotic PLD superfamily members demonstrate that the function of these 
enzymes stretches beyond generation of PA or classic catalytic product. New 
descriptions of protein-protein interactions and alternate catalytic products are 
only recently gaining an appreciation in the literature. 
 
Autotaxin 
 Lysophospholipase D activity has been described in human blood. 
Autotaxin (ATX or NPP2) was determined to be responsible for this lysoPLD 
activity and is the main source of LPA in human blood [30], [31]. ATX, a member  
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scPLD
A. “Hopping” Mode – Activity does not depend on a lipid binding cofactor. 
B. “Scooting” Mode – Activity depends on substrate presentation. 
Km
Ca2+
Ca2+
PC
scPLD
kcat
scPLD
PA
headgroup/choline
scPLD
PA
Fe3+ for catalytic activity
Mn2+, Zn2+, or Fe2+ for substrate 
binding
HKD
PLD
Ks
HKD
PLD Km
HKD
PLD
PC
HKD
PLD
PA
kcat
HKD
PLD
headgroup/choline
HKD
PLD
Metal & Ca2+ Independent
Metal & Ca2+ Dependent
PIP2 mammalian lipid binding co-factor
(Bacteria have non-specific hydrophobic interaction)
 
Figure 2. Mechanisms of phospholipase D enzyme activities.  Many bacterial PLD 
enzyme activities proceed in a hopping mode and are dependent on the presence of 
metal ions, whereas mammalian PLD activity proceeds in a scooting mode and is largely 
dependent on the interfacial lipid environment (figure from [19]). 
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of the nucleotide pyrophosphatase/phosphodiesterase family, is expressed as a 
preproenzyme and secreted into the extracellular milieu and serum via an N-
terminal secretion signal. This enzyme does not include a conserved HKD motif 
and is not related to scPLD or the PLD superfamily. In vitro characterization of 
ATX demonstrates  it has a range of activities, including phospholipase (to 
produce LPA and S1P) [32], [33], [34], and nucleotide pyrophosphate hydrolysis. 
Lysophospholipids, including lysophosphatidylcholine (LPC), 
lysophosphatidylethanolamine  (LPE), and LPS are high affinity substrates and 
predicted to be the physiologically-relevant target [35]. ATX uses two Zn2+ ions in 
the active site for coordination and intermediate stabilization. However, unlike the 
scPLD described above, ATX can perform both hydrolysis and 
transphosphatidylation [36]. Depending on the divalent cation identity and salt 
concentration in the microenvironment, ATX will either hydrolyze LPC to form 
LPA, or transphosphatidylate LPC, similar to scPLD, and use the free hydroxyl 
group in the sn-2 position to generate cyclic LPA (cLPA) [31]. This difference in 
reactions is critical since the physiological function of LPA is distinct from cLPA. 
LPA is important in chemotactic cell migration and platelet aggregation, whereas 
cLPA inhibits cell proliferation, tumor cell invasion and metastasis. Three splice 
variants of ATX have been identified, ATXα, ATXβ, and ATXγ [37]. ATXα and 
ATXβ both perform transphosphatidylation and generate cLPA. The 
transphosphatidylation activity of ATXγ has yet to be characterized, but is 
expressed in the brain where it is proposed to be responsible for the high 
concentrations of cLPA [37].   
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 The crystal structures of rat [38] and mouse [39] ATX were recently 
determined. Careful analysis of the structures in tandem with further biochemical 
characterization will be necessary to understand hydrolytic versus 
transphosphatidylation mechanisms and the role of divalent cations in serving as 
a switch between the two divergent reactions. Because of the stark contrast in 
signaling function of LPA versus cLPA it will be necessary to identify 
pharmacological agents that can be used to elicit one reaction over the other.  
 ATX knockout mice exhibit severe phenotypic deficiencies and die around 
embryonic day 9.5-10.5 [40], [41]. Much of this phenotypic response is thought to 
be due to the absence of ATX catalytic activity, since knock-in of a catalytic 
mutant elicits similar phenotypic deficiencies. However, analysis of ATX crystal 
structures shows two predicted LPA binding sites, and suggests that ATX may 
also serve as a lipid-protein carrier and deliver LPA directly to LPA receptors at 
the membrane via a hydrophobic tunnel [39]. Recent studies also suggest that 
via a C-terminal MORFO (modulator of oligodendrocyte remodeling and focal 
adhesion organization) domain, ATX may be important for eliciting focal 
adhesions during oligodendrocyte maturation and myelination [42], [43]. Two 
groups have implicated ATX in regulating lymphocyte trafficking [44], [45]. 
Further structural and biochemical characterization of this enzyme is necessary, 
but due to its role in generating both LPA and cLPA, autotaxin appears to be a 
novel therapeutic target. A recent study has identified ATX as a potential 
therapeutic target for atherosclerosis [46]. 
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HKD enzymes 
 In contrast to the varied sequence, catalytic, and biochemical 
characteristics found in non-HKD PLDs, HKD enzymes share a conserved 
catalytic domain. While these enzymes do not share significant sequence identity 
outside of this catalytic domain, conservation of this domain means these 
enzymes do share a similar structural core that hydrolyzes phosphodiester bonds 
with a similar reaction mechanism for a range of substrates. Historically there has 
been some dispute as to the classification of some or all of these HKD enzymes 
as members of the PLD superfamily. Differences in substrate (DNA backbone 
versus lipid) and function (endonuclease versus lipase) amongst HKD PLD 
enzymes have lead to discrepancies in definition of requirements for 
classification in the PLD superfamily. Here it is proposed that all 
phosphodiesterases with a conserved HKD or HKD-like motif are members of 
this diverse superfamily. Conservation of the HKD motif permits inclusion in PLD 
superfamily because, regardless of substrate identity, these enzymes share an 
SN2 ping-pong reaction mechanism that proceeds through a covalent phospho-
protein intermediate in phosphodiester hydrolysis (pg. 18). Members of the 
superfamily also perform transphosphatidylation in parallel with hydrolysis in the 
presence of alcohol versus water, respectively. Further subclassifications in the 
superfamily delineate differences in sequence, substrate and function, but 
superfamily classification based on the conserved HKD motif is a useful 
descriptor in characterizing the enzymological and mechanistic identity of an 
HKD enzyme. With this definition of the PLD superfamily described, the following 
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sections briefly highlight members possessing a variety of functional and 
biochemical characteristics.[47]   
 
Sequence 
 PLD enzymes have been identified in viruses, bacteria, plants, fungi and 
mammals and were historically classified based on biochemical activity. 
However, following cloning and sequencing of several PLD genes a common set 
of conserved motifs (I-IV) were observed [18]. Conserved motifs II and IV 
comprise the duplicate catalytic sequence, HxKxxxxDx6G(G/S)xN (referred to 
here as HKD). In fact, there is significant homology between motifs I & II and III & 
IV. Based on this internal homology and the presence of 1-HKD motif enzymes in 
viruses and lower prokaryotic species, there is considerable evidence for a gene 
duplication event (Table 2), resulting in many PLD superfamily enzymes 
containing two putative HKD motifs [20] (Figure 3). As discussed in a following 
section (pg. 18), the histidine residue of the HKD motif has been demonstrated to 
be the nucleophilic residue responsible initiating phosphodiesterase activity. Motif 
III is comprised of the highly conserved sequence of unknown function 
„IYIENQFF.‟ In between the catalytic HKD motifs, and N-terminal to motif III, a 
putative polybasic phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) binding 
domain has been described in higher eukaryotes. The C-terminus of all PLD 
superfamily members, despite the fact that it is not homologous, must be integral 
for catalysis, since activity decreases upon mutation in or truncation of this 
region. 
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Table 2.  Alignment of Catalytic motifs for PLD superfamily (table from [19]) 
ENZYME SOURCE CATALYTIC MOTIF ACTIVITY 
 
p37 Vaccinia Virus QNNTKLLIVDDE lipase towards phospholipids, DAG, & 
Lysolipids 
  
K4 Vaccinia Virus VLHTKFWISDNT endonuclease 
  
BfiI E.coli / B.Firmus ILHAKLYGTSNN site-specific endonuclease 
  
Nuc E.coli / 
S.typhimurium 
IQHDKVVIVDNV endonuclease 
  
PLD S. antibioticus WMHSKLLVVDGK lipid phosphodiesterase towards PC, PE, PS, 
PG 
  
PLDα1 A. thaliana YVHTKMMIVDDE lipid phosphodiesterase towards PC & PE 
  
PLDζ A. thaliana YVHSKMMIVDDE lipid phosphodiesterase 
  
Spo14 S. cerevisciae AHHEKFVVIDET lipid phosphodiesterase towards PC 
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 Ponting and Kerr suggested that enzymes with these four conserved 
motifs were members of the PLD superfamily as described above [18]. Within 
this superfamily, further classification was proposed based on sequence 
homologies. Class I comprises HKD PLDs from fungi and higher eukaryotes. 
Many of these enzymes have divergent N-terminal sequences that include lipid- 
or calcium-binding regulatory domains to allow tailored control of PLD activity in 
response to signaling cascades. Class II enzymes include bacterial PLDs, such 
as Yersinia murine toxin (YMT) and Streptomyces sp. PMF PLD (pg. 35) with 
known lipase activities. Classes III and IV include enzymes involved in lipid 
biosynthesis, bacterial cardiolipin synthase and phosphatidylserine synthase, 
respectively. The remaining classifications describe enzymes with significantly 
divergent functions. Class V enzymes include viral p37 and K4. Class VII and VIII 
comprise endonucleases Nuc and BfiI, respectively. 
 
Structure  
 Protein crystals of PLD superfamily members have been reported, 
including endonucleases and several bacterial enzymes [Nuc, BfiI, tyrosyl-DNA 
phosphodiesterase (tdp-1), YMT [48], cowpea [49], Streptomyces sp. PMF PLD 
[50], and Streptomyces antibioticus PLD, entered  in PDB, (unpublished)], and 
tertiary crystal structures have been reported for Nuc [51], BfiI, tdp-1 [52], [53] 
Streptomyces sp. PMF PLD [54] and S. antibioticus PLD. Structures for YMT and 
cowpea PLD were never reported. It is apparent  
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K4/Nick Joining Enzyme (424 aa)
Nuc (177 aa)
Streptomyces PLD (528 – 556 aa)
Plant C2 (810 – 1087 aa)
Plant PXPH (1039 – 1096 aa)
Spo14 (1683 aa)
PLD1 (1074 aa)
PLD2 (933 aa)
Mito PLD (252 aa)
HKD
HKD
HKD
HKD
HKD
HKD
HKD
HKD
HKD
HKD
HKD
HKD
HKD
PHPX
PHPX
PHPX
C2
LOCO/phos PHPX
HKDHKD
HKD
 
Figure 3. Comparison and domain alignment for different PLD superfamily enzymes.  
The HKD motif responsible for catalytic activity is conserved among all superfamily 
members.  Higher order PLD enzymes are composed of nonconserved regulatory 
domains (figure from [19]). 
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from the available structures that a conserved fold exists for the catalytic 
domains of PLD superfamily members. 
 Nuc endonuclease from Salmonella typhimurium, a 1-HKD PLD, 
crystallized as a homodimer with each monomer arranged around a 
crystallographic two-fold axis of symmetry [51]. Conserved HKD residues 
emanate from β-strands at the interface of the dimer and lie adjacent to one 
another to form the active site. Within each monomer, the eight β-strands form 
two β-sheets that are sandwiched by five α-helices.  
 Streptomyces sp. PMF PLD was the first reported crystal structure of a 2-
HKD PLD.[54] PMF PLD consists of 35 secondary structural elements situated in 
repeated α-β-α-β orientation (Figure 4). In the tertiary structure, similar to the Nuc 
endonuclease, a common β-sandwich fold is observed, with each of the two β-
sheets comprised of 8 β-strands sandwiched between 18 α-helices. This enzyme 
is bilobal with a pseudo two-fold axis of symmetry. Conserved HKD residues lie 
adjacent to one another along this axis, and at the interface exists the active site 
with a 30 Å aperture to allow substrate entrance. Biochemical studies with 
Streptomyces PLD point mutants have attributed function to specific structural 
elements (pg. 35, also reviewed [55]). Two flexible loops extend over the 
entrance to the active site and are thought to modulate interfacial lipid 
interactions and substrate specificity [56], [57]. The duplicate histidine and lysine 
residues exist on β-strands that line the active site and directly interact with 
substrate as it enters the active site. The aspartate residues do not directly 
interact with substrate, but do shuttle protons to the deprotonated histidine 
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residue during the reaction. The GG/GS residues line the base of the catalytic 
pocket and accommodate large substrate headgroups during 
transphosphatidylation headgroup exchange [58].   
 In contrast to bacterial PLDs, in vitro studies of eukaryotic PLD structure 
and mechanism are lacking due to difficulties in expression and purification of 
recombinant enzyme. In the absence of a crystal structure for a higher eukaryotic 
PLD, much of our enzymological understanding of the PLD mechanism is based 
on characterization of bacterial PLDs. 
 
Mechanism: hydrolysis versus transphosphatidylation  
 In nature, phosphodiester hydrolysis does not commonly occur in the 
absence of metals [59]. When it does, the mechanism must proceed through a 
nucleophilic attack of the substrate phosphate group, which facilitates breakage 
of the phosphodiester bond, and protonation via acid catalysis to enable release 
of the leaving group. Depending on the source of the initial nucleophile, 
phosphodiester hydrolysis can proceed in a single step, or in two steps, with a 
covalent phospho-protein intermediate. Decades of biochemical [48], structural 
[60], and biophysical [59] research support the latter mechanism for PLD 
superfamily enzymes, in which a nucleophilic protein residue forms a covalent 
linkage to the phosphate group of the substrate (Figure 5). This covalent 
intermediate is subsequently destroyed via nucleophilic attack of a water 
molecule or alcohol, releasing the hydrolytic or transphosphatidylation product, 
respectively. 
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PDB: 1FOI
PMF PLD 
side view
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90° rotation
Figure 4. Crystal structure of Streptomyces sp. PMF PLD (PDB ID: 1FOI), 2-HKD enzyme.  
The conserved HKD motifs are highlighted in blue (N-terminal motif) and red (C-terminal 
motif), and the loops characterized in mutagenic studies are shown in green (N-terminal 
loop) and yellow (C-terminal loop) (figure from [19]). 
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 More than four decades ago, Yang et al.[61] and Stanacev and Stuhne-
Sekalec et al.[62] proposed that PLD catalysis proceeds through a two-step ping-
pong reaction mechanism with a covalent phospho-protein intermediate. This 
postulation was based on analyses of cabbage PLD-induced product formation in 
the presence of primary alcohol. Subsequent hydrolysis and 
transphosphatidylation then proceed in parallel dependent on the presence of 
water or primary alcohol. Early studies suggested that the sulfhydryl group of a 
cysteine residue may serve as the nucleophilic residue.[61] This was proposed 
because p-chloromercuribenzoate (PCMB) treatment modified free sulfhydryl 
groups and disrupted catalysis, in the seven cysteine residue containing cabbage 
PLD enzyme.[61] 
 In the 1990‟s other studies to characterize the PLD superfamily reaction 
mechanism attempted to identify the nucleophilic protein residue that might 
catalyze phosphodiesterase activity. Following Ponting & Kerr[18] and 
Koonin‟s[20] observations of duplicate HxKxxxxDx6G(G/S)xN motifs in PLD 
superfamily members, it was suggested that the nucleophilic residue might exist 
in this sequence. Sung et al. proposed the conserved serine residue in the 
second HKD motif of yeast Spo14/PLD1 was the nucleophile.[63] This conclusion 
was based on studies with recombinant Ser911Ala mutant. Subsequent studies 
using a 1-HKD bacterial enzyme, Nuc endonuclease [64], and a 2-HKD bacterial 
PLD, YMT [48], demonstrated the serine mutation resulted in a significant drop in 
catalytic activity. However, it was ultimately determined  
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Figure 5. Proposed PLD superfamily reaction mechanism based on biochemical studies 
of bacterial PLD enzymes.  The histidine of the conserved HKD motif mediates a 
nucleophilic attack on the phosphate group of the lipid substrate, yielding a covalent 
intermediate.  A water molecule or a primary alcohol completes the hydrolysis or 
transphosphatidylation, respectively (figure from [19]). 
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that histidine residues, and not serine, are integral for catalysis. These studies 
used recombinant point mutants and varied pH or chemical treatments to isolate 
32P-phospho-histidine intermediates. These studies proposed the reaction 
mechanism that is currently favored within the field, where the N-terminal 
histidine residue within the HKD motif nucleophilically attacks the phosphate 
group of the substrate, (step 1, Figure 5) and forms a covalent phospho-histidine 
intermediate. The histidine residue of the C-terminal HKD motif serves as a 
general acid, and donates a proton to the leaving group (step 2, Figure 5). For 
PLD enzymes with lipase activity, this leaving group is generally choline, and the 
intermediate a covalent phosphatidyl-histidine. Formation of this phospho-
histidine intermediate has been proposed to be the rate limiting step, and 
subsequent nucleophilic attack of the hydroxyl group from either a water or a 
primary alcohol (steps 3 and 4, Figure 5) followed by PA or phosphatidylalcohol 
product release rapidly occurs in parallel.[25] For most HKD enzymes, including 
mammalian PLDs, short chain primary alcohols are the preferred nucleophile 
over water (in some cases more than 1000-fold preference), allowing 
transphosphatidylation to occur at very low concentrations of alcohol.[62] This is 
in contrast to the non-HKD PLD enzyme scPLD, which requires molar 
concentrations of alcohol to generate significant transphosphatidylation product. 
Some HKD enzymes, including certain bacterial, plant, and fungal PLD, are able 
to utilize methanol or branched alcohols in addition to other primary 
alcohols.[25],[65],[66] 
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 These mechanistic conclusions were further validated when structural 
evidence was found to support the N-terminal histidine as the nucleophilic protein 
residue that forms a phospho-histidine intermediate. Histidine residues in the 
duplicate HKD motifs are adjacent to one another at the interface of the 
Salmonella typhimurium Nuc homodimer. This is also observed for the histidine 
residues on the duplicate HKD motifs in the crystal structure of PMF PLD. As a 
follow up to the first crystal structure of a 2-HKD PLD, Leiros et al. soaked PMF 
PLD crystals with short chain soluble PC substrate (dibutyrylphosphatidylcholine) 
to capture crystal structures of reaction intermediates [60]. PMF PLD complexed 
with this substrate demonstrates that the N-terminal histidine (H170) forms a 
phospho-histidine intermediate Another study describes the C-terminal HKD 
histidine as the initial nucleophile and this may differ amongst PLD species [67]. 
In this structure a water molecule is positioned near the C-terminal HKD histidine 
(H448) and 4.02 Å from the phosphate group, an easy distance to serve as a 
nucleophile for completion of the hydrolytic reaction.[60] Structural data lend 
credit to the proposed SN2 reaction mechanism, and as the catalytic cores of 
PLD superfamily enzymes are predicted to share a similar bilobal structure with 
the conserved HKD residues oriented adjacent to one another in the active site, 
this reaction mechanism is thought to extend to all PLD superfamily enzymes. 
 Finally, biophysical data also support the two-step reaction mechanism for 
PLD superfamily enzymes. Measurement of the changes in enthalpy and Gibbs 
free energy of a one-step versus a two-step mechanism demonstrates significant 
thermodynamic favorability for a two-step reaction proceeding through a 
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phospho-histidine intermediate.[59] In addition to the thermodynamic likelihood of 
the SN2 mechanism, Orth et al. used sensitive electrospray ionization mass 
spectrometry (ESI-MS) analysis to capture the highly unstable covalent phospho-
histidine intermediate, demonstrating that it does indeed form in solution.[59] 
Build up of covalent intermediate to levels detectable by ESI-MS was suggested 
to occur because the second nucleophilic reaction is the rate limiting step. This 
contradicts earlier studies with bacterial PLD that proposed the formation of the 
phospho-histidine intermediate is the rate limiting step, and hydrolysis or 
transphosphatidylation occur rapidly in parallel.[25] Discrepancies in reaction 
rates require further characterization, and it is important to observe that specific 
activities vary depending on the biochemical reaction conditions used, including 
concentrations of divalent cation and substrate presentation. Such differences for 
in vitro activity assays are further discussed in the following section. 
 
Interfacial kinetics 
 Phospholipases act on substrate present in an insoluble aggregate (i.e. 
the membrane). Many phospholipases therefore demonstrate interfacial kinetics, 
and do not follow classic Michaelis-Menten kinetic assumptions because the 
substrate is not freely diffusible in solution and is not randomly encountered 
dependent on soluble substrate concentration [68], [69]. Therefore, 
phospholipase activities can be described as one of two modes: “hopping” and 
“scooting” (figure 2) [70]. In “hopping” mode surface dilution of substrate does not 
impact specific activity, and the interfacial component is contained in the 
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equilibrium dissociation constant, Km. Enzymes that exhibit “hopping” mode 
dissociate from the interface in between hydrolytic events. In contrast, enzymes 
that exhibit “scooting” mode first interact with the lipid interface independent of 
substrate interaction, in an event described by the equilibrium dissociation 
constant, Ks. Following interfacial binding, the enzyme laterally diffuses along the 
interface (in two dimensions) to encounter substrate. This is described by the 
equilibrium dissociation constant, Km. “Scooting” enzymes exhibit processive 
activity, and do not dissociate from the interface between hydrolytic reactions. 
 The non-HKD enzyme, scPLD, does not demonstrate protein-lipid 
interfacial binding independent of substrate interaction [25]. This enzyme 
functions in “hopping” mode, and directly binds substrate headgroup present at 
the interface [23]. Following hydrolysis, scPLD falls off the substrate aggregate 
and the cycle recommences. scPLD activity is dependent on substrate 
presentation, accessibility, divalent cation concentration and cofactor binding, 
and positive feedback through allosteric binding of product to enhance activity 
[25] (pg. 5).   
 HKD enzymes demonstrate a scooting kinetic mechanism. A lipid cofactor 
binds to a hydrophobic patch on the surface of the protein, at regulatory domains 
or within the catalytic domain, to enhance protein recruitment to the lipid 
interface. For many eukaryotic PLD superfamily enzymes, PI(4,5)P2 is a lipid 
cofactor that binds at the putative polybasic binding domain present between the 
catalytic HKD motifs. PI(4,5)P2 significantly enhances protein-lipid binding and 
decreases Ks. Once at the membrane, catalysis is controlled by multiple factors 
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including lipid interface charge, membrane fluidity, substrate presentation or 
accessibility, and substrate molar fraction [69], [71] (i.e. concentration of 
substrate present at the interfacial surface). Because of the significant impact of 
interfacial environment on PLD catalysis, the format of in vitro activity 
measurement is essential to consider (pg. 26, and Figure 6).   
 In order to study kinetic parameters for “scooting” mode enzymes, 
interfacial binding, Ks, must be measured separately from substrate affinity and 
reaction velocity. Bulk lipid binding, Ks, can be measured as described by Buser 
and McLaughlin [72]. Following determination of Ks, Michaelis-Menten kinetic 
assumptions can be applied for “scooting" mode enzymes if bulk lipid 
concentration >>>Ks, and interfacial binding is saturated. Molar fraction of 
substrate can then be varied while holding bulk lipid concentration constant by 
compensating for substrate molar fraction with a neutral lipid, called a neutral 
diluent. This format for studying kinetic parameters of an interfacial enzyme is 
referred to as surface dilution kinetics [71]. Beyond bulk lipid composition and 
substrate presentation, other regulatory mechanisms control eukaryotic catalysis, 
including binding of calcium to the C2-domain in plant PLDs, or small GTPase 
and PKC protein-protein interaction for mammalian PLD.  Elegant kinetic 
analyses of plant [73] and mammalian PLD [74] have been reported. 
 
In vitro activity assays 
 Initial characterization of PLD activity monitored substrate depletion and 
product formation using thin layer chromatography (TLC), and co-migration of  
 27 
 
 
 
 
 
Conical Lipids
(e.g. LPC)
Inverted Conical Lipids
(e.g. PE)
Cylindrical Lipids
(e.g. PC)
Micelle Hexagonal phase Bilayer sheet
Liposomal bilayer
Small Unilamellar Vesicle (SUV) Multilamellar Vesicle (MLV)
 
Figure 6. Substrate presentation in the liposome is highly dependent on the interfacial 
lipid composition due to biophysical properties of the lipid and headgroup exposure for 
lipid binding cofactors and substrate (figure from [19]). 
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specific lipid species with purified lipid standards. Next, in vitro assays with 
increased precision and sensitivity have been developed that use head group 
release or product formation as readouts of enzyme activity. It is important to 
keep in mind the specific readout being measured when drawing conclusions 
from in vitro assays. Commercial kits are available for measuring in vitro PLD 
activity. However, these kits indirectly measure choline release via two 
subsequent enzyme-catalyzed reactions, and this method is not uniformly 
suitable for activity measurement. Other in vitro assays have been developed 
that directly measure PLD activity, and can be used to directly measure kinetic 
parameters. 
 Early studies of bacterial PLD enzymes utilized soluble small molecules 
with phosphodiesterase bonds to serve as substrate analogs. These small 
molecules have a detectable shift in light absorbance following hydrolysis, and 
some are capable of differentiating phosphodiester versus phosphatase 
activities. Soluble monomeric substrates with short acyl chains can also be used. 
Despite the fact that affinity for these soluble substrates is often poor, requiring 
higher concentrations to detect product formation, the benefit of these two 
options are that Michaelis-Menten kinetics can readily be performed since Ks 
component is omitted.   
 Mixed micelle and micelle assays can also be performed. Use of this 
format allows simple surface dilution experiments, since detergent readily 
compensates to adjust molar fraction of substrate (titration of increasing amounts 
of detergent, that will insert into mixed micelle to dilute substrate) [75]. In the 
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micelle format, phospholipids and lysophospholipids are of a conical shape.[76] 
However, many eukaryotic PLDs exhibit low activity in the absence of lipid 
cofactor(s) and in the presence of detergents, especially anionic detergents such 
as Triton-X100. Therefore use of pure substrate lipid micelles or mixed 
detergent-lipid micelles is not practical for biochemical study of eukaryotic PLD 
superfamily members. 
 Liposome assays are more complex, but liposomes more closely mimic 
natural, physiologically relevant membranes [77], [78]. Higher eukaryotes 
demonstrate increased specific activity in the presence of the lipid cofactor, 
PI(4,5)P2. HKD-PLD enzyme will perform processive activity if bulk lipid binding is 
held saturated. Separate lipid compositions can be made to vary substrate molar 
fraction by changing ratio of substrate to neutral diluents. Sonication is frequently 
used for simple liposome generation, but this makes multilamellar vesicles 
[(MLV), Figure 6]. These are adequate for both simple measurements of activity, 
and for comparisons of different reaction conditions within an assay. However, 
surface concentration of substrate is not controlled in MLV, making them 
imprecise for measurement of kinetic parameters. Extrusion is the preferred 
method for generating more uniform, unilamellar vesicles. The biophysical 
properties of the lipids in phospholipid liposomes have a significant impact on the 
PLD activity of scooting enzymes (Figure 6). 
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Cellular Activity Assays   
 It has long been appreciated that PLD enzymes perform 
transphosphatidylation [61], [65]. Stanacev and Stuhne-Sekalec demonstrated 
that transphosphatidylation preferentially occurs in very low concentrations of 
alcohol [62]. This characteristic of PLD has been exploited in cellular studies of 
the enzyme [78]. Phosphatidylalcohols are metabolically more stable than PA, 
which fluxes quickly. Historically, thin layer chromatography (TLC) has been used 
to visualize phosphatidylalcohols by monitoring co-migration of radioisotopically 
labeled lipids (on the fatty acids) with phosphatidylalcohol standards. Recently, a 
non-radioisotope-based cellular assay was developed [78]. This assay uses ESI-
MS to monitor formation of deuterated-phosphatidylbutanol following incubation 
of cells with low concentrations of deuterated-butanol. However, results from 
alcohol-treated cell preparations to identify and parse the signaling functions of 
PLD may have been incorrectly interpreted. Some recent characterizations of 
PLD functions using RNAi and small molecule PLD inhibitors have not been able 
to recapitulate some of the earlier findings obtained through the use of alcohols 
[79], [80]. Small molecule inhibitors in combination with alkyne-modified lipids are 
powerful tools, and are being used to measure flux of specific pools of metabolic 
and signaling lipid [81]. 
 
 
 
 
 31 
 
Prokaryotic PLD 
Prokaryotes express PLD superfamily genes that range in function from 
hydrolysis of the DNA backbone, to protein-protein interactions with host 
signaling pathways, to the more classic lipase function. While PLD enzymes with 
lipase activity are not commonly expressed among bacteria compared to other 
phospholipases, bacterial PLDs with lipase activity have been identified in many 
pathogenic bacteria.[82] Even though most bacterial PLD enzymes have different 
activity, because of the ease of expressing and purifying these bacterial PLDs 
recombinantly, much of our structural and biochemical understanding of PLD 
enzymology stems from studies of bacterial PLD. 
 
Bacterial endonucleases 
Evidence that the PLD superfamily arose from a gene duplication event 
stems from studies of EDTA-resistant bacterial endonucleases with a single 
HxKxxxxD. In fact, initial characterization of the PLD superfamily was performed 
using Nuc, an ATP-independent, nonspecific endonuclease encoded on plasmid 
DNA found in Salmonella typhimurium and Escherichia coli. The crystal structure 
of Nuc was determined to 2.0 Å (PDB accession codes 1BYR and 1BYS, native 
and complexed with tungstate inhibitor, respectively), and found to contain a 
single HxKxxxxD motif that forms a homodimer with a crystallographic two-fold 
axis [51]. The HKD motif within each enzyme exists on two loops held at the 
interface of the dimeric subunits via hydrogen bonds to form a single active site. 
Structural and biochemical characterization of Nuc reveals a ping- pong-like 
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Table 3: BACTERIAL & VIRAL PLDs (table from [19]) 
SPECIES ENZYME ACTIVITY FUNCTION LOCALIZATION 
Orthopox virus p37 PLC, PLA, PLA2 IMV wrapping TGN & inner 
membrane wrapping 
of EEV 
  
  
  
(Vaccinia, 
variola) 
TAG lipase IEV fusion & release 
  transphosphatidylation   
Orthopox virus K4 endonuclease single strand 
(ss)/double strand 
(ds) DNA torsion 
release 
within IMV 
  
  
(Vaccinia, 
variola) 
Nick-joining 
enzyme 
Salmonella 
typhimurium, 
Escherichia coli 
Nuc nonspecific 
endonuclease 
ssRNA  periplasm 
  
  
  
  
breakage during 
DNA conjugation 
Escherichia coli Bfil site-specific 
endonuclease 
Degrades dsDNA 
during DNA 
conjugation 
periplasm 
  
Neisseria 
gonorrhoeae 
NgPLD PC hydrolysis combination of 
lipase & protein-
protein interaction 
elicits bacterial 
invasion 
host cell cytoplasm 
  
transphosphatidylation binds AKT to trigger 
membrane ruffling 
extracellular milieu 
  
Yersinia pestis  YMT PLD (PC/PE lipase) in vivo facilitates Y. 
pestis colonization 
of flea gut 
bacterial cytosol 
  
  
(formerly 
Pasteurella 
pestis) 
transphosphatidylation protects against 
murine plasma 
component 
Chlamydiae chromosoma
l pz PLDs 
PLD   unknown  reticulate bodies 
  
  
  
unknown lipase activity lipid acquisition 
from LD 
transphosphatidylation   
Acinetobacter 
baumanii 
Act bau PLD unknown   unknown function secreted 
  
  
enhances serum 
survival/host cell 
invasion 
Pseudomonas 
aeruginosa  
PLDa gene PLD (PC → PA)  increases long term 
infectivity/bacterial 
homeostasis 
periplasm 
  
  
transphosphatidylation 
Streptomyces 
sp 
PMF PLD PLD unknown periplasm 
  
transphosphatidylation   secreted 
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SN2 reaction mechanism that utilizes both HKD motifs within the active site. The 
imidazole group of one „HKD‟ histidine residues nucleophilically attacks the 
phosphate atom on the substrate, breaking the phosphodiester bond within the 
DNA backbone and generates a covalent phospho-histidine intermediate. The 
histidine of the second subunit‟s HKD donates a proton to the leaving group, 
which, in the case of an endonuclease, is the 3‟ end of the DNA backbone. 
Hydrolysis is complete upon a water molecule nucleophilically attacking the 
phosphate, breaking the phospho-histidine bond, and leaving a phosphorylated 
5‟ terminus [64]. This two-step, water-exchange reaction mechanism that 
proceeds through a covalent phospho-histidine intermediate is consistent with 
other HKD PLD enzymes, as previously described (pg. 18).   
Nuc endonuclease is encoded for on the 35.4 kilobase pKM101 plasmid, a 
member of the broad-host range IncN plasmid classification [83]. This plasmid is 
responsible for conjugal DNA transfer between bacterial cells via thin rigid sex 
pilli [84]. pKM101 plasmid renders bacterial drug resistance by encoding for 15 
genes that trigger spontaneous mutagenesis and error-prone DNA repair to 
facilitate survival [85]. Nuc is expressed as a 177 amino acid (19 kDa) protein in 
the bacterial cytosol, but is processed to 155 amino acids (17 kDa) when the 22 
amino acid signal sequence is cleaved upon secretion into the periplasmic space 
[86], where it is constitutively localized and never secreted into extracellular 
growth media. Nuc endonuclease nonspecifically hydrolyzes internal 
phosphodiester bonds within the backbone of single and double stranded duplex 
DNA and RNA (in vitro), but does not elicit exonuclease activity at terminal 
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phosphodiester bonds. Maximal activity is observed in the presence of divalent 
cations, but unlike other bacterial endonucleases, Nuc remains catalytically 
acitve in the presence of EDTA. This unique characteristic allowed 
characterization of Nuc endonuclease activity in the bacterial cell background 
[83]. Despite rigorous biochemical characterization of Nuc, its functional role 
remains unclear. Similar to the viral endonuclease, Nuc is nonessential for 
bacterial survival and does not degrade plasmid or phage DNA as it crosses the 
periplasmic membrane. Rather, Nuc is proposed to provide an ancillary role in 
DNA conjugation.   
 
Bacterial PLD as virulence factors 
Phospholipases are common toxins and virulence factors for pathogenic 
bacteria. These enzymes facilitate bacterial infection and replication through 
several functions, including penetration of basal cell membranes (e.g. mucus 
layer or blood vessel wall), triggering engulfment of the bacterium by the host 
cell, or cytolysis to release intracellular bacteria from host cells such as 
macrophages. Phospholipase C and Phospholipase A are the most common 
class of bacterial phospholipases that serve as virulence factors. These enzymes 
are capable of destabilizing or destroying host cell membranes directly, through 
lipid hydrolysis or indirectly, through upregulation of host cell signaling pathways 
via lipid product formation [87], [88], [89], [90]. Although less common, some 
bacterial PLDs have also been identified as virulence factors. The localization 
and functions of these enzymes in eliciting virulence are divergent, and the 
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unifying theme amongst these enzymes is the conserved HKD motif responsible 
for catalytic activity. 
Bacterial PLDs that function as virulence factors are generally expressed 
by Gram-negative pathogenic bacteria that are obligately intracellular, and 
require plant or mammalian host cell invasion in order to replicate (extensively 
reviewed [19]). These enzymes are often secreted by the bacteria into the 
extracellular milieu or directly injected into the host cell cytosol via one of several 
known secretion mechanisms. Several of these PLD genes have been proposed 
to be acquired by lateral gene transfer from other bacteria or host cells.[91] 
Acquisition of these bacterial PLDs can enable immune evasion, expand 
potential host colonization, and can provide pathogenic advantage. 
 
Streptomyces PLD  
Gram-positive Streptomyces encompass the largest genus within the 
Actinomycetes class of bacteria that includes Corynebacterium and 
Mycobacterium. Streptomyces bacteria flourish in soil and secrete secondary 
metabolites and enzymes, including phospholipases, able to scavenge the 
environment for nutrients. Streptomyces are rarely pathogenic to humans [92]. In 
fact, many Streptomyces species are of immense commercial and industrial 
value for several reasons. More than two thirds of all clinically relevant natural 
antibiotics are derived from these bacteria, including vancomycin, 
chloramphenicol, and rapamycin [92], [93]. Also, enzymes secreted by 
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Streptomyces species are used as biocatalysts in industrial manufacturing of 
foods, cosmetics, and pharmaceuticals [55], [94]. 
Enzymes belonging to the PLD superfamily have been isolated in 
secretions from Streptomyces species including S. antibioticus, S. cinnanoneus, 
S. halstedii, and S. septatus. These enzymes share significant sequence 
homology (>70 %) and are some of the most rigorously biochemically and 
structurally characterized members of the PLD superfamily [55]. In contrast to 
scPLD from Streptomyces chromofuscus, these Streptomyces enzymes maintain 
the conserved domains I-IV and are class II members of the PLD superfamily, 
similar to YMT, as characterized by Ponting and Kerr [18]. These enzymes are 
robustly expressed and secreted into the extracellular milieu, but their exact 
function is unknown.   
Robust expression and secretion of Streptomyces PLD, coupled with the 
observation that many of these enzymes display the highest 
transphosphatidylation activity of any bacterial PLD make these enzymes useful 
tools for industrial production of natural and synthetic phospholipids [94]. These 
enzymes exhibit broad substrate specificity that is exploited to facilitate 
headgroup exchange with natural and unnatural nucleophiles. In fact, use of 
these enzymes in industry has spurred rigorous enzymological characterization 
in order to engineer Streptomyces PLD with enhanced activities or altered 
substrate specificities for tailored use [95], [96].   
The crystal structures of Streptomyces  sp. PMF PLD [54], [60] and 
Streptomyces antibioticus (deposited in PDB, unpublished) have been 
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determined without substrate (PDB code: 1F0I, 1V0S, 2ZE4), in complex with 
short acyl chain substrate (1V0W, 2ZE9) or complexed with phosphate analog, 
tungstate (1V0R).  These structures are reviewed in detail (pg. 15). These 
structures, in addition to biochemical data, further validate the proposed two-step 
SN2 reaction mechanism. The Streptomyces PLD structures share a common 
fold to that of the Nuc endonuclease homodimer [51] and the endonuclease 
domain of BfiI [97]. The bilobal structure has an apparent crystallographic two-
fold axis of symmetry that cuts through the cone-shaped active site at the 
interface of the two lobes. The conserved HKD motifs exist on loops that lie 
adjacent to one another within the active site pocket. Crystal structures with 
complexed substrate or phosphate analogs demonstrate there is significant 
hydrophobic bonding between residues of the active site holding the substrate in 
place. The reaction mechanism proceeds via a covalent intermediate that is 
formed following N-terminal histidine, of the HKD motif, nucleophilic attack on the 
phosphate of the substrate headgroup. Biochemical analysis suggests formation 
of this covalent intermediate is the rate limiting step of catalysis, and that 
subsequent nucleophilic attack of the lone pair of electrons on the oxygen from 
either the water or primary alcohol molecule, for hydrolysis or 
transphosphatidylation reaction, respectively, can proceed in parallel with similar 
rates [25]. Crystal structures of PMF PLD suggest that Streptomyces PLD can 
also perform a second round of hydrolysis of PA, to release DAG and a 
covalently-bound phosphate to active site, referred to as the dead end reaction 
[55], [60]. although this reaction appears to be much slower (product reportedly 
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observed for crystals soaked with substrate for a week, this was reproduced 
using an in vitro biochemical assay, Selvy and Brown, unpublished observation). 
Because these enzymes are stably secreted into the extracellular growth 
medium, rigorous in vitro biochemical characterization of Streptomyces PLD has 
been possible. These enzymes possess a signal sequence that facilitates 
secretion from the bacterial cytosol into the non-reducing environment of the 
periplasmic domain. Some Streptomyces PLD have been reported to possess a 
critical disulfide bond that is thought to form in conjunction with proper folding 
only in the non-reducing environment of the periplasm [98]. Historically, much of 
the biochemical and structural studies have used secreted enzyme purified from 
the growth media of native Streptomyces cultures. Efforts to recombinantly 
express these enzymes in Gram-negative E. coli has proven difficult, and 
required use of secretion signal sequences [99] (to elicit periplasmic localization 
and secretion), or vectors with thioredoxin tags [100] (to enhance cytosolic 
disulfide bond formation). 
Following structural characterization, biochemical studies of Streptomyces 
PLD homologs with significant sequence identity have subsequently been 
performed to further probe the function of different components of the 
Strepotmyces PLD structure. S. septatus TH-2PLD has the highest specific 
activity and transphosphaditylation rates of any bacterial PLD identified to date 
[101], while pldp exhibits quite low activity. These differences in PLD activity 
between these two enzymes exist, despite the fact that these enzymes share 
significant sequence identity. This suggests that critical differences in a small 
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number of residues elicit major differences in PLD enzymatic activity. Uesugi et 
al. used these two PLD genes to generate a series of chimeric constructs [102]. 
Using a random repeat-length independent and broad spectrum, RIBS, in vivo 
DNA shuffle technique chimeric mutants were generated composed of stretches 
of TH-2PLD and pldp [102], [103]. Biochemical characterization of these 
constructs identified residues that were critical in modulating substrate specificity, 
interfacial activity, transphosphatidylation, and thermostability. The tertiary 
locations of these residues were then mapped in the Streptomyces PLD structure 
(models of TH-2PLD based on the PMF PLD structure) to further clarify their 
mechanistic function.   
The Streptomyces PLD structures show two flexible loops that gate the 30 
Å wide entrance to the active site cleft. The N-terminal loop is located between 
beta-strand 7 and alpha-helix 7. The C-terminal loop is between beta-strand 13 
and beta-strand 14. Chimeric analysis identified two residues in the N-terminal 
loop, (Gly188 and Asp191 for TH-2PLD) that dictate interfacial activity and 
sensitivity to substrate presentation [102]. Streptomyces PLD prefer substrate 
presented as monomer or mixed micelles, and demonstrate lower activity 
towards phospholipid vesicles [25]. Computer modeled docking of phospholipids 
into the Streptomyces PLD structure suggests these residues in the N-terminal 
loop might serve as a second phospholipid binding site for PA, PE, or PS [104]. 
The C-terminal loop, specifically residues Ala426 and Lys438 of TH-2PLD, are 
involved in enhancing the specific hydrolase and transphosphatidylation activity, 
regardless of substrate presentation. These residues also participate in 
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phospholipid head group specificity, and enhance thermostability of the enzyme 
[57]. Uesugi et al. used surface plasmon resonance and inactive mutants to 
measure substrate binding affinities [56]. The specificity for zwitterionic 
phospholipids over anionic phospholipids was narrowed down to the same 
residues, Ala426 and Lys438, in the C-terminal loop that are proposed to act as a 
gate at the entrance to the active site cleft [56]. Substrate specificity can be 
altered by point mutation of residues in this loop. Masayama et al. have exploited 
this characteristic by mutating residues in the C-terminal loop to facilitate 
production of phosphatidylinositols via head group exchange, an activity that is 
not observed with the wildtype enzyme [95]. 
Other studies have characterized the function of the conserved GG and 
GS residues that lie downstream of the HKD motifs, N-terminal and C-terminal 
motifs, respectively, in most PLD superfamily enzymes. Ogino et al. showed that 
the GG/GS residues, specifically the serine residue, downstream of the putative 
HKD motifs are critical for dictating the transphosphatidylation activity of the 
enzyme [58]. These residues line the base of the active site and are proposed to 
control active site conformation and stability, and subsequently modulate 
substrate specificity and ability to transphosphatidylate. Deletion of the serine 
residue decreases overall activity by a third compared to wildtype enzyme [58].  
 
Plant PLD 
Plant PLDs make up the largest family of HKD enzymes, with more than 
80 genes identified and several dozen cloned. These enzymes are more complex 
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than bacterial PLD, because they encode regulatory domains that facilitate 
differential activities under various signaling environments (reviewed [105], [106], 
[107], [108]). Plant PLD enzymes contribute to the rich history of the PLD 
superfamily, in that the first description of a PLD enzyme was made from 
carrot.[13] The PLD hydrolytic and transphosphatidylation activities were 
originally described in plants, in 1947 [14] and 1967 [61], [65], respectively.  Also, 
the first PLD enzyme was cloned from the castor bean in 1994 [109]. Cloning of 
the castor bean PLD by the Xuemin Wang lab subsequently facilitated 
identification and cloning of fungi [66], [110], and animal [111] homologs. The 
Arabidopsis thaliana genome has been sequenced, making identification of PLD 
superfamily members and genetic manipulation of this model organism feasible. 
The bulk of the plant PLD literature focuses on Arabidopsis, therefore this model 
organism will be the focus of this section. 
PA makes up less than 1 % total lipid in plants, but is an important second 
messenger [107], [112]. Several pathways have been characterized that 
generate PA, but in plants the two main signaling mechanisms for generating PA 
involve PLC-DAGK tandem activity, or PLD activity. Lipidomic analyses have 
been performed and characterized the major PA species in Arabidopsis as 
having long polyunsaturated fatty acids [34:2(16:0-18:2); 34:3(16:0-18:3); 
36:4(18:2-18:2); 36:5(18:2-18:3); 36:6(18:3-18:3)].[112] Different PA species 
change in response to different stimuli and environmental conditions. Drought 
and soil salinity are common environmental stresses, and are a major focus of 
plant research because these conditions affect crop production worldwide [112]. 
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Plant PLD enzymes have variant regulatory mechanisms to respond to 
extracellular stimuli such as these, and mediate intracellular responses via PA 
production and protein-protein interactions. 
 
Classes of plant PLD enzymes 
Plant PLD enzymes consist of two-conserved HxKxxxxD motifs separated 
by roughly 320 aa, which include the conserved region III (IYIENQFF). The 
function of this region is unknown, but is present in every PLD superfamily 
member with true phospholipase activity. Most plant PLD region III sequences 
encode „IYIENQYF‟, while two enzymes more closely related to the mammalian 
PLDs encode for „IYIENQFF‟ [113]. Plant PLD enzymes can be divided into two 
subdomains, C2-PLDs and PXPH-PLDs, based on the presence of amino-
terminal regulatory domains upstream of the catalytic domain [108], [114]. C2-
PLDs have an N-terminal C2 calcium binding domain that is distinct to plant PLD 
enzymes [112]. This domain is not found in other higher order PLDs. PXPH-
PLDs are more closely related to mammalian PLDs, and have amino-terminal 
phox homology (PX) and pleckstrin homology (PH) domains important for 
specific lipid interactions [112], [113]. At least 12 Arabidopsis genes have been 
identified, of which ten are classified as C2-PLD genes and two are classified as 
PXPH PLD genes [115]. Within these classes specific isoforms have been 
identified that exhibit differential genetic architecture, sequence identity, catalytic 
activities, and regulatory requirements [105], [113].  
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In contrast to the multiple crystal structures available for bacterial enzymes, a 
crystal structure for the more complex plant PLD does not exist, despite reported 
crystallization of cowpea PLD over a decade ago [49]. Therefore, the current 
model of proposed tertiary structure of the catalytic domain and reaction 
mechanism are based on the structure and characterization of the bacterial PLDs 
(pg. 15). The limited structural analysis of plant PLD that does exist has used 
non-crystallographic analytical tools. One such study used mass spectrometry 
analysis to characterize the sulfhydryl groups on cabbage PLD [116]. Increasing 
numbers of plant PLDs of both C2 and PXPH subfamilies have been cloned and 
recombinantly expressed in bacteria [73], [113], [117], [118], which has lead to a 
greater understanding of the individual biochemical characteristics of different 
plant PLD isoforms.  
 
C2-PLD 
In the mid to late 1990‟s following cloning of the castor bean PLD [109], a 
surge of plant PLD enzymes were identified, sequenced, and characterized by 
genetic and biochemical approaches [108]. Comparisons within this growing pool 
of plant PLDs led to observations of clusters of similar enzymes based on genetic 
architectures, sequences, and biochemical characteristics. Members of the C2-
PLD subdomain were subsequently categorized as PLDα, PLDβ, PLDγ, PLDδ, 
PLDε. It is important to note that as sequence and biochemical characterization 
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Table 4.  Plant PLD Enzymes (table from [19]) 
ENZYME REGULTORY 
DOMAIN 
CATALYTIC 
REQUIREMENTS 
SUBSTRATE SIGNALING 
PLDα C2-domain mM Ca2+ PC>PE hormone/stress 
response, 
senescence, nutrient 
sensing 
  
PLDβ C2-domain μM Ca2+, PI(4,5)P2 PC=PE=PS=NAPE actin polymerization 
  
PLDγ C2-domain μM Ca2+, PI(4,5)P2 PE=NAPE>PC hormone/stress 
response (?) 
  
PLDδ C2-domain μM Ca2+, oleate, 
PI(4,5)P2 
PE>PC cell viability, ROS 
response, binds 
microtubules  
  
PLDε C2-domain μM Ca2+, oleate, 
PI(4,5)P2 
PE>PC root growth, 
elongation 
  
PLDζ PX-PH PI(4,5)P2 PC root growth, 
elongation 
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improved, some initial cluster designations have changed (PLDα4 is no longer 
included as a PLDα isoform, and PLDδ1 was reclassified PLDβ2)[113].    
Regardless of cluster classification, all members of the C2-PLD subfamily 
encompass a conserved 130 aa C2 domain at the amino terminus that is 
important in calcium sensing and phospholipid binding [106], [108]. More than 
4000 consensus sequences have been reported for the C2 domain and are 
commonly present in proteins involved in lipid metabolism, signal transduction, 
and membrane trafficking [119]. The crystal structure for several C2 domains has 
been determined and a common antiparallel 8-β strand sandwich fold is 
conserved [120], [121], [122], [123]. Two or three calcium ions are known to bind 
at 4-5 acidic residues in the loops between the beta strands [119]. The β-strand 
sandwich fold is predicted to be conserved in plant PLD, but structural 
characterization of this domain from several C2-PLD isoforms demonstrates that 
a significant conformation change occurs upon calcium ion binding, which is not 
observed in C2 domains from other proteins or species [124]. This suggests plant 
C2 domains may be a variant of those previously characterized.   
In addition to the divergent protein conformations upon calcium binding, 
some plant PLD isoforms have substitutions in the C2 domain acidic residues 
[124]. This results in isoform-selective differences in calcium binding affinities 
and catalytic responses. C2 domains also bind lipids dependent on calcium 
concentration, therefore cytoplasmic calcium levels are thought to modulate C2-
domain conformation and lipid binding affinity [118]. C2-domains also 
demonstrate lipid binding specificity. Arabidopsis C2 domains bind PI(4,5)P2 and 
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PC in a calcium-dependent manner [124], [125]. C2 truncation mutants bind lipid 
vesicles but with lower affinity and these PLD enzymes display decreased activity 
[126]. Many C2 domains elicit constitutive binding to the lipid membrane (ie. no 
stimulus-induced translocation) therefore these enzymes are proposed to 
function in the scooting mode with processive catalytic activity. All C2-PLD 
enzymes characterized to date require some level of calcium for catalysis and 
can perform transphosphatidylation [126]. This plant PLD subfamily is 
responsible for the majority of the PA produced in response to environmental 
stress signaling.  
 
PXPH-PLD 
In contrast to C2-PLD enzymes, two plant PLDs have been identified that 
encode for phox homology (PX) and pleckstrin homology (PH) lipid binding 
domains at the amino-terminus, PLDδ1 and PLDδ2 [113], [127]. These genes are 
both located on chromosome III. PLDδ1 and PLDδ2 do not require calcium for 
catalysis, rather these enzymes selectively cleave PC in a PI(4,5)P2 dependent 
manner [113]. As such, these plant PLDs are more closely related to the 
mammalian PLD enzymes PLD1 and PLD2. In mammalian PLDs, the PX domain 
has been shown to bind PI(3,4,5)P3, and anionic lipids, while the PH domain 
binds PI and PIPn species. PLDδ1 and PLDδ2 also retain four of the five basic 
residues in the conserved PI(4,5)P2 binding motifs that flank the 2
nd HKD [113]. 
These polybasic motifs may serve to regulate PLDδ catalysis in response to 
PI(4,5)P2, similar to mammalian PLDs. 
 47 
 
Cellular characterization of this subfamily of plant PLD enzymes remains 
sparse, but some recent studies have shown PLDδ enzymes are involved in 
environmental stress responses. PLDδ2 is transcriptionally regulated in response 
to phosphate starvation and auxin levels [127], [128]. Exogenous auxin 
supplementation can stimulate PLDδ2 transcription. Plant PXPH PLDs have also 
been shown to mediate vesicular trafficking, phosphate recycling and root 
gravitropism [129]. 
 
Signaling 
Plant PLD enzymes are structurally more diverse and complex than 
bacterial homologs. As in other higher eukaryotes, PA is largely involved in 
stress-mediated signaling pathways in plants (detailed review recently published 
[130], including response to environmental conditions such as dehydration, high 
salinity, pathogenic defense and wound healing [107], As such, plant PLD 
enzymes have evolved diverse regulatory mechanisms to respond to specific 
extracellular stimuli. Plant PLD enzymes can be regulated at the level of 
transcription or translation, via post-translational modification (lipidation or 
phosphorylation), or via cytosolic and membrane cofactors and conditions 
(calcium, PI(4,5)P2, substrate presentation/membrane fluidity, and pH). PA 
signaling can also be regulated and attenuated post production by 
phosphorylation to generate DAG pyrophosphate (DGPP) [131]. It is currently 
unknown whether DGPP is itself also a signaling molecule.   
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Despite the historical precedent in plant studies of PLD, development of 
pharmacological tools to modulate the activities of these enzymes has lagged 
behind that of other eukaryotes. To this day, the use of knockout models and 
primary alcohols remain the only known tools with which plant PLD can be 
studied [132]. Using a primary alcohol, product formation can be diverted to the 
transphosphatidylation product phosphatidylalcohol (Figure 5). However, 
alcohols are imprecise tools because of their lack of specificity and potency. 
While only primary alcohols are able to serve as nucleophiles in the PLD reaction 
mechanism, both primary and secondary alcohols activate plant PLD activity 
[133]. Off target activation of heterotrimeric G proteins also occurs in response to 
alcohols, making it difficult to delineate the specific role of PLD in receptor-
mediated stress induced signaling pathways. A few plant stress response 
cascades are briefly described here to demonstrate a few of the numerous roles 
in which plant PLD enzymes have been implicated. 
 
Fungal PLD 
Fungal PLD, identified in yeast and slime mold, regulate critical 
developmental functions. Similar to plants, PLD activity was first described in 
yeast using biochemical methods. Nearly four decades ago glucose-stimulated 
PLD activity was measured for a species of budding yeast, Saccharomyces 
cerevisiae, grown in low (1 %) glucose content [134], [135]. These growth 
conditions induce glucose repression that triggers low oxygen uptake. Yeast 
harvested from these growth conditions demonstrated 14C-lecithin hydrolysis and 
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PA production in mitochondrial fractions [135]. This activity was increased in 
response to glucose repression during aerobic growth and decreased oxygen 
uptake. The increased activity was determined to be due to induction of an 
unknown cytosolic enzyme rather than a protein of mitochondrial origin since 
cyclohexamide blockage of cytosolic protein synthesis perturbed the PLD activity, 
and chloramphenicol inhibition of mitochondrial protein synthesis did not [135]. 
This observation was largely ignored until a series of parallel studies decades 
later identified specific PLD enzymes in different yeast species. Spo14, a PLD 
superfamily member also known as PLD1, was identified in the budding yeast 
Saccharomyces cerevisiae [66], [110], [136], [137], [138]. Other groups have 
identified similar Spo14-like enzymes in pathogenic budding yeast [139], Candida 
albicans [140], and in fission yeast, Schizosaccharomyces pombe [136]. In 
addition a biochemically distinct enzyme, PLD2 [139], has been described in 
Saccharomyces cerevisiae. Subsequent studies have demonstrated that the PLD 
activity initially observed in budding yeast (in the 1970‟s) is distinct from the PLD 
superfamily, and this activity has been attributed to PLD2 [141], [142]. Yeast 
PLD1 enzymes, including Spo14, share sequence and biochemical similarities to 
plant and other eukaryotic PLDs. These enzymes have been shown to function in 
yeast sporulation [110], [137], vesicular trafficking [143], mating [144], and 
virulence for the pathogenic species [145], [146]. 
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Budding yeast Spo14 
Spo14 was originally identified during phenotypic studies of fission and 
budding yeast deficient in meiosis and sporulation [136], [137]. The most 
extensive follow up studies of this gene and gene product have been performed 
using the budding yeast Saccharomyces cerevisiae. S. cerevisae have distinct 
regulatory pathways for mitosis separate from those observed for meiosis I and 
meiosis II during sporulation. Early studies observed sporulation defects in 
mutagenized yeast as a means of identifying genes that might be involved in 
meiotic signaling pathways [137]. In the first meiotic step, parental cells replicate 
genomic DNA and homologous chromosomes perform recombination as they 
align near the spindle pole bodies (SPB) in preparation for meiosis I. During 
meiosis I, similar chromosomes move to opposite poles of the nucleus and two 
diploid daughter nuclei are generated by separation of the chromosomes with the 
SPB. Reversal of meiosis is possible through meiosis I. In fact, cells with fully 
formed SPB are able to instead perform mitosis in response to changes in 
extracellular conditions and remain diploid. However, upon entry into meiosis II, 
the cell is committed to meiosis and unable to reverse to mitosis despite changes 
in extracellular growth conditions. During meiosis II, sister chromatids move to 
opposite poles of the nucleus to generate four haploid nuclei. These haploid 
nuclei are packaged into spores with prespore membrane (PSM), double layer 
membrane generated de novo, within the mother cell. This packaging is akin to 
acrosomes generated during spermatogenesis [141]. 
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Spo14 was identified as a gene involved in S. cerevisiae sporulation by 
Honigberg et al. [137]. In this study, mutagenized S. cerevisiae were subjected to 
various growth conditions, including changes in temperature, in order to observe 
phenotypic sporulation deficiencies. Cells with disrupted Spo14 genes showed 
1.5-fold less yeast transition through meiosis I, and 10-fold fewer cells complete 
meiosis II [110], [137]. The cells that did complete meiosis I and meiosis II had 
degraded nuclei and were not viable. It was also observed that cells with 
disrupted Spo14 did not commit to meiosis at meiosis II, a phenomenon in 
wildtype yeast referred to as “commitment to meiosis [147]. Rather, cells in later 
stages of sporulation with irregular nuclear composition were observed to reverse 
and mitotically divide [147]. 
In parallel, Ella et al. subjected S. cerevisiae to different growth medium 
and measured changes in PLD activity [66]. This group demonstrated that PLD 
activity is induced under nitrogen deprivation when yeast are grown in a medium 
containing a non-fermentable carbon source, ie. acetate [66]. Supplemental 
application of glucose to these growth conditions decreased PLD activity.  
Sporulation, more specifically meiosis I, is triggered under nutrient deprivation 
conditions but cells can be reversed and induced to mitotically divide if nutrients 
are supplemented prior to transition into meiosis II [137], [147]. These studies 
suggest PLD activity is increased during sporulation, and the activity measured 
by this group is the same as that characterized by Rose et al. [110]. Spo14, 
called PLD1 by this group [138] and others [148], is the enzyme responsible for 
the observed sporulation-induced activity. Spo14 is capable of PC hydrolysis and 
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can perform transphosphatidylation with primary alcohols [66]. These activities 
suggested that this newly-identified enzyme was indeed a PLD similar to PLDs 
identified in plants. 
 
Sequence, catalysis, and regulation 
Earlier cloning of castor bean PLD sequence facilitated cloning of Spo14 
[137], also known as PLD1 [138], [148], which later lead to cloning of the human 
PLD homolog [111]. Genomic sequencing of Saccharomyces cerevisiae 
identified Spo14 on chromosome XI. Spo14 is predicted to be the only HKD PLD 
in this organism, and is a member of the PLD superfamily. The gene for 
PEL1/PGS1, a phosphatidylglycerol phosphate synthase, is the only other gene 
encoding for an HKD enzyme in S. cerevisiae [141]. 
Spo14 protein sequence is 1683 amino acids, with a molecular weight of 
195.2 kDa. A stretch of 440 amino acids in the middle of the sequence are 21 % 
identical to castor bean PLD, demonstrating conservation of the catalytic domain 
observed for members of the PLD superfamily [110]. Separate groups cloned this 
enzyme, naming it either Spo14 [110], based on function in the initial sporulation 
defects study, or PLD1 [138], [148] to delineate this activity from an apparently 
separate PLD activity described in the 1970‟s. Spo14 sequence analysis shows 
this enzyme retains two conserved HKD catalytic motifs, present in the majority 
of eukaryotic PLD superfamily members. A putative polybasic PI(4,5)P2 binding 
domain, found in other PLD superfamily members and originally described in 
Spo14, exists between these HKD motifs [149].   
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Unique to yeast PLD, the amino-terminus contains a regulatory 
LOCO/phos domain encompassing residues 1-313 [150]. This region is 
hyperphosphorylated at serine and threonine residues upon meiotic initiation 
[150]. Hyperphosphorylation shifts the molecular weight of Spo14 from 195 kDa 
to roughly 220 kDa.  Hyperphosphorylation is a necessary regulatory mechanism 
for Spo14 function in meiosis, but not for other cellular functions of Spo14 or in 
vitro catalytic activity. Downstream of the LOCO/phos domain, the amino 
terminus also possesses PX and PH domains. The PH domain binds PI(4,5)P2 to 
facilitate basal protein-membrane localization as well as protein translocation 
within the cell [151], [152], [153]. As such, amino-terminal LOCO/phos and lipid 
binding domains are not integral to in vitro catalytic activity. 
In vitro biochemical characterization of Spo14 has been performed using 
recombinant protein heterologously expressed in either insect [110] or bacterial 
[138] systems. Similar to other eukaryotic PLD enzymes, PI(4,5)P2 binding at the 
putative polybasic motif, but not the PH domain, is requisite for catalytic activity 
[149]. Similar to some eukaryotic PLD enzymes, oleate (5mM) was shown to 
stimulate activity seven-fold [139]. However, Spo14 is unique from plant or 
mammalian PLD in that it is insensitive to calcium, and inhibited by magnesium.   
Spo14 catalytic activity is substrate-specific to PC, and little to no PI or PE 
is hydrolyzed [66]. Spo14 can catalyze transphosphatidylation reactions with a 
broader range of alcohols than other eukaryotic PLDs. Although preference is 
given for primary alcohols, such as n-butanol, branched-chain alcohols, such as 
3-methyl-1-butanol can also be used as nucleophilic substrates [66]. Spo14 
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appears to be less effective at transphosphatidylation than mammalian 
homologs. This is postulated to be due to Spo14 potentially hydrolyzing 
phosphatidylalcohols [141] shortly after production, but this remains to be 
demonstrated. Also, in vitro catalytic activity is stimulated in the presence of 
alcohol [66]. 
In vitro, Spo14 catalytic activity is regulated by access to lipid cofactor 
PI(4,5)P2 and substrate, PC. In contrast to other eukaryotic PLD enzymes, Spo14 
activity is not modulated by small GTPases, such as ADP-ribosylation factor (Arf) 
[154]. In contrast to in vitro regulation, cellular regulation of Spo14 is more 
complex and is dependent on the specific functional pathway, such as 
sporulation or mating. Cellular Spo14 is not directly regulated by Arf, but Arf 
GTP/GDP cycling via Arf GAP, Gcs1, does modulate Spo14 activity during 
sporulation [155]. Arf cycling is also is critical for sporulation [154]. In general, 
cellular Spo14 is transcriptionally and translationally regulated in most functional 
pathways in which it has been implicated. Induction of Spo14 RNA and protein is 
observed, 7-fold and 3-fold, respectively, in late meiosis. Post-translational 
modification such as phosphorylation has been shown to regulate Spo14 
localization. Finally, access to the lipid cofactor PI(4,5)P2 regulates both 
localization via the PH domain as well as activity via polybasic binding domain. 
Vegetative cells demonstrate PLD activity in both soluble and particulate 
fractions, likely localized to intracellular endosomal membranes, while Spo14 
translocation to specific membranes, such as the PSM, has been demonstrated 
for specific functional responses [139]. 
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In the 1970s, Dharmalingam et al. [134] and Grossman et al. [135] 
described glucose-stimulated PLD activity in S. cerevisiae. More recent 
characterization of yeast PLD activities suggests this observed PLD activity is 
due to a separate class of enzyme, likely that of PLD2 [141], [142], [156], [157]. 
PLD2 was described, but not cloned, as a calcium-dependent enzyme and does 
not require PI(4,5)P2 for activity. This activity was observed in Spo14 deletion 
mutants in the absence of EGTA or EDTA. This enzyme does not perform 
transphosphatidylation and preferentially hydrolyzes PE and PS rather than PC. 
This demonstrates PLD2 activity is distinct from that of Spo14. The fact that 
Spo14 is the only HKD PLD present in the S. cerevisiae genome, and that PLD2 
does not perform transphosphatidylation suggests this enzyme is likely a PLD-
like enzyme distinct from the PLD superfamily with a unique reaction mechanism. 
 
Function 
Spo14 deletion mutants do not demonstrate any phenotypic disruption in 
vegetative growth. Similar to the exocytic and vesicular function of HKD PLD 
enzymes in other higher eukaryotes, Spo14 appears to be integral for specific 
functional processes involving membrane formation, fusion, and secretion. In 
response to nitrogen deprivation and non-fermentable carbon sources, Spo14 
responds by translocating in preparation for sporulation [151]. Spo14 activity is 
integral for rescuing vesicular trafficking in a mechanism that responds to loss of 
PI-transfer protein Sec14 [152], [158]. Finally, Spo14 has recently been shown to 
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participate in mating and pheromone signaling pathways [144], and is a virulence 
factor integral for pathogenic yeast Candida albicans [145], [146].   
 
Dictyostelium PLD 
Another type of fungi that is extensively studied is the unique slime mold 
Dictyostelium discoidium. This model organism possesses PLD activity, and 
similar to budding yeast Spo14, this activity has proven integral for critical 
developmental processes. This slime mold is found in soil of Eastern North 
America and Eastern China, and is studied as a model organism because it 
exhibits several distinct life cycles dependent on environmental growth conditions 
[159]. Also, Dictyostelium bears many similar signaling pathways and 
mechanisms to eukaryotes in which PLD participates.   
Slime mold grows in monolayer or suspension cultures and feeds on 
bacteria. In the presence of ample nutrients, Dictyostelium exists as a haploid 
unicellular form that mitotically replicates. In response to low nutrients or high 
density, unicellular cells replicate in one of two cycles: sexual or assexual. These 
replication cycles are the reason that Dictyostelium are so intensely studied. 
Dictyostelium are referred to as social amoeba that exhibit social cooperation or 
altruism by sacrificing some individual cells for the benefit of the species [159]. 
Sexual replication occurs upon contact with a haploid cell of opposite mating 
type, and the cells and nuclei fuse to form a diploid zygote [160]. The zygote 
secretes cAMP and other chemoattractant molecules to coercively draw other 
cells near, whereupon the zygote cannibalizes them to harvest nutrients and form 
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the cellulose-bound macrocyst structure [159]. The macrocyst replicates via 
meiosis and then germinates. Signaling pathways and mechanisms in the sexual 
reproduction pathways have not been characterized, but this has been because 
the emphasis has been on the asexual cycle. 
In the absence of fusion with opposite mating type cells, Dictyostelium 
respond to low nutrient and high cell density by secreting chemoattractant 
molecules. This facilitates quorum sensing and triggers cell signaling responses 
in neighboring cells. Unicellular forms constitutively express a glycoprotein, 
conditioned medium factor (CMF), which is only secreted in response to low 
nutrient starvation conditions. In response to quorum sensing molecule CMF, 
heterotrimeric G-protein signaling pathways ensue. Under low nutrient and high 
density conditions Dictyostelium secrete waves of cAMP [160]. The waves of 
cAMP bind cyclin AMP-receptors (cAR), GPCRs at the surface of neighboring 
cells. Binding elicits signaling pathways that trigger cell migration and 
aggregation towards one another. A mound of cells forms, and continued waves 
of cAMP and bioactive molecule secretion, such as differentiation inducing factor 
(DIF-1), generate a molecular gradient of small molecules. This gradient elicits 
polarization of the cooperative cells into anterior and posterior regions, and DIF-1 
induces non-uniform cell differentiation into one of two types of pre-cells that 
ultimately generate either a stalk or spore-harboring fruiting body. The polarized 
cell aggregate, called a slug, is able to migrate greater distances than unicellular 
forms and is protective from predatory consumption (e.g., C. elegans). Once a 
new location is selected, the pre-stalk and pre-spore forms further differentiate 
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into mature stalk and spore, destined for cell death, or dispersal and germination, 
respectively.   
PLD activity has been described in Dictyostelium for the different growth 
stages of the three distinct reproductive cycles. Three PLD transcripts were 
identified, plda, pldb, and pldc [161], [162]. The plda is constitutively expressed at 
unaltered levels in vegetative and reproductive cell types, whereas pldb mRNA 
message and protein levels fluctuate with changes in growth or reproductive 
cycle. As such, pldb is the most extensively studied isoform, and has been 
shown to participate in quorum sensing and facilitate polarized cell migration. 
This 867 aa enzyme is 32 % similar and 21 % identical to human PLD1, with 
conserved PH and CRI-IV domains, and loop and tail regions. The pldb is 
PI(4,5)P2-dependent and performs transphosphatidylation with primary alcohols. 
However, in contrast to human PLD, Dictyostelium pldb preferentially hydrolyzes 
ether-containing PE species [163]. 
The pldb negatively regulates quorum sensing in two ways. First, PLD-
generated PA counteracts cell responses to CMF by modulating heterotrimeric 
G-protein signaling responses and RGS (regulatory of G-protein signaling) 
regulation [161], [164]. Also, pldb-generated PA is suggested to facilitate cAR 
receptor internalization and recycling [161], [162], [164]. Unicellular Dictyostelium 
treated with primary alcohol, or pldb deletion mutants aggregate at lower 
densities independently of CMF. This is likely due to enhanced cAR levels at the 
plasma membrane (lack of receptor internalization or recycling) and increased G-
protein signaling in the absence of RGS modulation. The pldb overexpression 
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mutants increase the density and CMF signaling threshold necessary to trigger 
unicellular aggregation [161].   
The pldb is also necessary for actin localization and actin-based motility in 
two ways. Pldb localizes to the leading pseudopodia extensions of the slug, and 
PLD-generated PA levels are highest at the leading edge, with a decreasing 
gradient towards the posterior [165]. PA facilitates membrane curvature 
necessary for pseudopodia formation, but PA also activates PI4P5K, which 
generates PI(4,5)P2 in a positive feedback loop on pldb [163]. In addition to 
activating PLD, PI(4,5)P2 localizes actin nucleating factors (Arp2/3 complex) to 
the leading edge of pseudopodia for F-actin polymerization [163]. As a result of 
primary alcohol treatment, actin assembles in the nucleus and results in aberrant 
morphologies. In light of the importance of PA in specific signaling and structural 
capacities, pldb activity is integral to asexual reproduction in Dictyostelium. 
Further study will determine the role of PLD in vegetative or sexual reproduction 
cycles. 
 
Zebrafish PLD 
Seminal work in characterizing the function of PLD in the context of a 
whole vertebrate was recently performed using zebrafish, Danio rerio. In 2003, 
Ghosh et al. partially cloned a PLD enzyme (aa 380-916) from zebrafish embryos 
and determined it was expressed during gastrulation [166]. Zeng et al. followed 
up this study with cloning the complete zPld1 sequence [167]. This 1042 aa 
enzyme contains the two HKD motifs present in most eukaryotic PLDs, and is 64-
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68 % and 50 % homologous to mammalian PLD1 and PLD2, respectively. zPld1 
regulation is also similar to mammalian PLD, with conserved PKC (1-314 aa) and 
Rho (859-1010 aa) binding domains. In vitro characterization shows this enzyme 
is activated by Arf1 and PKC. A second zebrafish PLD isoform, 927 aa zPld2, 
has been partially cloned. 
Zebrafish are uniquely suited to whole organism studies of PLD activity 
and function because, as Zeng et al. demonstrated, PLD activity can be 
stimulated and measured with whole organism treatment of phorbol ester (PMA) 
and deuterated n-butanol. zPld1 activity was monitored using MS by monitoring 
deuterated phosphatidylbutanol formation [78]. Similar to other zebrafish 
phospholipases, in whole animal studies, zPld11 was determined to be involved 
in vascular development. This was determined using two parallel methods: (1) 
zPld11 was either knocked down using targeted morpholinos to disrupt zPld11 
translation and mRNA splicing, or (2) zebrafish were treated with n-butanol to 
divert zPld11 activity to transphosphatidylation. Unlike the development of other 
systems including motor neuron organization, there was a severe deficiency in 
intersegmental blood vessel formation. More recent studies have observed 
zPld11 mediates Golgi secretory vesicle formation [168]. Aberrant zPld11 activity 
due to unregulated Arf-stimulation results in decreased lipid absorption in the 
intestine. Utility of zebrafish in measuring PLD activity and monitoring substrate 
and product localization in a whole vertebrate animal will facilitate determination 
of the function of PLD with respect to the whole organism. 
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Mammalian PLD 
While PLD was first identified in plants in 1947 [14], PLD activity was not 
described in mammalian tissues until 1973 by Kanfer and colleagues [169]. 
Subsequently, multiple mammalian PLD enzymes and isoforms have been 
cloned, rigorous biochemical characterization performed, and extensive cell 
signaling studies undertaken. From this, mammalian PLD enzymes have been 
implicated in critical cell signaling pathways involved in development and cell 
death. These pathways modulate cell growth, proliferation, survival, and 
migration. As such, aberrant PLD activity has been detected in disease states, 
including cancer, inflammation, pathogenic infection, and neurodegeneration. 
 
Isoforms  
Cloning of plant and yeast PLD enzymes facilitated cloning of a full length 
PLD enzyme from HeLa cell cDNA [111] and rat [170] PLD1. Shortly thereafter, a 
second mammalian PLD enzyme, PLD2, was cloned [171], [172], [173]. These 
two isoforms share 50 % sequence homology, mostly at the catalytic domain that 
includes two conserved HxKxxxxDxxxxxxG(G/S)xN catalytic motifs separated by 
variable length of sequence predicted to form a thermolabile loop. N-terminal to a 
conserved polybasic PI(4,5)P2 binding domain [149], the loop region differs for 
these two PLD isoforms. PLD1 harbors an extended thermolabile loop prone to 
proteolytic cleavage [174]. The length of this loop region is variable dependent on 
the splice variant [175] (PLD1a = 116 aa versus PLD1b = 78 aa), while PLD2 
does not possess a significant loop region (4 aa predicted loop). Shortened 
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splice variants of both PLD1 and PLD2 have been identified that compose 
catalytically inactive enzyme [173]. Expression of these inactive enzymes is 
observed in different tissues, including the brain, but their function is unknown. 
At the amino-terminus, PLD1 and PLD2 share similar regulatory domains 
to PLDζ and Spo14, including PX and PH lipid binding domains. The PX domain 
binds polyphosphoinositides with high specificity, and anionic lipids with lower 
specificity [176], but this domain has also been implicated in protein interactions 
with regulatory proteins, including Dynamin and Grb2. Tyrosine residues in the 
PLD2 PX domain can be phosphorylated. The PH domain binds anionic 
phospholipids with low specificity. This domain is palmitoylated at two conserved 
cysteine residues that facilitate protein localization and do not impact catalytic 
activity (Figure 7). 
Despite similarities between the regulatory domain architecture of the 
classic PLD isoforms, the majority of the sequence divergence between these 
two mammalian PLD isoforms exists at the amino-terminus. Deletion of the PX 
domain enhances PLD1 activity. Truncation of the PLD1 PX domain and a 
portion of the PH domain further increases activity. However, conserved residues 
in a predicted α-helix at the C-terminal end of the PH domain are necessary for 
catalysis in the liposome activity assay [177] (unpublished data, Henage, Selvy 
and Brown). Cell-based studies demonstrate that N-terminally truncated PLD1 
enzymes maintain high activity levels upon cellular stimulation. This suggests, 
similar to the extended loop region of PLD1, the amino terminus of PLD1 is 
autoinhibitory, whereas deletion of the amino-terminus of PLD2 decreases 
 63 
 
activity and suggests PLD2 amino-terminus might facilitate increased basal 
activity. 
PLD1 and PLD2 share homologous C-terminal sequences. The specific identity 
of the residues in this sequence must be maintained for mammalian PLD activity. 
Non-conserved point mutation or deletion impairs catalytic activity [178]. The C-
terminal residues are suggested to interact with the catalytic core [178]. Studies 
by Steed et al. support this with identification of naturally occurring PLD2 splice 
variants with truncated C-termini that result in significantly decreased activity 
[173].  
The bulk of mammalian PLD activity is attributed to these classical PLD 
isoforms. These two isoforms, and subsequent splice variants, hydrolyze 
phospholipids to generate phosphatidic acid, and readily perform 
transphosphatidylation in the presence of low concentrations of alcohol to 
perform headgroup exchange and phosphatidylalcohol formation. Both isoforms 
are capable of hydrolyzing PC, PE, PS, LPC, and LPS, but are not capable of 
hydrolyzing PI, PG or cardiolipin. Although PA is the major hydrolytic product, 
hydrolysis of a lyso-lipid generates LPA. Recently, mammalian PLD was 
proposed to generate cLPA from lyso-lipids [179]. cLPA could be formed similar 
to the transphosphatidylation of LPC observed with autotaxin, where the internal 
sn-2 hydroxyl group serves as the secondary nucleophile to cyclize the product 
(pg. 8). 
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Figure 7. Conserved domains in mammalian PLD include HKD motifs responsible for 
catalytic activity, and phox homology (PX) and pleckstrin homology (PH) lipid binding 
domains thought to be involved in regulation of the enzyme.  Other known sites of 
protein interaction are illustrated as well (figure from [19]). 
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In addition to PLD1 and PLD2, two mammalian enzymes have been 
identified with significant sequence homology to viral and prokaryotic PLD. PLD3, 
also called Hu-K4, bears significant sequence homology to viral PLD enzymes 
K4 (48 %) and p37 (25-30 %) [180]. This enzyme has two HxKxxxxD/E motifs (in 
one motif the aspartate is mutated to glutamate) and was recently shown to 
harbor a predicted N-terminal type II transmembrane domain [181]. This 
facilitates protein insertion into the ER, with 38 aa exposed to the cytosol, and 
the large C-terminus, including the HKD motifs and multiple glycosylation motifs, 
exposed to the ER lumen. Catalytic activity has not been detected for this PLD 
isoform, but it has been postulated that this enzyme might hydrolyze lipids at the 
lumenal phase of the ER, or may not bear lipase activity, similar to the 
endonuclease activity of viral K4 [181]. The murine homolog of this enzyme, 
Sam9, is expressed in the forebrain during late neural development [182]. 
Catalytic activity has yet to be defined for this enzyme as well. 
A single-HKD enzyme with homology to Nuc endonuclease, called 
mitoPLD, was described [183]. This enzyme bears an N-terminal mitochondrial 
localization sequence (MLS) in place of PX or PH lipid binding domains. 
However, this localization sequence is not processed, and instead may facilitate 
insertion or anchoring into the outer mitochondrial membrane. This enzyme is 
predicted to homodimerize, similar to Nuc. This is not the first description of PLD 
activity localized at the mitochondria [184], but previous reports suggested 
mitochondrial PLD hydrolyzed PE to generate PA. Instead, mitoPLD hydrolyzes 
cardiolipin, an abundant mitochondrial lipid, to generate PA.  This product 
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facilitates mitochondrial fusion events, since overexpression of mitoPLD results 
in formation of a single large perinuclear mitochondrion, whereas expression of a 
catalytically inactive mutant resulted in fragmented mitochondria [185]. 
 
Tissue expression and subcellular localization 
The classic PLD isoforms, PLD1 and PLD2 are expressed in nearly all 
mammalian tissues. Due to the lack of clean, specific antibodies northern blot 
analysis has routinely been used to characterize PLD expression patterns. PLD1 
and PLD2 are both robustly expressed in heart, brain, and spleen. PLD1 exhibits 
low expression in peripheral blood leukocytes and PLD2 is poorly expressed in 
liver and skeletal muscle.     
While classic PLD isoforms, PLD1 and PLD2, catalyze the same reaction, 
and utilize similar substrates to generate PA or transphosphatidylation species, 
these enzymes are differentially localized within the cell. There has been some 
discrepancies in reports of subcellular localization of each PLD isoform, but this 
could be due to differences in the cellular systems, growth conditions, or the 
methods of detection (ie. subcellular fractionation or immunofluroescence of 
native versus tagged proteins; note that tags can impact localization).   
 
PLD1 subcellular localization 
It is generally accepted that PLD1 is localized to perinuclear membranes, 
including early endosomes, and Golgi under basal conditions [171], [186], with no 
reported difference in localization for splice variants PLD1a and PLD1b [186]. 
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Different regions of the protein contribute to basal subcellular localization.  
Truncation and point mutations have been used to identify the contribution of 
these different regions. Sugars et al. determined PLD1 basal localization is 
dependent on the PH domain, specifically an acidic region (residues 252 and 
253) thought to be important for IP3 binding, and conserved tryptophan residues 
in a predicted α-helix that is critical for catalytic activity [187]. PLD1 is 
palmitoylated on two cysteine residues in the PH domain and this lipid 
modification supports basal protein localization at intracellular membranes [177]. 
Point mutation of these cysteine residues impairs palmitoylation and results in 
aberrant protein localization. In the presence of serum protein basally localizes to 
the plasma membrane [187], whereas in the absence of serum these 
palmitoylation mutants are dispersed in the cytosol and translocation is triggered 
to the plasma membrane only upon serum stimulation [188]. Hughes and Parker 
suggested the C-terminal residues of PLD1 might also be necessary for 
endosomal localization [186]. This region of the enzyme is certainly necessary for 
catalytic activity, and native splice variants of PLD1a and PLD1b that lack these 
C-terminal residues do not basally localize to endosomes. However, it has been 
suggested that the C-terminus is integral for catalysis because it supports the 
structure of the active site [178]. Therefore enzymes lacking this region may not 
in fact be folded properly, and this could result in aberrant localization rather than 
the C-terminus itself directly participating in protein localization. Catalytic activity 
is not requisite for protein localization. Catalytically inactive point mutants (PLD1b 
K466E and K860E) localize to perinuclear endosomes similar to wildtype enzyme 
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[186]. It should be noted that individual domains of PLD1 expressed in isolation 
do not localize similar to the full enzyme [187], [188], [189]. This suggests that 
multiple components and regions of the enzyme participate in basal localization. 
Upon cell stimulation, PLD1 translocates to the plasma membrane or late 
endosomes. However, the type of stimulation results in differences in 
translocation, for example serum stimulation in Cos7 cells results in translocation 
to late endosomes and plasma membrane, whereas PMA stimulation triggers 
translocation to the plasma membrane [188] (unpublished data Selvy and 
Brown). PLD1 translocation to the plasma membrane in response to cell 
stimulation is thought to be due to PI(4,5)P2 binding at the polybasic binding 
region between the HKD motifs [188]. Point mutations in this polybasic region, 
including mutation of highly conserved arginine residues 691 and 695, impair 
PLD1 translocation to the plasma membrane upon stimulation. These data are 
supported by evidence that production of PI(4,5)P2 positively increases PLD 
activity. Finally, N-terminal PX and PH domains facilitate recycling to specific 
intracellular membranes [188].  
Nuclear PLD activity that responds to GTPγS via Rho GTPase, but not Arf 
activation, has been described [190]. A recent report suggests this activity is due 
to nuclear import of PLD1 via direct protein interaction with importin-β [191]. A 
highly conserved putative nuclear localization sequence (NLS) was identified 
between residues 553 and 564 for PLDb (KxRKxxKxxxxK). Importin-β binds the 
NLS and facilitates active transport into the nucleus. The NLS sequence exists in 
the loop region between the catalytic HKD motifs, and is not present in PLD2. 
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Mutation of any or all of the conserved residues in this NLS sequence impairs 
nuclear localization. Similar to the plasma membrane, PC is the major 
phospholipid present in nuclear membrane. Nuclear PLD activity generates PA 
that is rapidly metabolized to DAG. Jang et al. report this PLD activity stimulates 
nuclear PKCα and ERK phosphorylation and activation [191]. Catalytically-
inactive PLD1 point mutants and PLD-selective small molecule inhibitors disrupt 
nuclear PKCα and ERK activation, supporting the lipase-dependent activation 
mechanism. Immunofluoresence microscopy and subcellular fractionation 
analysis have also identified a nuclear PLD2 population, however a putative NLS 
has not been identified in PLD2 sequence [191], and further study is necessary 
to determine the mechanism for PLD2 nuclear import. The intriguing report of a 
PLD1 nuclear import mechanism begs further investigation to determine the 
potential signaling pathways modulated by nuclear PA production. 
 
PLD2 subcellular localization 
In contrast to the intricate regulation of PLD1 via protein translocation, 
PLD2 is generally observed to be constitutively localized to the plasma 
membrane under basal conditions and translocates to recycled vesicles with 
agonist-stimulated and desensitized receptors [171]. PLD2 also binds to and 
localizes with β-actin [192], and in response to EGF-stimulation localizes at 
membrane ruffles [193]. Instead of translocation upon cell stimulation, as is the 
case for PLD1, PLD2 activity and protein interactions are modulated via 
phosphorylation at multiple residues. 
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PLD activity has also been described for crude preparations of 
mitochondria.  Biochemically, this PLD activity differs from that attributed to 
MitoPLD. In these mitochondrial fractions, calcium-stimulation of an unknown 
enzyme hydrolyzes PE to generate PA. This enzyme may not be a member of 
the PLD superfamily since it is unable to perform transphosphatidylation [194]. 
In some studies, PLD1 and PLD2 were observed to colocalize at 
perinuclear and plasma membrane under basal conditions. The finding that PLD 
isoforms may form intracellular complexes might explain why introducing catalytic 
point mutants results in dominant negative effects and reduces basal PLD activity 
[63], [195]. 
 
Regulation 
PA is a critical lipid second messenger for a range of signaling cascades, 
but makes up 1-4 % total lipid in the cell [196]. PLD contributes to signaling pools 
of PA, and therefore this enzyme is under tight regulation by elaborate 
mechanisms including cofactor availability, signal induced subcellular 
translocation, post-translational modifications, and protein-protein interactions.   
 
Divalent cations 
Similar to other PLD superfamily members, mammalian PLD catalysis 
responds to divalent cation concentrations. However, in contrast to other 
superfamily members, including many plant enzymes, mammalian PLD catalysis 
is largely unresponsive to calcium concentration in vitro [175]. In vivo, however, 
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PLD activity is mediated by cellular calcium fluctuations, which suggests calcium 
facilitates protein-activator activation, such as PKC, and indirectly modulates 
PLD activity. In contrast, optimal catalysis levels require the presence of 
magnesium. In vitro PLD activity responds to changes in magnesium 
concentration, with half maximal Arf-activated PLD activity at 100 μM 
magnesium. This concentration of magnesium may facilitate catalysis directly, 
because this divalent cation does not impact in vitro protein-lipid binding 
(unpublished data Selvy and Brown). 
 
Post-translational modification 
Shortly after cloning of the first mammalian PLD enzymes, reports 
emerged that these enzymes were post-translationally modified in response to 
specific signaling pathways. Further characterization highlights lipid modification, 
phosphorylation, ubiquitination, and proteolytic mechanisms of PLD regulation.  
 
Lipid modification 
PLD1 [177] and PLD2 [197] are post-translationally palmitoylated at two 
cysteine residues in the PH domain. In vitro, this modification does not 
significantly impact catalytic activity, suggesting palmitoylation serves to regulate 
protein localization [177], [187]. In the cell, however, this lipid modification 
facilitates protein sorting into specific intracellular and plasma membrane 
domains including lipid rafts. In PLD1, Cys240 and Cys241 are palmitoylated, 
with Cys241 the dominant modification site. As determined by modeling the 
 72 
 
PLD1 PH domain onto the crystal structure of PLCδ PH domain, these residues 
exist in a region predicted to be an extended loop of the PH domain [177], [187]. 
Lipid modification requires expression of full length, catalytically-competent 
PLD1. Expression of the PH domain in isolation, or of severely truncated 
constructs of the enzyme do not result in modification [187]. ΔPX PLD1 
construct, lacking first 210 amino acids, is the shortest truncation that can be 
expressed that yields similar localization and catalytic activity to wildtype PLD1, 
and this truncation construct is lipid modified. 
 
Phosphorylation 
Mammalian PLD isoforms PLD1 and PLD2 are phosphorylated in 
response to signal transduction as a regulatory mechanism. PLD was originally 
determined to be phosphorylated when it was immunoprecipitated with polyclonal 
phospho-tyrosine antibodies [198]. Since this initial discovery, rigorous 
biochemical and molecular biology techniques have been employed to determine 
specific residues that are modified and the resulting impact on PLD activity and 
signal transduction. 
PLD1 regulatory mechanisms reported to date largely center on protein 
translocation, while multiple PLD2 phosphorylation sites have been described. 
Therefore, few reports of PLD1 phosphorylation exist. Early studies used 
sequence analysis to identify two putative tyrosine phosphorylation sites 
[RK](x)2/3[DE](x)2/3Y in PLD1 (aa 288-295 and aa 807-815). Evidence of 
phosphorylation at these residues does not exist. PLD1 phosphorylation occurs 
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in response to H2O2 stimulation, and increased phosphorylation has been shown 
to correlate to increased lipase activity [199]. c-Src has also been reported to 
phosphorylate PLD1, but this does not modulate lipase activity, rather modulates 
c-Src activity for downstream protein substrate [200]. PKC isoforms are also 
known to modulate PLD1 activity [201]. Despite the evidence that PKC activation 
of PLD1 is phosphorylation-independent, three residues are phosphorylated by 
PKC (Ser2, Thr147, Ser 561) [202]. In vitro catalytic analysis demonstrates that 
PKC phosphorylation of PLD1 likely serves as an inhibitory mechanism [203]. 
Maximal PKC-stimulated PLD activity is observed roughly one minute following 
PLD-PKC mixing. The timecourse of this activation suggests protein-protein 
interactions induce PLD activation.  Maximal PLD1 phosphorylation at threonine 
147, however, occurs nearly 60 minutes after PLD-PKC mixing [203]. Maximal 
PLD1 localization to the membrane also occurs at 60 minutes. 
Multiple PLD2 residues are reportedly capable of being phosphorylated by 
numerous kinases. Gomez-Cambronero and colleagues have characterized 
tyrosine residues in the PLD2 PX domain that mediate lipase activity and binding 
with SH2 domains. Tyr169 is highly conserved in all eukaryotic PLD and is 
proposed to be important for high PLD2 basal activity [204]. Tyr179 is present 
only in mammalian PLD and has been proposed to negatively regulate Ras 
signaling [204]. (Ras/MAPK signaling is increased nearly two-fold with Y179F 
mutation). Phosphorylation at these residues recruits the SH2 domain of Grb2, 
which binds the Ras GEF, Sos, via its SH3 domain, to activate MAPK pathway 
[204]. The kinase responsible for phosphorylation of these residues has not been 
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identified. However, kinases responsible for phosphorylation at other PLD2 
residues have been identified. Tyr175 exists in a consensus Akt phosphorylation 
site, and was identified using a polyclonal antibody for tyrosine phosphorylation 
at these consensus sequences [205]. Phosphorylation at Tyr175 reportedly 
increases DNA synthesis via MEK activation. 
Recently, a better understanding of the regulation of PLD2 activity via 
phosphorylation was reported [206]. Cycling of phosphorylation and 
dephosphorylation of PLD2 results in differences in lipase activity and 
downstream signaling consequences. PLD2 binding Grb2 via phosphorylated 
tyrosine residues in the PX domain results in increased lipase activity, while 
dephosphorylation of these residues by tyrosine phosphatase, CD45, increases 
cell proliferation [206]. Further studies have used MS-based proteomic analysis 
to identify other modified residues [207]. Epidermal growth factor receptor 
(EGFR) negatively regulates PLD2 lipase activity via phosphorylation at Tyr296. 
In contrast, JAK3 increases PLD2 lipase activity via Tyr415 phosphorylation. 
Finally, Src, also shown to modify PLD1, phosphorylates Tyr511 on PLD2. The 
latter modification does not directly modulate lipase activity, instead likely 
impacts protein interaction with Src and facilitates downstream events, similar to 
Src interaction with PLD1. Multiple phosphorylation modifications can be 
integrated to finely tune the activity level of PLD2 dependent on signaling 
requirements. 
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Ubiquitination 
A recent report demonstrated a previously uncharacterized post-
translational modification of PLD1, but not PLD2, important for modulating both 
protein localization and curbing lipase activity [208]. PLD1 is multi-
monoubiquitinated at the PH domain in a catalytic and palmitoylation-dependent 
manner. Catalytically-inactive point mutants are not ubiquitinated, and treatment 
with PLD-selective pharmacological inhibitors (chapter II) but not primary alcohol, 
disrupts PLD1 ubiquitination. Also, disruption of PLD1 palmitoylation impairs 
ubiquitination. Taken together, this suggests that properly localized and 
catalytically-competent PLD1 allows ubiquitination, and this modification is not a 
substrate-product feedback mechanism. The precise E3 ubiquitin ligase 
responsible for this modification is unknown, but following ubiquitination PLD1 is 
shuttled to the proteasome for degradation rather than the lysosome. Also, this 
modification translocates protein from endosomal membranes to an enlarged 
vesicle structure present in all cells transfected with stably ubiquitinated PLD. 
These stably-ubiquitinated constructs are not processed by de-ubiquitinating 
enzymes. As this modification results in changes in PLD1 localization and marks 
PLD1 for proteosomal degradation, ubiquitination of PLD1 is likely an important 
regulatory mechanism to change or curb lipase activity [208].  
 
Proteolysis 
Classic mammalian PLD isoforms PLD1 and PLD2 have been implicated 
in pro- and anti-apoptotic signaling mechanisms, and were recently reported to 
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be substrates for proteolytic caspase cleavage. Caspase cleavage of the PLD 
isoforms appears to divergently regulate these enzymes during apoptotic 
signaling. In vitro [209] and in vivo [174], [210] studies demonstrate PLD1 is 
cleaved in multiple locations by activated caspase 3, 7, and 8, while PLD2 is 
cleaved at several sites by caspase 3, and 8. During apoptosis initiation, caspase 
8 cleaves pro-caspase 3 to generate active caspase 3. Caspase 3 cleaves 
amyloid β4a precursor protein, making this enzyme the dominant caspase in 
neuronal cell death mechanisms in Alzheimer‟s disease. Caspase-3 cleavage of 
PLD2 occurs at two or three sites near the N-terminus (aa13-28, a region N-
terminal to the PX domain) and does not result in significant changes to 
molecular weight, catalytic activity, localization, or apoptotic signaling.[174],[209] 
PLD2 renders an anti-apoptotic response, likely via induction of anti-apoptotic 
protein expression (Bcl-2 and Bcl-XI) and down-regulation of pro-apoptotic 
proteins (Egr-1 and PTEN). Inhibition or RNAi knockdown of PLD2 increases 
apoptotic signaling. 
In contrast, caspase proteolysis appears to be a significant regulatory 
mechanism for PLD1. In vitro, PLD1 is cleaved by caspase 3 in three positions 
(Asp41, Asp545, Asp581) [209]. In vivo, position 545 is the dominant cleavage 
site [174]. This residue lies in the PLD1 loop region that separates the two 
catalytic HKD motifs. Cleavage at this position produces a 56 kDa C-terminal 
fragment (CF-PLD1) which localizes to the nucleus via an exposed nuclear 
localization sequence, and a 60 kDa N-terminal fragment (NF-PLD1) that 
remains in the cytosol [174]. Full length PLD1 activity is protective against 
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apoptosis by suppressing p53 signaling. NF-PLD1 acts as a dominant negative 
for full length PLD1 (via hydrophobic interactions), inhibiting PLD1 activity, and 
resulting in de-repression of p53 [210]. Therefore, caspase cleavage of PLD1 
decreases in vivo activity, and induces p53-dependent apoptotic signaling. Steed 
et al. identified a PLD1 splice variant, PLD1c, that expresses a PLD1 enzyme 
with an early stop codon at residue 513 [173]. This protein is expressed in human 
brain, and may function in a pro-apoptotic mechanism, similar to NF-PLD1. 
Further study of this truncated splice-variant and NF-PLD1 induced signaling is 
necessary. Jang et al. demonstrated PLD1 proteolytic processing is 
pathologically relevant [174]. Analysis of post-mortem brain tissue from 
Alzheimers patients demonstrated increased active caspase 3 and evidence for 
caspase-proteolyzed PLD1 fragments, compared to age-matched brain tissue.   
 
Lipid cofactors 
PLD localization and subsequent post-translational modification have a 
significant impact on lipase activity. In cells, lipid cofactors are thought to mediate 
subcellular localization through directly interacting with lipid binding domains of 
the enzyme as deletion or mutation of these domains changes subcellular 
localization. In some cases the mutant constructs change the ability of the 
enzyme to interact with membranes basally or change translocation of the 
enzyme to membranes upon cell stimulation. Recruitment of PLD upon PIP2, or 
PIP3 production allows upstream lipid kinases or phosphatases to mediate PLD 
lipase activity. It has been observed that when PLD fails to localize properly or be 
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recruited to the proper membrane substrate upon stimulation total lipase activity 
is impaired. 
In vitro, phospholipids directly and indirectly modulate lipase activity. Many 
of the observed in vitro effects of specific lipid species must be rigorously 
confirmed, because the properties of the lipid substrate presentation can 
modulate PLD activity in ways that may or may not be physiologically relevant. 
For example, inclusion of high concentrations of negatively charged phospholipid 
may impair the ability of the enzyme to interact with the lipid interface or with 
substrate head group. Also, lipase activity on lysolipid substrates is significantly 
enhanced when presented in a lyso-lipid micelle when compared to more 
complex presentations, such as lyso-lipids in a diacyl phospholipid liposome 
(unpublished observations Scott and Brown). As previously discussed, this is 
likely due to headgroup access, rather than a direct allosteric modulatory affect 
on the enzyme. 
The presence of some lipid species can directly affect protein-interface 
binding (Ks) by directly binding the enzyme. Separate from the active site, three 
other allosteric lipid binding sites have been described for PLD1 and PLD2, 
including the PX, PH, and polybasic PI(4,5)P2 lipid binding motif. The PX domain 
binds polyphosphoinositides [PI(3,4,5)P3>>PI(3)P>PI(5)P>other PIs] with high 
specificity at the putative primary binding pocket composed of conserved lysine 
and arginine residues [176]. At a secondary site, likely in the form of an exposed 
protein surface rather than a binding pocket including a conserved arginine 
(present in PLD1 and not PLD2), anionic lipids including PA and PS also bind. 
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However, in comparison to the other two lipid binding domains, the PLD PX 
domain binds lipids with poor affinity. This suggests the PX domain likely acts as 
a tertiary regulatory domain, to fine tune protein-lipid interactions initiated by 
another lipid binding site. 
The PH lipid binding domain binds PI(3,4)P2 and PI(4,5)P2 with specificity 
over other phosphoinositides [153], [211]. However, as discussed, this domain is 
lipid modified, and many of the observed effects of deletion of this domain may 
be due to the absence of this palmitoylation. In vitro, the entire PH domain is not 
requisite for PLD activity, although deletion of a conserved alpha-helix at the C-
terminus of the PH domain does impair lipase activity towards substrate present 
at an interface. 
Finally, the polybasic PI(4,5)P2 binding motif binds PI(4,5)P2 with high 
specificity and affinity [149]. Lipid binding at this motif facilitates interfacial lipid 
interaction and enhances catalytic activity. Human PLD1 bulk lipid binding 
constant (Ks = 10 μM) for PE:PC:PI(4,5)P2 lipid vesicles (87:8:5 mol %) is more 
than 7-fold higher than bulk lipid binding constant for PE:PC vesicles 
(unpublished data Selvy and Brown). Optimal PI(4,5)P2 mol %, 5-8 %, in a 
phospholipid vesicle enhances stimulation by regulatory proteins including Arf 
GTPase [74] (pg.). Some reports of in vitro lipase activity can be measured for 
full length PLD in the absence of PI(4,5)P2 with the addition of molar 
concentrations of ammonium sulfate (optimal activity at 1-1.6 M) [212], [213].   
Other reports of modulatory phospholipids are scattered in early PLD 
literature, but have not been followed up on. An intriguing observation by 
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Nakayama et al. suggested that PE, including dioleoyl and plasmalogen-rich 
species but not dipalmitoyl-containing species, enhances PC hydrolytic activity of 
PLD isolated from bovine kidney [212]. Another report suggested that that PI, 
LPI, and LPS, but not PS, negatively impact PLD activity [214]. It is unknown 
whether these effects are direct or indirect and whether they were specific to the 
in vitro assay format.   
 
Regulatory proteins  
With increased ease of recombinant PLD expression and measurement of 
in vitro PLD activity, a growing number of proteins have been reported to 
modulate PLD activity. Some of these proteins have been shown to directly 
modulate mammalian PLD activity through a protein-protein interaction; those are 
described here, whereas others may indirectly regulate PLD and participate in 
PLD signaling pathways, these proteins are mentioned in Table 5. 
 
Small GTPases 
Small GTPases were the first proteins demonstrated to directly modulate 
PLD activity through allosterically binding PLD. These enzymes are 
conformationally-activated upon binding GTP in place of constitutively-bound 
GDP, sometimes with the aid of guanine exchange factors (GEF) proteins, in 
response to signal transduction. GTPase activating proteins (GAPs) functionally 
inactivate the GTPases through facilitating intrinsic GTP hydrolysis.  Subfamily 
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members of the Ras GTPase superfamily, including Arf [77], [215], and Rho 
family of GTPases [201], [216], [217] stimulate PLD activity in vitro. 
Arf GTPases, including Arf1 and Arf6, stimulate PLD activity [77]. These 
were the first proteins demonstrated to activate mammalian PLD in an in vitro 
reconstitution system. Early in vitro characterization of PLD1 and PLD2 
suggested that PLD1 alone was stimulated by Arf [171]. Subsequent studies 
have shown that PLD2, while not activated to the same extent, can be stimulated 
2-fold over the already high basal activity with GTPγS-activated Arf [172], [218]. 
Henage et al. demonstrated that Arf1 increases total maximal activity (kcat) in a 
concentration dependent manner. At 150 nM Arf1, PLD1 activity increased 4 to 
6-fold over basal levels [74]. Arf stimulation is strongly dependent on the 
PI(4,5)P2 mol %. This has lead some to speculate that Arf may indirectly activate 
PLD by rearranging the phospholipid head groups at the interface in a PI(4,5)P2 
dependent fashion [219]. This may be true, but we have recently demonstrated 
that Arf activates PLD in the absence of PI(4,5)P2 [220], [221] (unpublished data 
Selvy and Brown), suggesting possibly a second mechanism of activation for Arf. 
Intriguingly, synergistic stimulation of PLD1 activity is observed when Arf is 
combined with PKCα or Rho family GTPases [74]. This demonstrates that Arf 
acts in concert with other modulatory enzymes to titrate the PLD response, and 
this finding could be of immense consequence in vivo. Some groups have 
attempted to identify the precise PLD binding site for Arf, [222], but to this date 
the site has not been unambiguously determined. In vitro, Arf activates N-  
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Table 5.  Mammalian PLD regulatory proteins (table from [19]) 
CLASS ACTIVATOR PLD ISOFORM CONSEQUENCE 
small GTPase Arf PLD1, PLD2 activate (kcat) 
  
  RhoA PLD1 activate (Km) 
  
  Rac1 PLD1 activate (Km) 
  
  Rac2 PLD2 activate 
  
  Cdc42 PLD1 activate (Km) 
  
Kinase PKC PLD1 (PLD2) activate (kcat & Km) 
  
  Src PLD2 phosphorylate 
  
Other Gβγ   inhibit 
  
  Grb2 PLD2 activate 
  
  F-actin   activate 
  
  G-actin   inhibit 
  
  Amphyphysin II   inhibit 
  
  AP3/AP180   inhibit 
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terminally truncated PLD1 [74] and PLD2 [218], therefore the site likely exists 
somewhere in the catalytic domain. Arf is myristoylated at its amino-terminus. 
Arf-activation of PLD does not require this lipid modification, but stimulation is 
enhanced with N-myristolated Arf. In fact, the N-terminus Arf is the specific 
region implicated in PLD interactions [223]. 
The Rho family of GTPases, including RhoA, Cdc42, Rac1 and Rac2 
directly activate mammalian PLD. Rho, Cdc42, and Rac1 are binding activators 
of PLD1, and stimulate substrate binding affinity (1/Km) [74]. Arf and Rho family 
GTPases synergize to significantly increase PLD1 activity beyond an additive 
response. PLD1 does not have a putative CRIB (Cdc42 and Rac-interactive 
binding) motif, but using truncation deletions, the Rho family-PLD1 binding site 
was mapped to a region in conserved domain IV in the carboxy-terminus of PLD1 
[224]. In a GTP-dependent mechanism, the Rho family GTPases bind PLD 
through the switch I region [225]. However, binding occurs independently from 
activation. Geranylgeranylation of Cdc42 is not required for PLD binding, but is 
required for PLD activation [225]. Cdc42 activation of PLD1 is mediated through 
the Rho-insert region, an alpha helix conserved in all Rho GTPases. However, 
this insert is not necessary for RhoA or Rac activation of PLD1 [226]. Rho, 
Cdc42, and Rac1 selectively activate PLD1. However, a recent report suggests 
that Rac2 may activate PLD2 via previously uncharacterized mechanism [227]. 
This report identifies two poorly conserved CRIB motifs (CRIB1 aa 255-270, and 
CRIB2 aa 306-326) in or near the PH domain of PLD2. Rac2 co-
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immunoprecipitates with PLD2, and mutation within these regions disrupts this 
interaction [227]. 
Two other Ras GTPases have been proposed to directly modulate PLD. 
RalA, a Ras-like GTPase implicated in cancer cell transformation, co-
immunoprecipitated with PLD1 but not PLD2 [228]. In another study, 
identification of the RalA binding site on PLD1 was attempted [222]. This study 
suggested that RalA binds at a site independent of Arf, allowing Arf and RalA to 
synergistically activate PLD1 [222]. In vitro, RalA enhanced PLD1 activity in a 
GTP-dependent mechanism [222], [228]. Rheb, a member of the Ras GTPase 
family, has also been reported to directly activate PLD1 in vitro [229].   
 
Kinases  
As mentioned above, PLD is phosphorylated post-translationally as a 
regulatory mechanism.  Therefore, it is not surprising that kinases directly interact 
with PLD to regulate activity. Protein kinase C (PKC) isoforms are the most well 
studied kinases that directly interact with PLD. Classic PKC isoforms α, β, and γ 
are stimulated by calcium and DAG, and are therefore responsive to PMA-
stimulation. In cells, these classic isoforms stimulate PLD1 and PLD2 activity 
downstream of PLC activation. PKCα phosphorylates PLD1 [202] and PLD2 
[230] at serine and threonine residues, but activation is not phosphorylation-
dependent. In timecourse studies, PMA-induced PLD activity occurs immediately, 
and phosphorylation only occurs later with a concomitant decrease in lipase 
activity, suggesting phosphorylation decreases PLD activity [203], [230]. The 
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PKC binding domain was mapped to the amino-terminus of PLD1 [231], 
however, PKC is able to activate N-terminally truncated PLD1 in a 
phosphorylation-independent mechanism [74]. PKC modulates PLD activity in a 
bimodal fashion. PKC enhances kcat as well as substrate binding (Km), and 
therefore synergistically activates PLD1 in combination with catalytic activator Arf 
GTPase [74]. However, amino-terminally truncated PLD1 constructs only show 
enhanced Km in response to PKC. 
 
Other regulatory proteins 
Numerous proteins have been reported to modulate PLD activity in 
response to signaling pathway activation, and a number of them have been 
demonstrated to do so directly. PED/PEA-15 (phosphoprotein enriched in 
diabetes/phosphoprotein enriched in astrocytes) is overexpressed in many 
tissues in type II diabetes patients. This protein directly binds CR IV of PLD and 
enhances PKC-activation of PLD [232]. This interaction impairs insulin regulation 
of the glucose transporter and insulin secretion, whereas competing for the 
PED/PEA-15 protein interaction with expression of the PLD1 CRIV domain 
restores insulin secretion [232]. This interaction is suggested by the authors to be 
a novel therapeutic target for type II diabetes. Grb2 is another protein that 
positively regulates PLD activity. Grb2 serves as a scaffolding protein to recruit 
signaling proteins including Sos, the Ras GEF, to the plasma membrane. The 
Grb2 SH2 domain binds PLD2 through phospho-tyrosine residues [204]. The 
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SH3 domains that flank the SH2 domain have been suggested to stimulate PLD 
activity. 
Direct protein interactions that curb lipase activity have also been 
described. The heterotrimeric Gβγ subunits, dissociated from the Gα subunit 
upon GPCR stimulation, directly interact with the catalytic domain of PLD1 and 
PLD2 to inhibit activity [233]. PLD has been implicated in synaptic vesicle 
trafficking. Two synaptic vesicle-associated proteins, amphiphysin I and AP3 
(also called AP180) directly bind PLD and inhibit lipase activity. Amphiphysin I 
heterodimerizes with Amphiphysin II in order to associate with clathrin coated 
vesicles. The N-terminus of Amphiphysin I directly binds PLD1 and PLD2 with 
affinities of roughly 15 nM, inhibiting catalytic activity. Assembly protein 3 (AP3, 
also called AP180) binds clathrin-coated vesicles and the C-terminus of PLD1 to 
inhibit lipase activity. 
Cytoskeletal components directly modulate PLD activity. Monomeric G 
actin inhibits PLD activity. Conversely, PLD activity triggers actin polymerization, 
and polymerized F-actin stimulates PLD activity. This divergent signaling 
mechanism may enhance cytoskeletal reorganization in localized subdomains of 
the cell. PLD2 has also been shown to directly bind microtubules, again 
suggesting that these interactions sequester the protein as a means of ensuring 
phospholipase activity is limited to the correct locations within the cell. Other 
proteins originally thought to directly interact with PLD and inhibit activity include 
α-synuclein, which has subsequently been shown to not inhibit PLD activity in 
vitro or in cells overexpressing this protein [234].  
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Recombinant protein expression and purification  
A limiting factor in studying the biochemical and structural character of 
mammalian PLD enzymes is that, to date, the enzymes have proven 
tremendously difficult to express and purify recombinantly. In contrast to plant 
and fungal enzymes, which are readily expressed and isolated from bacterial 
expression systems, mammalian PLD enzymes have not, to date, been 
expressed as catalytically active proteins in prokaryotic expression systems. 
Even plant and yeast enzymes with highly conserved regulatory and catalytic 
domains, such as PLDζ and Spo14, are catalytically active when expressed and 
purified from bacteria, whereas catalytically competent mammalian PLD 
enzymes have not been expressed or isolated from bacteria [235]. In Escherichia 
coli, mammalian PLD protein is highly proteolyzed and localizes to inclusion 
bodies, where insoluble, unfolded, aggregate protein is collected. Attempts to 
purify and refold mammalian PLD from inclusion bodies have not been reported.  
However, there are multiple instances of recombinant mammalian PLD 
expression in eukaryotic systems, including insect cells, Spodoptera frugiperda  
[78], [111], yeast, and Schizosaccharomyces pombe [236]. Catalytically active 
mammalian PLD1 and PLD2 can be expressed and partially purified from these 
eukaryotic recombinant systems. Since post-translational modifications, including 
lipid modification and phosphorylation, are not necessary for catalysis and 
refolding from inclusion bodies has never been successful, this suggests 
eukaryotic protein chaperones may be integral for proper folding of mammalian 
PLD enzymes. Intriguing studies from John Exton‟s group support this by 
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demonstrating that the amino and carboxy terminal domains can be expressed 
on separate plasmids and co-purified as catalytically active complex [189]. 
However, mixing of amino and carboxy termini that were expressed and purified 
in isolation does not yield catalytically active protein. 
When expressed in insect cells (monolayer cultures of Sf21 or Sf9 cells), 
the bulk of mammalian PLD1 protein is soluble or loosely membrane-associate 
and is easily extracted with mid ionic strength buffers and can be purified in the 
absence of detergent. Mammalian PLD2, however, is mostly membrane-
associated, and efficient protein extraction requires high salt and detergent. 
Throughout purification, this enzyme is not stable without detergent, which can 
be used at concentrations below the critical micelle concentration (cmc). 
Purification of mammalian PLD1 and PLD2 using classic chromatographic 
methods, such as ion exchange, heparin, and size-exclusion, yields partially pure 
fractions. Purity is further enhanced when mammalian PLD is expressed with 
affinity-tags, the best results are obtained through the use of multiple tandem 
affinity purification steps coupled with classic chromatographic methods. 
However, placement of the affinity tag at the amino-terminus is critical.  
Modification to the carboxy terminus significantly decreases catalytic activity, as 
would be expected based on PLD2 splice variants with truncated carboxy termini 
that yield proteins with 8-12 % of the activity of full length PLD2 enzyme [173]. 
Despite the increased purity afforded by tandem affinity tags, mammalian 
PLD, particularly PLD1, is poorly expressed in insect cells. Low expression levels 
may be due to the fact that expression of catalytically active PLD enzymes is 
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deleterious to insect cell viability. Supporting this is evidence that expression is 
significantly increased for catalytically-inactive mutants or amino-terminally 
truncated constructs that do not exhibit proper localization or catalytic activity in 
cells. Recent studies demonstrate that truncation of the amino terminus of PLD1 
coupled with use of a large affinity tag (bacterial maltose binding protein, 
commonly used to enhance solubility of recombinant proteins) significantly 
increase expression and enable one-step affinity purification of homogenous PLD 
[74], [78].   
 
Signaling pathways 
More than 15 years after the cloning of the first mammalian PLD, this 
enzyme, its activity, and products continue to be implicated in a wide range of 
signaling pathways and cellular functions. These pathways include receptor-
mediated responses, growth and survival pathways, and vesicular trafficking. 
PLD-mediated cytoskeletal reorganization in response to chemoattractants, and 
pathogenic infection are critical immunologic functions. Only recently have potent 
and isoenzyme selective small molecule inhibitors of mammalian PLD isoforms 
become available. Many studies continue to utilize primary alcohols to implicate 
PLD in different signaling pathways. In the presence of low concentrations (<3 %) 
of primary alcohol, mammalian PLD will perform transphosphatidylation and 
generate a metabolically-stable phosphatidylalcohol instead of phosphatidic acid. 
Discrepancies are now emerging between functions of PLD previously reported 
using alcohols, and those demonstrated using RNAi knockdown, small molecule 
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inhibitors, or those observed in knockout animals [237]. Signaling roles for PLD 
mentioned here include those determined using primary alcohols as well as 
knockdown or pharmacological inhibition. However, further characterization of 
PLD activity using these newer methods is necessary to clarify and validate 
previously-defined roles of mammalian PLD. 
 
Receptor-mediated signaling 
Extracellular stimuli trigger intracellular responses via cell receptors 
present at the plasma membrane. These include GPCRs, receptor tyrosine 
kinases (RTKs), and integrins, all of which mediate signaling through PLD 
activation. The specific mechanisms for receptor-mediated PLD activation differ 
between cell types, but the canonical pathways are described here. 
 
GPCR signaling 
G protein-coupled receptors (GPCR) trigger dissociation of Gα and Gβγ 
heterotrimeric G proteins upon agonist stimulation. Uncoupled heterotrimer 
subunits elicit signaling cascades through downstream effector proteins. Many of 
these pathways elicit functional responses through signaling to PLD in multiple 
ways (figure 8). In the canonical pathway, upon agonist stimulation, GTP-Gαq 
stimulates PLCβ hydrolysis of PI(4,5)P2, producing DAG and IP3 (see excellent 
reviews on PLC subtype activation [238], for review on Gq family [239], and [240]. 
IP3 triggers calcium release from the ER, and this coupled with DAG 
synergistically activates PKCα, which in turn bimodally activates PLD. Litosch 
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and colleagues recently showed that this PLCβ signaling is potentiated by PLD-
produced PA [241], [242]. Dissociated Gβγ also activates PLCβ, to indirectly 
activate PLD in a PKC-dependent manner. Additionally, Preninger et al. 
demonstrated that the Gβγ subunit of the heterotrimer can directly inhibit PLD 
activity via interactions through the PLD catalytic domain [233]. Gβγ interaction 
disrupts both basal and Arf-stimulated activity [233], [243]. As illustrated in Figure 
8, levels of PLD activation are intricately titrated in response to specific agonist-
mediated or intracellular circumstances.   
The G12/13 class of heterotrimers activates PLD in a small GTPase 
dependent manner. Gα12 activates RhoA via Pyk2, a focal adhesion tyrosine 
kinase, which directly stimulates PLD1 activity. As shown in Figure 8C, Gα13 
activates the γ subtype of PI3K to generate PIP3. Upon PIP3 binding, ARNO and 
Rho GEF trigger GDP for GTP exchange on Arf and RhoA, respectively [244]. 
These activated small GTPases then directly activate PLD. Gq and G12 also 
stimulate Src, which tyrosine-phosphorylates both PLD at the PH domain, and 
the receptor tyrosine kinase, EGFR (Figure 9). PLD phosphorylation does not 
affect cellular phospholipase activity, but the direct interaction does enhance Src 
kinase activity [200]. EGFR phosphorylation results in homodimerization, 
autophosphorylation, and GPCR-EGFR transactivation in the absence of EGFR 
agonist [245], [246]. 
Roles for PLD in pathogenic response have been reported, many of which 
are GPCR-mediated and result in changes in reactive oxygen species formation, 
vesicular trafficking or transcription. In leukocytes, PLD1 expression is induced in 
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response to pathogenic and pro-inflammatory stimuli through activation of 
membrane receptors including the Gi-coupled f-Met-Leu-Phe receptor (fMLPR). 
PLD activity in macrophages and neutrophils is implicated in respiratory burst 
[247], engulfment of bacteria, and reorganization of cytoskeletal elements. 
Recently, PLD was shown to be involved in HIV replication via CCR5, an MIP-1 
chemokine receptor that interacts with an HIV glycoprotein [248], In response to 
CCR5 agonist stimulation, PLD is activated in an ERK1/2-dependent manner to 
activate transcription factors, including NFĸB, that facilitate replication of the 
latent HIV genome integrated into the host genome.    
PLD is a major source of PA generated by cell surface receptor-mediated 
signaling pathways. Its primary substrate in mammalian cells is PC, but 
consistent with its catalytic mechanism it can also utilize other amine containing 
glycerophospholipids as substrates (e.g., PE and PS). The molecular species of 
PA generated by PLD are predominantly mono- and di-unsaturated species, 
particularly 16:0/18:1 containing fatty acyl species. Work from Michael 
Wakelam‟s laboratory provided an insightful comparison of DAG and PA species 
generated from PLC and PLD sources, respectively [249], [250]. The authors 
reported differences in cellular targets modulated by these distinct signaling 
pathways, such as the lack of PKC activation by molecular species of DAGs 
generated downstream of PLD. Activated in parallel by many of the same cell 
surface receptors, PLC isoenzymes generate two second messengers from the 
hydrolysis of PI(4,5)P2 , namely DAG and IP3. The DAG generated via the PLC  
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Figure 8. G protein coupled receptor activation of PLD through Gαq, and protein kinase C 
(panel A), Gα12 and RhoA (panel B), and Gα13 and Arf (figure from [19]). 
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pathway is typically polyunsaturated (e.g., 38:4 DAG) reflecting the major species 
of the PIP2 substrate available in mammalian cells [251]. The polyunsaturated 
DAG generated from PLC provides a second and distinct signaling source of 
cellular PA via the transfer of a phosphate from ATP to DAG through the action 
of a DAG kinase. An excellent review of DAG kinase isoenyzmes types and 
regulation was recently published [252].  Different isoenzymes of DAG kinases 
have distinct substrate specificities. Recent advances in electrospray ionization 
mass spectrometry have identified a surprising diversity of DAG molecular 
species that can now be resolved and quantitated using a linear regression 
algorithm [253]. This type of analysis has revealed that DAK kinase isoenzymes 
have extremely diverse functionalities and substrate preferences leading to 
differences in the array and relative concentrations of acyl species of DAGs in 
cells following perturbations, such as overexpression or genetic knockouts [254], 
[255]. For example, the DAG kinase epsilon shows the ability to select acyl 
chains on both the sn-1 and sn-2 positions of the glycerol backbone of the DAG 
substrate as well as on its product, PA, which modulates a feedback inhibition of 
this isoenzyme [256]. This PLC-DAG kinase pathway provides a distinct phase of 
PA that appears later in the temporal sequence of receptor-mediated PA 
generation. By contrast the PA molecular species generated by PLD appear 
rapidly after receptor activation, but are also rapidly metabolized into DAG via the 
actions of lipid phosphatases. The ultimate metabolic fates and functional 
distinctions of these two sources of signaling PA species are not as yet fully 
defined, but recent development of new types of lipid probes that utilize alkyne-
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cobalt chemistry [81] provides opportunities to track and identify lipid metabolites 
even after multiple biotransformations. This will facilitate identification of distant 
metabolites and allow the functional consequences of different sources of PA 
production to be unambiguously determined.  
 
Canonical RTK signaling via EGFR 
The EGFR, is highly conserved in eukaryotic organisms, and is a 
representative member of the ERBb family of growth factor receptors with 
intrinsic tyrosine kinase activity. EGFR activates downstream signaling pathways 
including those responsible for growth, survival, and cytoskeletal reorganization. 
Aberrant EGFR signaling has been implicated in tumorigenesis. 
Upon GPCR transactivation or binding epidermal growth factor (EGF), 
EGFR homodimerizes and tyrosine phosphorylates the adjacent receptor in the 
cytosolic region to generate an active receptor complex (activation mechanism 
reviewed [257]). These phosphotyrosine residues serve as docking sites for 
downstream effector proteins, including PLCγ1, Grb2, and PI3K. Even prior to 
cloning the mammalian PLD isoforms, PLD activity was shown to be activated by 
EGFR stimulation. Critical characterization of the multiple, and sometimes 
overlapping, mechanisms in which EGFR signaling activates PLD activity has 
been performed. For simplification, these are illustrated and described in 
separate schematics. 
PLD2 can be localized to EGFR via its PX domain. In Figure 9A, the PX 
domain of PLD2 binds the SH3 domain of PLCγ1, which directly localizes to the 
 96 
 
EGFR. PLCγ1 hydrolyzes PI(4,5)P2 to generate DAG ad IP3. Similar to GPCR-
activation of PLCβ, PLC-derived products induce PKCα activation of PLD.   
Changes in actin polymerization can occur in response to GPCR or RTK 
signaling. PLD has been shown to directly bind actin, resulting in mutual 
regulatory interactions.  
In a separate mechanism of PLD activation PLD2 directly interacts with 
the EGFR. At the receptor, phosphotyrosine residues in the PLD2 PH domain 
bind the Grb2 SH2 domain [258]. This interaction enhances phospholipase 
activity, via Grb2 SH3 interaction, to generate PA. Recently Zhao et al., 
demonstrated that the Ras GEF, Sos localizes the PLD2-produced PA, where it 
is activated by Grb2 [259]. Subsequent Ras activation elicits a host of signaling 
cascades. Ras activates PI3K, which generates PIP3 and induces Akt 
translocation and activation. Ral GEF is also a Ras effector protein, which results 
in GTP-Ral activation of PLD [228], [260]. Finally, Ras activates Raf, which 
localizes to the plasma membrane via PLD-produced PA interactions. Ras 
signaling through Raf triggers activation of the MAPK pathway and via NFĸB, 
subsequently upregulates transcription of genes involved in survival, proliferation, 
and differentiation.  
Somewhat more controversial is the role of PLD in EGFR-stimulated 
mTOR signaling (reviewed [261], [262]) illustrated in Figure 9C. Several reports 
suggest PLD generated PA competes for rapamycin and FKBP binding in the 
FRB domain of mTOR [5], [263]. These studies were performed using primary 
alcohols to show mTORC1 kinase activity was significantly decreased upon  
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Figure 9. Activation of PLD through epidermal growth factor receptor (EGFR), a 
canonical receptor tyrosine kinase.  Activated EGFR and PLCγ regulate PLD (panel A); 
EGFR activation of Grb2 and Sos induces PLD activation (panel B); and EGFR activation of 
PI3K regulates PLD and mTOR signaling (panel C) (figure from [19]). 
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diverting PLD activity to generation of transphosphatidylation product. A follow up 
study used NMR to map the PA binding site within the FRB domain [264]. The 
small GTPase Rheb was recently suggested to stimulate PLD1 as a feed forward 
mechanism of mTORC1 activation [229]. Again these studies relied heavily on 
the use of primary alcohols, RNAi knockdowns, and a somewhat incomplete 
biochemical analysis. Subsequent use of PLD-selective small molecule inhibitors 
(chapter II) and genetic knockouts may illuminate that the role of PLD in mTOR 
regulation is considerably more complex with both feedforward and feedback 
modulation. 
 
Integrin signaling 
Integrins support cell adhesion as well as growth and survival by 
functioning as both an anchor to the extracellular matrix (ECM) as well as a 
signaling receptor. Although integrins do not possess intrinsic enzymatic activity, 
upon ligand binding, these receptors elicit similar signaling pathways to those of 
growth factor receptors by heterodimerizing and binding various effector proteins 
at their cytosolic face. Integrins heterodimers can signal independently or 
complexed with growth factor receptors to trigger chemotaxis, cell differentiation, 
proliferation, and survival (reviewed [265]). As in EGFR signaling pathways, PLD 
is activated downstream of integrin receptors via multiple mechanisms. 
Focal adhesion kinase (FAK) directly binds the integrin receptor to induce 
Ras-mediated signaling and MAPK activation. Ras activates PI3K to generate 
 99 
 
PIP3.  In response, the Rho GTPase, Rac, undergoes guanine nucleotide 
exchange thereby triggering PLD activation.[266] Canonically, PLD1 is directly 
stimulated by C-terminal interaction with Rac1. However, Pang et al. have shown 
that Rac2 directly interacts with PLD2 via CRIB domains in the PLD N-terminal 
regulatory domain [227]. In vitro the C-terminus of Rac selectively binds PA. In 
cells, PLD-produced PA triggers Rac translocation to membrane ruffles and 
lamellipodia [266]. Treatment with n-butanol results in cytosolic localization of 
GTP-bound Rac, supporting the role of PLD in Rac translocation. At regions of 
membrane protrusion and lamellipodiae formation, Rac facilitates cytoskeletal 
reorganization. PLD colocalizes at these membrane microdomains and induces 
actin polymerization. 
Integrin signaling also mediates Arf activation of PLD. Integrin effector 
proteins  elicit Arf GAP, ASAP, localization to the leading edge of migrating cells 
to attenuate Arf signaling (reviewed [267]) and perturb Arf-activation of PLD 
(reviewed [268]). This bimodal mechanism of small GTPase regulation titrates 
levels of phospholipase activity during integrin-mediated membrane ruffling, cell 
migration, and invasion.  
Similar to the role of PLD in Dictyostelium migration, mammalian PLD 
isoforms have been implicated in chemotaxis. These enzymes, stimulated by 
Rho GTPases downstream of integrin, chemokine, and growth factor receptors, 
trigger cytoskeletal rearrangement and membrane ruffling. Primary butanol and 
PLD-selective inhibitors disrupt these pathways, suggesting PA formation as well 
as protein-protein interactions participate in these signaling responses.   
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As discussed above, PLD-produced PA has been suggested to directly 
activate mTOR and facilitate mTOR complex formation and signaling, including 
mTORC2 and subsequent Akt phosphorylation. Akt and mTORC2 signaling not 
only support pro-survival signaling via MDM2 stabilization, and BAD and Bcl-XI 
activation, but also induce cytoskeletal reorganization. mTORC2 induces actin 
polymerization and triggers myosin II assembly and cell migration via PAK and 
myosin phosphorylation. PLD activity also induces secretion of proteolytic matrix 
metalloproteases that degrade surrounding ECM to facilitate cellular movement. 
 
 Vesicular trafficking 
Mammalian PLD enzymes differentially localize to cellular membranes to 
directly and indirectly induce changes in membrane curvature and fusion that 
facilitate endocytosis/exocytosis and vesicular trafficking. PLD1 primarily 
localizes to intracellular membranes including TGN and endosomal membranes 
and has constitutively low basal activity. Upon cell stimulation, PLD1 translocates 
to plasma membrane and is activate. PLD2 is generally constitutively localized to 
the plasma membrane and has high basal activity.  
Arf GTPases activate the otherwise low basal activity of PLD1. Arf1 
stimulates Golgi-localized PLD [269], while Arf6 stimulates PLD1 at the plasma 
membrane [270]. In an independent mechanism, Arf present at either membrane 
cooperates with Arf-stimulated PA to facilitate vesicles formation [271], [272]. In 
contrast to the Sec14 bypass mechanism in yeast, PA accumulation, rather than 
DAG, facilitates vesicle budding. This may be due to several PA-related 
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mechanisms. PA is a cone shaped lipid, and induces changes in membrane 
curvature. Arf and PA also trigger recruitment of coatomer proteins, including 
COPI [273], [274]. PA activates PI4P5K, which generates PI(4,5)P2 and induces 
translocation of coatomer proteins and proteins involved in vesicle 
budding,including dynamin (a GTPase involved in endocytosis and membrane 
scission) and AP180 (a clathrin assembly protein) (Figure 10). Following 
recruitment, AP180 directly inhibits PLD activity [275], [276]. Recently, PLD was 
also reported to directly interact with dynamin. This interaction occurred in a 
GTP-dependent manner, and it was suggested that the PX domain of PLD2 
might serve as a GAP for dynamin [277]. 
PLD and PA-dependent mechanisms function in vesicle formation to 
facilitate receptor internalization and recycling (Figure 10), SNARE-mediated 
synaptic vesicle fusion (similar to that observed in Spo14-mediated prospore 
membrane formation), and exocytic mechanisms including respiratory burst [278] 
and degranulation [279]. 
 
PLD inhibitors 
A large body of knowledge of the role of PLD in signaling pathways has 
been determined using small molecules as tools.  A wide range of chemically 
diverse small molecules have been reported to be PLD inhibitors. In the 1960‟s 
short-chain primary alcohols (e.g. n-butanol) were identified as compounds that 
could modulate PLD product formation [61], whereas secondary and tertiary 
alcohols do not. Primary alcohols function as a preferred nucleophile to water in  
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Figure 10. The role of PLD in endocytosis and receptor internalization  (figure from [19]). 
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the second phase of the reaction mechanism (figure 5), resulting in formation of 
the transphosphatidylation product phosphatidylalcohol.  Therefore these 
compounds do not inhibit PLD activity, a common misnomer in the literature.  
Instead, PA product formation is simply diverted to a more metabolically stable 
transphosphatidylation product.  These characteristics make primary alcohols an 
attractive tool in cell signaling studies.  As such it has historically been the most 
commonly utilized small molecule for studying PLD signaling.  However, recent 
studies have suggested that primary alcohols may not effectively divert all 
phosphatidic acid formation, and that phosphatdidylalcohols such as 
phosphatidylbutanol may not be as physiologically inert as once predicted [269].  
Also, some of the signaling capacities attributed to PLD through studies using 
alcohols do not hold true when RNAi and small molecule inhibitors are employed 
[237].  This suggests primary alcohols may have an off target effect on certain 
signaling pathways, as has been demonstrated in plants.   The need to validate 
the role of PLD in signaling pathways and evidence that PLD may serve as a 
novel therapeutic target has been the impetus for the recent development of 
small molecule inhibitors for mammalian PLD (Chapter II).  
 
Indirect PLD inhibitors 
Historically, two classes of PLD inhibitors have been described- those that 
act indirectly or directly on the enzyme. Some groups have identified compounds 
that indirectly inhibit PLD activity.  These compounds, highlighted in Figure 11  
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Figure 11. Reported indirect PLD inhibitors 1-10. 
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include natural compounds such as resveratrol(1), honokiol (2), and triptolide. 
Members of this class of compounds inhibit PLD activity in cells, but have not 
been demonstrated to inhibit PLD activity in the biochemical liposome 
reconstitution assay. Resveratrol, isolated from the skin of red grapes, yields an 
anti-inflammatory effect by indirectly inhibiting sphingosine kinase and PLD 
translocation and activity [280].  Honokiol, the natural anti-microbial compound 
derived from seeds of magnolia, inhibits Ras activation and thereby blocks Ras-
dependent PLD acivity [281].  The natural anti-inflammatory compound, triptolide 
suppresses PLD1 and PLD2 protein expression by blocking NFĸB activation 
[282]. 
 
Direct PLD inhibitors 
Compounds that directly inhibit PLD activity, as demonstrated using 
purified recombinant protein in the biochemical liposome reconstitution assay, 
have also been identified (Figure 12) but many are not selective to mammalian 
PLD and hence are poor tools for studying cellular and in vivo functions of the 
enzyme.  Such compounds include presqualene diphosphate (17) which was 
demonstrated to inhibit both mammalian PLD1b and scPLD (a non-HKD enzyme) 
in the biochemical reconstitution assay, but the mechanism was not determined 
[283].  Certain compounds in the selective estrogen receptor modulator (SERM) 
class (e.g. raloxifene (19) and 4-OH tamoxifen (20), further detailed in chapter IV) 
directly inhibit mammalian PLD isoforms [284].  Catalytic site inhibitors were 
identified from crystal structure characterization of bacterial PLD enzymes, and 
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were later validated for mammalian PLD (Henage, Selvy, and Brown, 
unpublished data). These compounds include the phosphate mimetics tungstate 
(12) and vanadate (13), which are thought to compete for phospholipid 
headgroup binding at the orthosteric site, but there is some evidence that these 
compounds may bind at a second allosteric site as these compounds bind with a 
two-site binding model, disrupt interfacial binding, and displace a select class of 
phospholipids that co-purify with recombinant PLD (Chapter IV). 
More recent reports of direct PLD inhibitors have centered around a class 
of compounds based on the chemical structure of the anti-psychotic halopemide. 
From this class, novel isoform-selective inhibitors have been identified (referred 
to here as VU-series compounds) and structure-activity relationship (SAR) 
rigoursly characterized (Chapter II). Subsequent studies have characterized the 
molecular mechanism of action for this class of compounds and demonstrate 
their specificity towards mammalian PLD (Chapter III). The VU-series 
compounds are significantly more potent than previously reported PLD inhibitors, 
have desireable pharmacokinetics, are brain penetrant, and do not present 
toxicity issues when tested in humans, which was performed in the early 1980‟s 
as a function of screening this class of compounds as an experimental 
antipsychotic.  These factors suggest the VU series compounds might be a good 
starting point for developing inhibitors to screen for systemic implications of PLD 
inhibition in concordance with disease studies such as those for cancer, 
Alzheimer‟s, and thrombosis. 
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Figure 12. Reported direct PLD inhibitors 11-20. 
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PLD as a potential therapeutic target 
Several groups have used a combination of RNAi and the newly available 
PLD1-/- or PLD2-/- knockout mice (for which no phenotype is observed in healthy 
mice) to validate a role for PLD in several disease states. Aberrant PLD activity 
has been implicated in several types of cancer, such as colon, breast, and 
glioma. Its role in oncogenesis is likely due to its ability to increase growth and 
proliferation, and to facilitate cancer cell invasion and metastases.  Studies by 
Buchanan et al. demonstrated that overexpression of dominant negative PLD 
can impede the ability of rat fibroblasts transfected with H-RasV12 to form tumors 
in soft agar or nude mice [285]. Exogenous supplementation of PLD product PA 
rescues the tumor-forming phenotype. 
Dysregulated PLD activity has recently been validated as key player in 
Alzheimer‟s disease [7]. Oligomeric amyloid β increases PLD2 activity in cultures 
of neuronal cells. In the whole organism, increased PLD activity is observed in 
mice with a rodent model disease for Alzheimer‟s with a severe memory deficit 
phenotype. However, PLD2-/- mice with the same rodent model disease and the 
same amyloid β plaque load as a wildtype animals with the disease, do not 
present a memory deficit phenotype [286]. This suggests PLD2 might be a 
worthy therapeutic target for limiting the decreased memory phenotype in 
Alzheimer‟s patients. 
PLD was also recently implicated in integrin-mediated thrombosis.  Elvers, 
et al. demonstrated that PLD1-/- mice are protected from thrombotic formation 
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and ischemic brain injury without increasing bleeding time [237].  Chemically or 
mechanically induced arterial occlusion was significantly decreased in PLD1-/- 
mice.  This provocative data suggests targeting PLD1 may protect against 
thrombotic disease without the compensatory increased risk of bleeding common 
for current therapies (e.g. aspirin and warfarin). 
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Chapter II 
 
IDENTIFICATION AND DEVELOPMENT OF NOVEL 
ISOFORM-SELECTIVE PLD INHIBITORS 
 
 
 
 
Recent studies using RNAi and PLD1-/- or PLD2-/- animals suggest both 
mammalian PLD isoforms are of potential value as therapeutic targets for a 
number of diseases.  In conjunction with these whole animal studies, further 
interrogation of the role for PLD in critical stress-mediated signaling pathways is 
necessary.  However, until recently the only small molecule that was both readily 
available and widely used as a validated tool for studying PLD signaling was 
primary alcohol.  As mentioned in chapter I, although primary alcohols do divert 
product formation to a more slowly metabolized transphosphatidylation product 
that can also be monitored as a readout for PLD activity, recent studies have 
shown discrepancies between signaling roles of PLD elucidated using alcohol 
and other methods of blocking PLD-mediated PA formation (e.g. RNAi).  Thus, it 
was necessary to identify and develop small molecule inhibitors of PLD that 
could readily be used in place of primary alcohol.  The aim of these studies was 
to develop a class of compound that would not only be significantly more potent 
than previously-described inhibitors, but also lend isoform-selectivity for studying 
the roles of each isoform in isolation. 
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Halopemide 
In 2007 a group from Novartis reported on a class of benzimidazolone-
containing compounds that were identified in a highthroughput screen as novel 
PLD inhibitors [287].  This class, which includes halopemide an antipsychotic 
agent, was reported to inhibit PLD2 without mention of PLD1 or the type of 
screening assay used to determine this. In the late 1970‟s halopemide, a known 
antiemetic, was identified as a dopamine antagonist that also limits GABA 
uptake, but had micromolar potency and derivatives were ineffective in vitro, 
suggesting a metabolite was the active compound [288].  Human trials in the 
early 1980‟s identified halopemide as a non toxic effective anti-psychotic agent 
with psychic energizer properties that significantly benefitted withdrawn patients 
with schizophrenia and autism [289].  In the Novartis report, halopemide was 
identified as a low micromolar inhibitor of PLD2 (IC50=1.5μM) [287], while in our 
own experience potency towards PLD1 was slightly greater (PLD1 IC50=220nM 
versus PLD2 IC50=310nM in biochemical assay).  Follow up studies described 
nanomolar potencies for both isoforms for a halopemide derivative, coined FIPI 
(5-Fluoro-2-indolyl des-chlorohalopemide; PLD1 IC50=25nM, PLD2 
IC50=25nM)[79].  Due to excellent potency and potential druggability of this class 
of compounds, halopemide was selected as the lead compound for our diversity-
oriented medicinal chemistry project. 
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Development of novel isoform-selective compounds 
In collaboration with Craig Lindsley‟s lab, an initial library of 263 compounds was 
generated to explore the chemical space and identify components that elicit 
isoform selectivity.  Halopemide was divided into three structural elements 
(scaffold, linker, and eastern portion/ amide cap) that were synthetically varied in 
order to generate a diverse library of small molecules from which we could 
screen to identify isoform-selective PLD inhibitors.   
This library of compounds was initially screened at a single micromolar 
concentration in the biochemical liposome assay to measure efficacy towards 
partially purified recombinant PLD1 and PLD2. A significant portion of the 
compounds were triaged in this first screen, and only compounds that 
demonstrated significant inhibition at the single concentration were then further 
characterized for isoform selectivity by generating concentration response curves 
for both PLD1 and PLD2.  30 compounds were secondarily screened in this 
manner, from which classes of compounds began to emerge (examples from 
each class shown in figure 13).  Some small molecules inhibited both isoforms 
equivalently, which are referred to as dual isoform inhibitors. Other compounds 
elicited selectivity towards a single isoform and are referred to as PLD1- or 
PLD2-selective [290]. Striking chemical differences are apparent when 
comparing compounds from these three classes.  Dual isoform and PLD1-
selective compounds maintain the benzimidazolone scaffold present in 
halopemide (figure 14). Substitution of this scaffold to a triazaspirone engenders  
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Dual Isoform PLD1-Selective PLD2-Selective
 
Figure 13.  In vitro inhibition of recombinant PLD with select compounds.  Graphs 
demonstrate CRCs for three classes of inhibitors on recombinant human PLD1 and PLD2 
normalized to myr-Arf-1-stimulated activity +/-s.e.m. (representative data from a single 
30-min experiment done in triplicate) (figure from [290]). 
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PLD2 selectivity.  However, regardless of scaffold identity (either 
benzimidazolone or triazospirone)PLD1-selectivity can be dialed in with the 
addition of a S-chiral methyl to the linker region.  An increase in overall potency 
of the benzimidazolone-containing compounds was observed by addition of a 
halogen, such as a chloro group, to the 5-position of the benzimidazolone. 
In parallel to the biochemical screens, this library of compounds was also 
screened in a cell based assay previously described in detail elsewhere [78]. 
Sarah Scott, a postdoctoral fellow in our lab, performed the cell based screen, 
which uses two cell lines that owe the majority of their PLD activity to a single 
isoform (as determined by siRNA knockdown) [290].  ESI-MS was used to 
measure PtdBuOH formation as a readout for PLD activity in these cell lines 
following addition of small molecule and cell stimulation.  Following concentration 
response curve generation for the same 30 compounds as characterized 
biochemically, similar classes of dual and isoform-selective inhibitors emerged 
(figure 15).  Thus initial SAR held true for this new class of PLD inhibitors, 
referred to as the VU-series PLD inhibitors.  However, every compound 
demonstrates increased potency in the cell based assay compared to the 
biochemical assay.  This as of yet is unexplained, but there is evidence that 
these lipophilic compounds partition into PC-containing membranes possibly 
decreasing compound concentration accessible to recombinant protein in the 
biochemical assay (Selvy, Milne, Brown, unpublished data).  Another possibility 
is, despite the fact that there is as of yet no evidence for off target effects in cells  
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Figure 14. Focused lead optimization strategy to improve PLD1 potency and selectivity 
within scaffold 25, and strategy to improve PLD2 potency and selectivity within scaffold 
26  (figure from [19]). 
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A
B Dual Isoform PLD1-Selective PLD2-Selective
 
Figure 15. Cell-based activity assay utilizes deuterated n-butanol as a readout for PLD 
activity measured with ESI-MS (A). Small molecules potently inhibit cellular PLD activity.  
CRCs were obtained for multiple small-molecule PLD inhibitors for both PMA-stimulated 
Calu-1 cells (featuring predominantly PLD1 activity) and basal HEK293-gfpPLD2 stable 
cell line (featuring predominantly PLD2 activity) (figure modified from [291], [290]). 
 
 
 
 
 
 117 
 
(off target screens have included other unrelated phospholipases, kinases, and 
receptors), the binding affinity of the compound may improve when then PLD 
protein is in a protein complex (as is possible in cells) rather that recombinantly 
expressed and purified (as in the biochemical assay).  Regardless, rigorous 
characterization of the VU-series compounds to demonstrate both biochemical 
and cell-based efficacy suggests their potential power as a tool in studying PLD 
enzymology and signaling. 
 
Structure-activity relationship characterization of novel PLD inhibitors 
Following the initial description of the VU-series inhibitors, a larger library 
of compounds was generated in attempts to improve the potency and fold 
selectivity of these VU-series inhibitors.  Extensive SAR characterization was 
undertaken for a library of more than 800 compounds generated in Dr. Craig 
Lindsley‟s lab.   These compounds were screened for potency and selectivity in 
both biochemical and cell based assays.  These studies lead to compounds with 
sub nanomolar potencies and in some cases more than 1700-fold selectivity.  
SAR from this larger library tested the identity and position of the halogen 
substitution on the benzimidazolone, chemical space available around the ethyl 
diamine linker, and experimented with modifications or substitutions to the amide 
cap in the eastern portion of the molecule.  Overall potency was almost always 
enhanced with halogen substitution of the scaffold, but the most significant 
increase in the potency of PLD1-selective compounds was afforded by bromo 
rather than chloro substitution of the 5-position on the benzimidazolone. There is 
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no flexibility in the length or size of constituents on the linker region.  The S-
methyl group continued to elicit PLD1 selectivity regardless of scaffold or amide 
cap identity. Finally, screening for optimal amide cap elements identified that the 
racemic transphenyl cyclopropane enhanced PLD1 selectivity over the diphenyl 
cap present in halopemide.  Taken together, these modifications enhance PLD1 
selectivity and potency (figure 16).  These modifications yield VU0359595, our 
best PLD1-selective compound to date that has sub nanomolar potency and 
1700-fold selectivity for PLD1 (in cells PLD1 IC50=3.7nM versus PLD2 
IC50=6.4μM). 
In contrast to PLD1-selective inhibitors, which were identified from direct 
modifications of the halopemide lead compound, potent PLD2-selective 
compounds were more elusive.  From the initial screen for isoform-selective 
compounds the triazaspirone appeared to be a suitable alternative to the 
benzimidazolone scaffold that elicits PLD2-selectivity.  However, the fold 
selectivity was not impressive, so in the subsequent SAR characterization, varied 
amide caps were screened.  Substitutuion of a 2-quinoline amide congener yields 
increased PLD2 potency and selectivity (IC50=90nM and 21-fold PLD2 selective). 
Further screening identified halogen substitution of a fluoro-group on the 
triazaspirone scaffold, which yields increased PLD2 potency and selectivity.  This 
compound (VU0364739) at 75-fold PLD2-selective is the most selective and 
potent PLD2-selective compound reported to date (figure 17). 
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Figure 16. The progression from halopemide, a 14-fold PLD1-selective inhibitor, to 
VU0359595, a 1700-fold PLD1-selective inhibitor.  Functional groups shown in red 
conferred significant PLD1 selectivity (figure from [19]). 
 
 
 
 
Figure 17. The progression from halopemide (21) to VU0364739 (36), a potent 75-fold 
PLD2-selective inhibitor.  Functional groups shown in blue conferred significant PLD2 
selectivity (figure from [19]). 
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Initial demonstration VU-series inhibitors act directly 
Extensive SAR characterization has been performed using the 
biochemical liposome assay as a means of demonstrating that the compounds 
act directly to inhibit enzyme activity.  Use of this assay in the initial screening is 
essential to confirm the compounds are not acting to inhibit activity through an 
upstream activator, as is possible when testing efficacy in the cell based assay 
alone.  Such is the case for other reported PLD inhibitors that act indirectly, such 
as honokiol and resveratrol.  However, the basal activity of full length PLD1 is 
very low, and to get the activity within the linear range of the biochemical assay 
the protein activator myristoylated Arf1 GTPase was included in every condition 
(including PLD2 screens for consistency).  Therefore, it was important to 
demonstrate that these compounds inhibit PLD activity through direct interaction 
with the protein and not through the activator. For these studies an amino 
terminally-truncated form of PLD1, called PLD1.d311 (illustrated in figure 18) was 
used.  PLD1.d311 can be purified to homogeneity and has significantly higher 
basal activity. Concentration response curves were generated using this 
truncation construct for two representative benzimidazolone-containing 
compounds in order to compare compound potency for basal versus Arf-
activated activity.  There is no shift in potency of the VU-series PLD inhibitors, 
demonstrating these compounds are acting directly to inhibit the enzyme. 
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B
C
 
Figure 18.  Direct small molecule inhibition of PLD.  Schematic representation of 
truncated PLD1.d311 cosntruct (A).  In vitro concentration response curves for two dual 
isoform compounds demonstrating direct inhibition of purified PLD1.d311 basal or myr-
Arf-1-stimulated activity (B).  The protein used for these studies was of high purity, as 
demonstrated with colloidal-stained SDS-PAGE gel (C) (figure from [290]). 
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A second possibility for how the inhibitors could be blocking PLD activity is 
through indirectly perturbing the liposome or lipid interface, such as partitioning 
into the lipid vesicle surface to impede access to substrate.  Although we have 
demonstrated that the compounds do in fact partition into the liposome 
dependent on mole% PC (Milne, Selvy, and Brown, unpublished data), we used 
both scPLD (non HKD) and PMF PLD (HKD) and showed that these enzymes 
are not inhibited by the VU-series compounds (inhibition does occur in some 
cases at very high concentrations of compound, >10uM).  Lack of inhibition 
towards these bacterial enzymes demonstrates that these compounds do not 
non-specifically inhibit non mammalian PLD enzymes, and do not disrupt 
substrate access or interface architecture.   
The specificity of these compounds taken together with their ability to 
directly inhibit a highly purified amino-terminally truncated mammalian PLD 
demonstrates that the compounds allosterically inhibit the enzyme at a site that 
does not require the presence of the amino terminus.  It is important to note that 
the potency of the compounds is shifted rightward for PLD1.d311, which may 
suggest a second compound binding site in the amino terminus, or that the 
amino terminus enhances potency through conformational change or provide 
support or stability to the small molecule binding site.  The small molecule 
binding site and mechanism of action for these inhibitors is further addressed in 
chapter III. 
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Cellular ramifications for use of VU-series PLD inhibitors 
Since the first report of the halopemide and VU-series PLD inhibitors, 
several groups have gone on to demonstrate their utility in studying the signaling 
roles for PLD.  Other members in our group have demonstrated this class of 
compounds is of potential therapeutic value in blocking invasive migration, 
decreasing  cancer cell viability, and inducing apoptosis.  In the initial report of 
the VU-series compounds, our lab demonstrated that invasive migration was 
significantly blocked for three highly metastatic cancer cell lines (MDA-MB-231, 
mouse metastatic breast cancer 4T1, and PMT mammary tumors).  Using the 
first generation of VU-series PLD inhibitors, both dual and isoform-selective 
compounds significantly decreased invasive migration at high concentrations (2-
20μM).  Recent studies using more potent and isoform-selective compounds 
demonstrate a time and dose-dependent decrease in proliferation and cell 
viability, particularly for the PLD2-selective inhibitors.  The decrease in viability is 
enhanced under conditions of cell stress (e.g. serum-starvation), and the results 
are more significant for transformed versus non transformed cells.  Increased 
apoptosis was also observed for cancer cells, as measured by caspase 3 and 7 
activation.  Taken together, these results suggest transformed cells rely heavily 
on PLD signaling for viability and proliferation, as other signaling pathways may 
not be intact.  Thus preliminary studies suggest the VU-series PLD inhibitors may 
be effective therapeutically as anti cancer compounds. 
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Chapter III 
 
 
 
 
MOLECULAR MECHANISM OF ISOFORM-SELECTIVE 
PHOSPHOLIPASE D INHIBITORS 
 
 
 
 
Phosphatidic acid (PA) is a critical lipid second messenger that not only 
facilitates lipid bilayer curvature for membrane fusion, but also serves as a node 
for the recruitment and activation of signaling proteins at the plasma membrane 
and is a precursor to diacylglycerol and lysophosphatidic acid.  These varied 
roles put PA at the intersection of cell signaling and metabolic pathways.  PA is 
generated in response to receptor stimulation by phospholipase D (PLD) 
hydrolysis of phosphatidylcholine (PC) at the terminal phosphodiester bond.  PLD 
activity is tightly regulated by a myriad of mechanisms that differ between the two 
canonical mammalian isoforms PLD1 and PLD2.  PLD1 is directly activated by 
PKC, Arf and Rho GTPases and is basally localized to perinuclear, endosomal, 
and Golgi vesicles via protein-protein interactions at its Phox homology (PX) 
domain and palmitoylation in the PH domain [188].  PLD2 maintains higher basal 
activity and is constitutively localized at the plasma membrane.  Upon activation 
PLD translocates to late golgi vesicles and the plasma membrane where it binds 
at the lipid interface to access phospholipid substrate.  Multiple protein domains 
define PLD-lipid binding interactions (Ks) and control translocation and 
subsequent internalization.  PX (aa 79-209) and pleckstrin homology (PH, aa 
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220-328) lipid binding domains at the amino-terminus promiscuously bind 
polyphosphatidylinositols and negatively-charged phospholipids.  These domains 
are also predicted to elicit regulatory functions that may dictate differences in 
isoform subcellular localization, activity, and protein-protein interactions.  There 
are also reports of a conserved PI(4,5)P2 binding motif that lies between the 
conserved catalytic H(x)K(φ)4D motifs and facilitates translocation to PI(4,5)P2-
containing membranes and catalytic activity.   
Until recently it has not been possible to acutely and pharmacologically 
inhibit PLD catalytic activity in order to study its enzymology and specific function 
in cell signaling pathways.  Historically, RNAi and primary alcohols have been the 
only tools available. RNAi knocks down PLD protein production over a short 
period of time allowing for compensation within signaling pathways, while 
treatment with primary alcohol merely diverts product formation to 
phosphatidylalcohol.  Primary alcohols exploit the transphosphatidylation reaction 
characteristic of PLD-family members, in which the primary alcohol is the 
preferred nucleophile to water during substrate hydrolysis.  Recently, in response 
to the void in the field, we reported identification and characterization of a class 
of small molecules that potently and isoform-selectively inhibit PLD activity, 
called VU-series compounds (chapter II) [290].  Structure-activity relationship 
characterization of this class lead to the development of compounds that are 
>1700-fold PLD1-selective[292], and >75-fold PLD2-selective [291] to use as 
tools in delineating the distinct signaling roles of each isoform.  Subsequent 
studies, in our own lab and in others, using these small molecule inhibitors have 
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yielded different results from those published using primary alcohols [79], [237].  
This suggests that either the roles of PLD as discerned using primary alcohols 
have been widely overstated, or the mechanism of action of these small molecule 
PLD inhibitors extends beyond inhibiting PA formation. To address this 
discrepancy, we used backscattering interferometry (BSI), a highly sensitive and 
novel method for measuring protein-small molecule and protein-lipid binding 
affinities, to characterize the mechanism of action of these small molecule PLD 
inhibitors. For these studies we focus our characterization on the mammalian 
PLD1 isoform, and propose that a similar molecular mechanism also applies to 
VU-series-compound mediated PLD2 inhibition.   
Here we demonstrate that these compounds directly target PLD1 and 
allosterically block lipid binding and catalytic activity.  These in vitro findings are 
confirmed with cellular studies demonstrating that these compounds do not 
perturb basal PLD1 localization, but block stimulated enzyme translocation.  This 
is a unique and underappreciated mechanism for inhibiting a lipid signaling 
enzyme, and is akin to the mechanism recently reported for an allosteric  
pharmacological inhibitor of Akt, Inhibitor VIII [293], [294]. 
 
 
Backscattering interferometry measures protein-ligand interactions 
PLD is an interfacial enzyme that must bind at the lipid surface (S, figure 
2) prior to binding and hydrolyzing substrate.  As such, the nature of the lipid 
interface has a great impact on the binding affinity for the lipid surface (1/Ks), 
accessibility and affinity for substrate (Km), and catalytic activity of the enzyme  
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Figure 19.  Backscattering interferometry (BSI) technique optimized for measuring 
protein-small molecule and protein-lipid binding affinities  (figure modified from[295]). 
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(kcat). Therefore, it was important to determine whether these small molecules 
were eliciting inhibition through direct interaction with soluble/non-lipid bound 
enzyme, or indirectly influencing the lipid interface, as is the case for neomycin 
[296] and tamoxifen [297] (unpublished data Selvy and Brown), or potentially 
selectively binding to interfacially-bound enzyme (Es), as is the case for some 
PLA2 inhibitors [298].  BSI has been validated as a method for measuring 
picomolar receptor-ligand binding affinities using nanomolar concentrations of 
protein [295], [299], [300], and was used here to measure protein-small molecule 
binding affinities for PLD1.  In contrast to isothermal titration calorimetry (ITC) 
and surface plasmon resonance (SPR), binding affinities can be measured using 
BSI in a microliter-scale format for untagged protein free in solution.  In this 
technique, a laser is reflected and refracted through a sample contained within 
the channel of a microfluidic chip and an interference pattern is created.  The 
interference pattern consists of a specific set of well defined fringe spots, and a 
shift in the fringe spots correlates to a change in refractive index due to a change 
in salvation of a protein upon ligand binding (i.e. change in protein conformation).  
A shift in fringe spots is quantified as a change in phase of a wave function using 
Fourier transform.  The phase is measured for any set of samples and then 
graphed as the absolute change in phase relative to a control sample upon 
increasing ligand concentration.  
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Development of novel human PLD1 construct facilitates in vitro studies 
To ensure phase changes, as recorded by BSI, are due to bimolecular 
interactions between PLD1 and small molecule, highly purified recombinant 
protein was necessary.  Recombinant expression of full length PLD1 is poor and 
because of the myriad of protein binding partners, full length protein remains a 
heterogeneous population following multiple chromatographic purification steps.  
Therefore several robustly expressed and homogenously-purified truncation 
constructs of PLD1 were used to demonstrate direct bimolecular interactions.  In 
our earlier report [290]  we demonstrated that the VU-series compounds could 
inhibit an amino-terminally-truncated rat PLD1 construct lacking the first 311 
amino acids.  This construct comprises a truncation of the PX and PH domains, 
leaving 16aa of an alpha-helix at the C-terminus of the PH domain that is 
necessary for lipid binding (Henage, Selvy, and Brown, unpublished data).   
For more rigorous mechanistic characterization of these VU-series 
compounds, however, we chose to study human PLD1.   Characterization of 
human PLD1 splice variants using cDNA libraries detected a poorly studied 
PLD1c form. This PLD1 splice variant was initially reported by Steed et al. [173] 
as a shortened protein whose transcript contains a single nucleotide deletion that 
results in a frame shift in protein translation.  In nature, the PLD1c frame shift 
results in an early stop codon and a protein that is truncated following the first 
HKD motif (figure 20).  Insertion of a single nucleotide corrects the frameshift and 
results in a catalytically active 2 HKD PLD enzyme with an 18 amino acid stretch 
of residues in the catalytic loop region.  The shorter catalytic loop region,  
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Figure 20.  Illustration of the domains of the human PLD1 splice variants. 
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as compared to the loop regions found in PLD1a and PLD1b splice variants, 
facilitates robust recombinant expression, enhanced protein stability, and 
straightforward chromatographic purification. Corrected PLD1c maintains all the 
same biochemical and cellular characteristics of the natural PLD1a and PLD1b, 
including protein-activator response and robust receptor-stimulation. 
 
VU-series PLD inhibitors directly interact with enzyme 
Using BSI and silver-stain pure preparations of the amino-terminally 
truncated PLD1c splice variant, referred to here simply as PLD1.d311, we 
demonstrate this construct directly binds the compounds in a one-site binding 
model in the absence of lipid (figure 21).  The Ki for benzimidalozone-containing 
small molecules (VU0155056 and VU0359595) was similar to IC50s measured for 
respective compounds in the biochemical liposome reconstitution assay.  
Because the affinities and potencies for the benzimidalozone-containing 
compounds are similar for their respective compounds, we conclude that these 
compounds are acting directly on the enzyme and not indirectly inhibiting activity 
by disrupting access to PI(4,5)P2 or substrate at the lipid interface. 
 
Small molecule PLD inhibitors block lipid binding 
PLD‟s phospholipid substrate is located at a lipid interface and is not freely 
soluble, therefore classic Michaelis-Menten assumptions do not apply.  In order 
to study PLD kinetics and the mechanism of action for these small molecule 
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Figure 1. PLD1c.d311 directly binds VU-series PLD inhibitors to inhibit catalytic activity.
 
Figure 21. PLD1c.d311 directly binds VU-series PLD inhibitors to inhibit catalytic activity.  
A, Structures of VU-series small molecule PLD inhibitors  B, Ki small molecule binding 
affinities were measured for two representative benzamidazolone-scaffold VU-series 
PLD inhibitors (VU0155056 and VU0359595) using BSI. These compounds directly bind 
to purified PLD1.d311 (aa 312-966) with similar binding affinities (Ki) to IC50 values 
measured from concentration response curves using a reconstituted liposome activity 
assay. 
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inhibitors, the interfacial binding affinity must first be measured (figure 2, Ks), and 
subsequent studies must saturate lipid binding in order to apply Michaelis-
Menten assumptions.  Historically, intricate and imperfect methods have been 
applied to measure Ks (FRET and lipid binding “strips” of immobilized lipid).  
Despite its resource and time-consuming nature, the sucrose-loaded vesicle 
(SLV) binding assay[72] has been the standard method for measuring 
cosedimentation of protein with increasing concentrations of bulk lipid.  Using a 
defined vesicle composition (87%mol PE, 8%mol PC, 5%mol PI(4,5)P2), 
PLD1.d311 cosedimentation was measured for increasing bulk lipid 
concentrations (figure 22a). The Ks value derived from the SLV assay was then 
compared to the Ks value obtained using BSI as a means of measuring protein-
lipid binding (figure 22b).  Using a similar vesicle compostion, phase change was 
measured for PLD1.d311 with increasing concentrations of extruded large 
unilamellar vesicles (LUV).  Similar Ks values were obtained for both methods, 
validating the use of BSI as a novel and highly efficient method for measuring 
protein-lipid binding.   
Regardless of assay method, the PLD1-selective small molecule inhibitor, 
VU0359595, noncompetitively blocked bulk lipid binding at absolute inhibitory 
concentrations (10μM).  Reports in the literature propose PI(4,5)P2-dependent 
binding at a polybasic region in the catalytic domain is solely responsible for PLD 
translocation to the plasma membrane.  Therefore, it was important to determine 
whether the in vitro lipid binding measured here was PI(4,5)P2 -dependent.  
Protein lipid binding was measured for vesicle compositions lacking PI(4,5)P2.  
 134 
 
Despite the fact that Ks was significantly shifted to the right in its absence, bulk 
lipid binding (and catalytic activity, data not shown) was detectable and saturable 
without PI(4,5)P2 (figure 22c).  In fact, bulk lipid binding also occurs in the 
absence of PC or PE, the preferred and secondary substrate, respectively, as is 
found when measuring Ks for PG-only vesicles.  PG is not a substrate as 
confirmed by LC/MS (Milne, Selvy, and Brown, unpublished data).  For each 
vesicle composition VU0359595 noncompetitively blocked bulk lipid binding 
(figure 22c).  From these studies we conclude in vitro PLD binds and hydrolyzes 
lipid in the absence of PI(4,5)P2, and the small molecule PLD inhibitor non 
competitively blocks this interaction regardless of lipid vesicle composition. 
In order to demonstrate that these small molecules do not nonspecifically 
disrupt interfacial binding for other lipid binding proteins, we also measured VU-
series interactions with phospholipase C delta 1 (PLCδ1, provided by Ken 
Harden‟s lab), a well characterized phospholipase which binds PI(4,5)P2 with 
high affinity via its PH domain in order to hydrolyze PI(4,5)P2.  In the absence of 
lipid, VU0359595 does not interact with or bind PLCδ1, and protein-lipid binding 
is not perturbed due to the compound (figure 22d).  The absence of any 
interaction with an unrelated phospholipase demonstrates that the VU-series 
compounds do not nonspecifically perturb protein-lipid binding. The non 
competitive disruption of PLD-lipid binding, regardless of lipid identity, suggests 
these compounds are allosterically impacting a hydrophobic phospholipid binding 
site on the catalytic domain likely through inducing a significant conformational 
change. 
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Figure 22. VU-series PLD inhibitors block bulk lipid binding regardless of lipid interface 
composition.   Bulk lipid binding was measured for purified PLD1.d311 using the classic 
sucrose-loaded vesicle technique (A), and backscattering inerferometry (B). These 
techniques give similar Ks, validating the BSI technique, and demonstrating that the 
small molecule inhibitor blocks bulk lipid binding.  C, PLD1.d311 bulk lipid binding was 
measured for varied lipid vesicle compositions omitting PI(4,5)P2 and substrate (PC and 
PE).  Regardless of lipid vesicle composition, inhibitory concentrations of VU0359595 
continue to noncompetitively disrupt bulk lipid binding. Inhibition of bulk lipid binding is 
not mediated through indirect disruption of the interface as the VU-series compounds 
do not nonspecifically bind PLCδ1, another lipid binding protein (D), and do not perturb 
PLCδ1 bulk lipid binding (E). 
 136 
 
 
VU-series compounds inhibit catalytic activity  
in the absence of a lipid interface 
 
Subsequent to demonstrating that the VU-series compounds allosterically 
disrupt lipid binding, it was important to interrogate whether the small molecules 
perturbed catalysis for substrate not present at an interface. PLD activity was 
monitored in the absence of the lipid binding component (Ks) by measuring 
hydrolysis of monomeric 14:0 PC (used below the critical micelle concentration) 
via direct and indirect techniques (i.e. LC/MS or amplex red reagent, 
respectively).  Concentration response curves of VU0359595 generated for 
different substrate presentations (e.g. lipid-bound (32:0 PC) or monomeric 14:0 
PC) were comparable for PLD1.d311 and full length PLD1 (figure 23a and b, 
respectively).  IC50‟s are similar for in vitro concentration response curves 
generated using these different assay formats, demonstrating VU0359595 
potency is unchanged regardless of substrate presentation.  This suggests that 
the VU-series compounds mediate inhibition not only by blocking lipid binding but 
also through inhibiting catalytic activity.  Soluble monomeric PC allows 
measurement of catalysis in the absence of the lipid binding component, which 
ultimately allows for Michaelis-Menten kinetic analysis.  Upon increasing 
substrate concentration, the activity of PLD1.d311 was measured in the presence 
of vehicle or constant concentrations of VU0359595 (near the IC50= 0.25μM, and 
well above= 10μM; figure 23c).  In both VU0359595-treated cases, catalysis was 
decreased from that of vehicle-treated, and increases in substrate could not 
compete for its inhibitory effect. This demonstrates that the compounds non  
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Figure 23. VU-series compounds inhibit PLD1.d311 activity regardless of substrate 
presentation.  VU035959 inhibits PLD1.d311 (A) and full length PLD1c (B) with the same 
potency regardless of substrate presentation, as determined from concentration 
response curves in liposome and monomeric substrate assays.  C, VU-series compounds 
do not compete for substrate binding, as determined using an Amplex Red assay with 
varied monomeric substrate (14:0 PC) concentrations for VU0359595 near Ki (0.25uM) 
and >>Ki (10uM). This demonstrates the VU-series compounds inhibit catalytic activity at 
a site allosteric to the substrate binding site. 
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competitively inhibit catalytic activity by directly interacting with the enzyme at a 
site allosteric to the substrate binding pocket. 
 
Protein truncation constructs illuminate the small molecule binding site 
Following demonstration that the compounds directly interact with 
PLD1.d311 to disrupt both protein-lipid binding and catalytic activity, we went on 
to determine the allosteric site of small molecule interaction.  Using several 
protein truncation constructs composed of lipid binding or catalytic domains, we 
measured small molecule binding affinities (illustrated in figure 24b).  These 
studies allowed us to narrow the small molecule binding site to a previously 
uncharacterized region of PLD1 that lies between the PH and catalytic domains.  
This stretch encompasses amino acids 329-352 and is predicted to be a loop 
region, which because of its proximity to the PH and catalytic domains is 
hereafter called the linker loop.   
A catalytic domain construct lacking the PXPH domains and the entire 
linker loop (PLD1.d352) is inactive towards liposomal substrate but can hydrolyze 
monomeric substrate.  As measured in the amplex red reagent assay using 
monomeric substrate, PLD1.d352 catalytic activity is not inhibited by VU0359595 
(figure 24c). Also, this construct does not directly interact with the small molecule 
as determined by BSI (figure 24a).  The inhibitor resistant nature of PLD1.d352 in 
conjunction with data from PLD1.d311 suggested that the region encompassing 
amino acids 311-352 were critical for small molecule efficacy.  
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In our first report on the VU-series compounds we described a 3 to 24-fold 
shift in potencies of the VU-series inhibitors between full length PLD1 versus 
PLD1.d311[290].  This suggested the PLD1.d311 truncation construct lacked a 
portion of the small molecule binding site or lacked a second small molecule 
binding site.  To better understand these discrepancies in IC50s we used purified 
amino-terminal constructs encompassing the PX and PH domains (aa1-375, aa1-
329) and used BSI to measure Kd for the benzimidalozone compound 
VU0359595 (figure 24).  Truncation construct PLD1.PXPH aa1-375 directly 
interacts with the small molecule, but does so in a two-site binding model 
(p=0.0003 for two-site over one-site model) with a high affinity and low affinity 
binding site.  The shortened construct PLD1.PXPH aa1-329, which lacks the 
linker loop region (residues 329-352), also directly interacts with the small 
molecule, but does so in a one-site binding model with a single low affinity 
binding site. Consistent with truncation data from the catalytic domain, 
differences in VU0359595 binding for the PXPH constructs suggest the high 
affinity binding site lies within the linker loop region. Based on the somewhat 
hydrophobic nature of the VU-series compounds it is not surprising that a low 
affinity binding site remains for the PXPH construct even in the absence of the 
linker loop.  This second site of small molecule interaction may be at one of  
several remaining lipid-binding hydrophobic patches on the protein surface, or 
may loosely contribute to the tertiary small molecule binding site in the full length 
enzyme.  However, as the affinity observed for the low affinity binding is well 
outside of the range that elicits potent isoform-selective inhibition of PLD1, we 
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Figure 24. Truncation constructs suggest VU-series PLD inhibitors directly bind PLD in a 
loop region C-terminal to the PH domain.  A, Using BSI, small molecule binding affinities 
were measured for several PLD1c truncation constructs. VU0359595 directly binds 
PLD1.PXPH aa 1-375 at two distinct sites, only one of which is high affinity. PLD1.PXPH 
aa 1-329 only encompases the lower affinity binding site. PLD1.311 binds VU0359595 
with high affinity, while PLD1.d352 does not bind the compound. B, Cartoon alignment 
of conserved domains within these truncation constructs illustrates that PLD1.PXPH aa 
1-375 and PLD1.d311 overlap at a region C-terminal to the PH domain, while PLD1.PXPH 
aa 1-329 and PLD1.d352 do not include this region.  This suggests this site encompasses 
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the VU0359595 high affinity binding site. C, To further demonstrate that this region 
encompasses the binding site we examined the activity of PLD1.d352 +/- VU0359595. 
This construct retains catalytic activity towards monomeric substrate, but VU0359595 
does not inhibit activity. 
 
propose that this second site does not contribute to the mechanism of small 
molecule inhibition and is not relevant for further analysis in these studies.  
An important observation from the binding curves for these two PXPH 
constructs is the significant difference in Bmax (phase change).  As mentioned 
above, the phase measurement in BSI is essentially the refractive index of the 
protein-ligand solution.  Changes in refractive index are a measurement of 
change in protein solvation (i.e. protein conformation) upon protein-ligand 
binding.  Therefore, the larger the change in phase, the larger the predicted 
change in protein conformation upon ligand binding.  From PXPH binding curves 
it is evident that PLD1.PXPH 1-375 undergoes a significantly larger change in 
protein conformation upon small molecule binding than PLD1.PXPH 1-329.  
From these protein-small molecule binding studies, we conclude that these small 
molecule inhibitors directly interact with high affinity at the linker loop, a region of 
the protein encompassing amino acids 329-352 that has a predicted loop-like 
secondary structure, and subsequently undergo a significant change in 
conformation. 
 
Confirmation of small molecule binding site with point mutant constructs 
Upon further analysis of the linker loop (the region of predicted high affinity 
VU-series compound interaction) we observe a predicted loop region flanked by 
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more rigid structural elements (e.g. alpha-helices and a short beta sheet, figure 
25a).  Linker loop sequence comparison between PLD1 and PLD2 demonstrates 
some amino acid variability, while the predicted secondary structural elements 
are conserved.  SAR studies (chapter II) suggest these compounds bind at a 
similar site on the two isoforms, but certain chemical modifications of the 
compounds are able to dial in selectivity by taking advantage of some unknown 
differences in the specific isoform binding site.  Comparison of the linker loop 
sequence for PLD1 and PLD2 highlights a few conserved residues that may be 
integral for VU-series compound binding.  To secondarily confirm the linker loop 
is the site of VU-series compound binding, these conserved residues (shown in 
purple in figure 25) were systematically point mutated to alanines in the full 
length PLD1c enzyme.  The potency of VU0359595 was subsequently measured 
for each mutant in vitro. From these studies, His338Ala and Trp354Ala mutations 
significantly decreased the potency of VU0359595, but did not ablate inhibitory 
action.  Therefore, a dual mutant in which both His338 and Trp354 were mutated 
to alanines was generated and assessed for inhibitor resistance using several 
methods.  The small molecule binding affinity of PLD1.PXPH 1-375 H338A, 
W354A was compared to PLD1.PXPH 1-375 S342A (a mutation which yields no 
shift in VU0359595 potency) and wildtype PLD1.PXPH 1-375.  Consitent with 
S342A mutation not impacting VU0359595 potency in the full length enzyme, 
PLD1.PXPH 1-375 S342A demonstrated a two-site binding model (p<0.0001) 
with large change in phase similar to wildtype PLD1.PXPH 1-375.  However, 
mutation of both H338A and W354A significantly alters the binding curve profile 
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(figure 25b).   This double mutant construct yields a single low affinity binding site 
with a small change in phase, comparable to the PLD1.PXPH 1-329 construct 
that entirely lacks the linker loop.  This binding data is consistent with the 
suggestion that His338 and Trp354 contribute to the small molecule binding site 
in the linker loop.    
In order to demonstrate that the double mutation of both His338 and 
Trp354 does not significantly alter the folding of the enzyme and non specifically 
alter VU0359595 affinity, we measured PLD activity for this construct transfected 
into an HEK293 cell.  Following serum-starved conditions, cellular PLD activity 
was measured for vector, wildtype PLD1c, and PLD1c H338A, W354A.   
Although double mutant activity is ~30% of the wildtype activity (consistent with 
preliminary in vitro studies of the double mutant) this activity is measureable 
above vector control, suggesting that the protein is correctly folded and a viable 
construct to test for inhibitor resistance.  An inhibitory concentration of 
VU0359595 does not affect double mutant activity (figure 25c).  This cell based 
activity data is consistent with the PXPH binding experiments demonstrating that 
His338 and Trp354 are integral for high affinity small molecule binding, as 
mutation of these residues generates inhibitor resistant PLD activity.  In vitro 
studies will further demonstrate that these conserved residues in the linker loop 
are integral components of the high affinity binding site for the VU-series 
compounds. 
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Figure 25. Point mutations confirm VU-series PLD inhibitors directly bind PLD in a loop 
region C-terminal to the PH domain. A, Closer analysis of the protein sequence in the 
linker loop for both human PLD1 and PLD2 isoforms demonstrates a conserved pattern 
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of predicted secondary structure (PredictProtein) and conserved residues (shown in 
purple, numbered residues correspond to PLD1 sequence) in a region predicted to be a 
loop (shown in green). B, An  H338A, W354A double mutant was generated to ablate 
the high affinity binding site. This double mutant was generated in PLD1.PXPH aa 1-375, 
and VU0359595 binding was measured using BSI to demonstrate that the high affinity 
binding site was ablated, similar to the PLD1.PXPH aa 1-329 construct that lacks the 
linker loop region entirely.  An inert mutation (S342A) that does not shift the potency of 
VU0359595 also does not perturb high affinity binding. C, The H338A, W354A double 
mutant was generated in the full length PLD1c.  While the overall activity of the double 
mutant is decreased as compared to wildtype, resistance to VU0359595 is observed for 
double mutant activity as measured in the cell.  This data taken as a whole confirms the 
linker loop contributes to the high affinity small molecule binding site. Western blot 
analysis was used to demonstrate similar transcription efficiency and protein expression 
of the strep-tagged PLD1c constructs, anti-actin demonstrates equal loading between 
lanes. 
 
 
Small molecule PLD inhibitors block cell signal-mediated translocation 
Subcellular protein localization studies were performed to test conclusions 
from the in vitro studies in a cellular context.  EGFP-tagged PLD1 was 
transfected into Cos7 cells, 24 hours later cells were serum-starved, and the 
following day visualized with live-cell fluorescent-microscopy.  Basal localization 
was observed following 5 minute pre-treatment with vehicle or 10μM VU0359595, 
while stimulus-induced translocation was demonstrated following 1 hour 
treatment with phorbol ester.  In the presence of vehicle, EGFP-tagged PLD1 is 
basally localized to perinuclear membranes and early endosomes (not nucleus 
as determined by DAPI-stain, figure 26).  This is consistent with basal localization 
of PLD1 previously reported in Cos7 cells.[188]  Upon stimulation with 1μM PMA 
(figure 26) or 10-20%serum (not shown), the protein is observed to translocate to 
plasma membrane or late endosomes, respectively, for stimulation types.[188] 
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Basal localization of EGFP-tagged PLD1 is unchanged in the presence of 
VU0359595.  This observation is consistent with other reports in the literature 
that claim protein-protein interactions and palmitoylation-modifications mediated 
by the PXPH domain control basal localization of PLD1 in Cos7 cells rather than 
protein-lipid interface interactions[188].  However in the presence of VU0359595, 
upon cellular stimulation EGFP- tagged PLD1 translocation to late endosomes or 
the plasma membrane is blocked.  This observation is consistent with in vitro 
data presented herein, where interaction between PLD and lipid interface is 
blocked in the presence of the inhibitor.  Truncation studies suggest the high 
affinity small molecule binding site lies in the linker loop (a loop region C-terminal 
to the PH domain and N-terminal to the start of the catalytic domain).  Cellular 
data suggests that small molecule binding does not perturb protein-protein and 
palmitoylation-mediated interactions known to maintain basal PLD1 localization, 
but likely results in a conformational change that inhibits general bulk lipid 
binding (both PI(4,5)P2- and non PI(4,5)P2-mediated interactions). Therefore VU-
series compounds inhibit PLD in a bimodal format through binding with high 
affinity at the linker loop.  These compounds disrupt both cell stimulation-induced 
translocation to the plasma membrane and catalytic activity. 
 
Model of VU-series compound mechanism of inhibition 
These studies define the binding site and mechanism of action for the 
potent and isoform-selective VU-series PLD inhibitors.  Using BSI, a novel and 
highly sensitive method for measuring bimolecular interactions, we demonstrate  
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Figure 26. PLD1 basal localization is unperturbed, but stimiulus-induced  translocation is 
blocked by treatment with 10μM VU0359595. 
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that the VU-series compounds directly interact with purified PLD1 enzyme at a 
defined loop region resulting in non competitive inhibition of protein-lipid interface 
interaction, regardless of the interface composition.  Through binding at this 
single high affinity binding site these compounds also allosterically inhibit 
catalytic activity towards monomeric substrate.  Cellular protein localization data 
supports this mechanism, demonstrating that while basal localization of PLD1 is 
undisturbed by inhibitory concentrations of VU0359595, stimulation-induced 
translocation of the protein is inhibited.  These results are consistent with reports 
that protein-protein or palmitoylation mediated interactions maintain basal protein 
localization, while lipid interactions are important for stimulation-induced 
translocation to the plasma membrane and late endosomes.    
The biochemical data herein demonstrates VU-series compounds directly 
interact with the enzyme at a high affinity binding site within a loop region at the 
junction between the PH domain and the start of the catalytic domain.  This 
previously uncharacterized region of the enzyme, herein called the linker loop, 
shares little homology with a loop region at the N-terminus of the Streptomyces 
PMF PLD and Streptomyces antibioticus PLD catalytic domains. Through binding 
at this allosteric site, this class of compounds has tapped into a previously 
unappreciated regulatory region of the protein that is both specific for mammalian 
PLD (as bacterial enzymes are unaffected by these compounds) and can be 
exploited to elicit isoform selectivity.  With the composite biochemical and cellular  
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Figure 27. Model of the molecular mechanism of action for the VU-series PLD 
inhibitors. The VU-series compounds directly bind PLD at a loop region C-terminal to the 
PH domain to allosterically block both bulk lipid interface interaction and catalytic 
activity. This is similar to the mechanism of action recently described for the Akt I/II 
inhibitor, in which small molecule binds at the interface of the PH lipid binding and 
catalytic domain.  This induces a closed protein conformation that prevents 
translocation to the lipid interface as well as catalytic activity.  
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data we propose a mechanism of action for the VU-series compounds (figure 27) 
in which the small molecule directly binds the enzyme at this linker loop resulting  
in a significant conformational change that inhibits both interfacial interactions 
(e.g. translocation to plasma membrane) and catalytic activity.   
This proposed mechanism is similar to that recently described for a small 
molecule inhibitor of Akt, a serine/threonine kinase that is activated downstream 
of the PI3K pathways.  Similar to the domain structure for mammalian PLD, Akt 
consists of an N-terminal PH domain, bilobal kinase domain, and C-terminal 
hydrophobic motif (HM).  This enzyme is basally localized in the cytosol but upon 
PI3K activation Akt translocates to the plasma membrane where it binds PIP3 via 
its PH domain.  At the plasma membrane Akt is subsequently activated by two 
sequential phosphorylation events: PDK1 phosphorylates Akt at threonine 308 (in 
the activation loop), and mTORC2 subsequently phosphorylates Akt at serine 
473.   Orthosteric and allosteric inhibitors of Akt have been described that block 
kinase activity through divergent mechanisms.  Orthosteric inhibitors include pan- 
kinase inhibitors that bind at the active site in an ATP-competitive manner.  
These compounds do not affect PH-mediated translocation to the plasma 
membrane, and therefore leave the compound in what is termed the PH-out 
conformation (figure 28a).  Allosteric inhibitors of Akt, including the dual Akt 1/2 
inhibitor, inhibitor VIII, block catalytic activity by binding at the interface of the PH 
and kinase domain, inducing a PH-in conformation (figure 28b).  As visualized in 
a recent crystal structure of this protein-compound complex[294], the 
benzimidazolone scaffold of inhibitor VIII binds in a cavity within the PH domain  
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Figure 28. Crystal structures demonstrating the mechanism of orthosteric or allosteric 
Akt inhibition.  A, ATP-competitive inhibitors (orange) bind in the orthosteric site 
alongside the catalytic loop (red).  These inhibitors merely compete for ATP, and do not 
change the overall conformation of the enzyme. In this PH-out conformation, the PH 
domain (green) is still accessible for PIPn binding (shown bound to IP4 in this crystal 
structure) and the activation loop harboring Thr308 in the kinase domain is accessible 
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for phosphorylation.  B, Allosteric inhibitors of Akt, such as inhibitor VIII, bind at the 
interface of the PH and kinase domains.  This locks the enzyme in a PH-in conformation 
in which the PH domain is inaccessible from binding PIPn and the activation loop (not 
shown in this structure) is shielded by the PH domain. The significant difference in 
position of Trp80, integral for inhibitor VIII binding, is shown in both structures. 
 
 
and the eastern portion of the molecule locks the enzyme in a PH-in 
comformation that is mediated by hydrogen bonding, for which Trp80 is a notable 
contributor (as deletion of Trp80 generates an inhibitor resistant enzyme).[293]  
In vitro studies with recombinant full length Akt demonstrate that inhibitor VIII non 
competitively blocks PIP3 binding to the PH domain.[293] In cells inhibitor VIII 
does not change basal localization of Akt, but stimulus-induced translocation to 
the plasma membrane is blocked.   
Allosteric Akt inhibitors, including derivatives of inhibitor VIII such as 
MK2206, are proving highly beneficial as therapeutics.  Since these compounds 
specifically target Akt (unlike the pan-kinase ATP-competitive compounds) and 
allosterically prevent translocation to the plasma membrane by inducing a 
conformation in which the PH domain is inaccessible, these compounds are 
useful against many cancers in which Akt is found constitutively localized to the 
plasma membrane.  In these cancers a somatic mutation of glutamate 17 to 
lysine allows for PIP2 rather than PIP3 mediated translocation, bypassing PI3K 
signaling.   
The inhibitor VIII mechanism of inhibition is strikingly similar to the 
mechanism of action proposed here for VU-series PLD inhibitors. The VU-series 
compounds enable isoform-selectivity because they non competitively bind in an 
allosteric and previously-unappreciated regulatory region of mammalian PLD, 
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and as such render a novel means of inhibiting a lipid-modifying enzyme. We 
propose that, similar to the PH-in conformation observed following Akt-inhibitor 
VIII interaction, the VU-series compounds induce a significant conformational 
change in the enzyme that prevents both protein-lipid and protein-substrate 
interaction.  Preliminary evidence obtained by a postdoc in the lab (Sarah Scott) 
also supports this proposed conformational change.  A decrease in potency is 
observed for VU0359595 when a lyso-lipid substrate is used versus a diacyl 
substrate in the amplex red reagent assay.  This suggests that the 
conformational change in the active site sterically blocks access to bulky diacyl 
substrates, but less effectively prevents lyso lipid binding.  
We go on to propose that the molecular mechanism outlined here for 
PLD1 may also extend to the PLD2 isoform.  Rigorous SAR characterization 
supports the existence of a single high affinity small molecule binding site for 
both isoforms.  Preliminary in vitro data from several PLD2 constructs suggests 
the VU-series PLD inhibitors bind the enzyme in the linker loop.  BSI studies 
show that the compounds directly interact with PLD2.PXPH domains in a two-site 
binding model (one high affinity, and one low affinity site) and a catalytic domain 
construct similar the PLD1.d311 (called PLD2.d308, which maintains the lnker 
loop) is also inhibited by the VU-series compounds.  In contrast to the PLD1 
isoform, PLD2 is constitutively localized to the plasma membrane and maintains 
high basal activity.  Therefore it is possible that if a similar mechanism of 
inhibition applies to PLD2, different patterns of cellular localization might emerge 
(i.e. basal cellular localization to the plasma membrane may be perturbed). 
 154 
 
Further studies are necessary to thoroughly interrogate the mechanism of 
inhibition for PLD2 and possible differences in functional outcomes of VU-series 
compound use for each isoform. 
This report represents the first detailed mechanistic characterization of the 
VU-series PLD inhibitors.  Using the unique and highly sensitive BSI method for 
measuring binding affinities, these studies provide insight into the regulation and 
enzymology of mammalian PLD1.  These studies offer a unique model for 
targeting and inhibiting other lipid signaling enzymes. 
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Chapter IV 
 
 
 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
 
The PLD superfamily is a diverse collection of enzymes from multiple 
species that serve a varied range of functional roles and hydrolyze a range of 
substrates.  The common denominator to superfamily members is thought to be 
a conserved core structure of the catalytic domain that likely means these 
enzymes share a similar SN2 reaction mechanism for hydrolyzing phosphodiester 
bonds. Mammalian PLD serves multiple functional roles in cell signaling 
pathways highlighted in chapter I.  Aberrant mammalian PLD activity has been 
implicated in disease states including several cancers, neurodegenerative 
diseases, and thrombosis.  Recent studies with RNAi and knockout animals 
suggest PLD might be a good therapeutic target because healthy animals are 
unaffected with a single isoform knockout, but disease-related stress-mediated 
pathways that signal through PLD are perturbed, thereby ablating aberrant PLD-
mediated signaling, and preventing the disease-related phenotype.     
Efforts described in chapter II detail the identification and characterization 
of the VU-series PLD inhibitors, the first class of druggable PLD inhibitors 
specific to mammalian PLD that can selectively inhibit each isoform.  Rigorous 
SAR characterization describes the chemical space and components that elicit 
isoform selectivity.  The studies described in chapter III go on to characterize the 
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mechanism of action for the VU-series compounds. Assays using BSI were 
optimized and used to efficiently measure binding to demonstrate these 
compounds directly inhibit PLD in a noncompetitively bimodal manner. In cells 
this translates to PLD1 basal localization being unchanged, but stimulated 
translocation being blocked.  This cell-based data supports the biochemical 
studies detailed in chapter III and suggests some possible ramifications to using 
these compounds as tools to study PLD signaling.  In addition to blocking product 
formation, as is expected for an enzyme inhibitor, these compounds likely 
change protein-protein interactions that occur at the plama membrane thereby 
disrupting the role of PLD1 as a scaffolding protein.  It is important to be aware of 
the mechanistic effects of applying a small molecule to a whole-cell, and care is 
necessary when interpreting signaling results.  Others in the lab are following up 
on the effects of the VU-series inhibitors on known protein-protein interactions. 
Still to be characterized are protein structural changes that occur in 
response to small molecule binding.  NMR studies of small molecule binding in 
the linker loop, both alone and in the context of the PH domain, have been 
initiated in collaboration with Chuck Sanders.  Specific residues that are found to 
be critical for small molecule interactions may explain some of the isoform-
selective SAR that has been observed and point to other possible compound 
modifications that may icrease potency, selectivity, or broaden the chemical 
diversity of this class of compounds that may prove necessary as whole animal 
pharmacokinetic studies commence.  Ultimately a mammalian PLD protein 
crystal structure, both with and without inhibitor, will be necessary to truly 
 157 
 
understand the conformational changes that occur upon small molecule binding.  
These structures may further elucidate the molecular mechanism described 
herein.  However, given the position of the small molecule binding site and the 
noncompetitive bimodal mechanism of inhibition, it is proposed that the small 
molecule-induced conformational change results in a closed enzyme.  This is 
predicted to be similar to the Akt-inhibitor-induced conformational change where 
the N-terminal PH domain folds over the catalytic kinase domain preventing 
access to both lipid binding sites and the orthersteric site.  
In collaboration with Eric Dawson, homology modeling efforts are currently 
underway to model the mammalian PLD1 catalytic domain onto the 
Streptomyces bacterial PLD structures.  The linker loop has preliminarily been 
modeled into position in reference to the 1st HKD motif of the catalytic domain 
(figure 29), however this loop shares little homology with any sequence in the 
bacterial enzyme, and therefore de novo modeling and more structural restraints 
are necessary in order to model the accurate orientation of this loop region in 
relation to the catalytic domain as well as the possible conformational changes 
that occur upon small molecule binding. Biochemical data suggests His338 and 
Trp354 are integral for small molecule binding in the linker loop, but these 
residues are quite a distance apart according to both linear sequence and 
preliminary homology modeling of the linker loop (roughly 19 , figure 29).  Based 
on the significant conformational changes that occur in Akt upon inhibitor VIII 
binding (figure 28), it is proposed that in the tertiary PLD1 small molecule binding  
 
 158 
 
 
 
 
 
 
 
 
 
 
 
Trp354
His338
 
Figure 29.  Homology model of human PLD1 (green, amino acid 312 through first HKD 
modeled) onto the C-alpha backbone of the bacterial Streptomyces PLD crystal structure 
that is complexed with tungstate (orange, observed in the orthosteric site). Highlighted 
in blue, the small molecule binding loop is loosely modeled onto an amino-terminal 
region of the protein.  (Model provided by E. Dawson). 
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site His338 and Trp354 are brought within close proximity of the compound and 
stabilize the interaction through as yet uncharacterized means.  
The biochemical studies herein have enhanced our understanding of 
mammalian enzymology.  Future related studies may consider biochemically 
characterizing the mechanism of action for other classes of direct PLD inhibitors, 
regardless of their specificity for PLD in the cellular setting.  Such studies might 
follow up on some preliminary observations made for the SERM class in which 
raloxifene and 4-OH tamoxifen were determined to be direct inhibitors of 
PLD1.d311, while tamoxifen indirectly inhibited (figure 30a).  This is likely through 
a known mechanism of tamoxifen partitioning into PI(4,5)P2 membranes and 
sequestering the lipid binding cofactor/enhancer.  CRC studies with tamoxifen 
and 4-OH tamoxifen also demonstrate that the PLD1 and PLD2 isoforms respond 
differentially to these small molecules, while PLD1.d311 behaves more similarly 
to Streptomyces PMF PLD, an enzyme that also lacks the PXPH domain (figure 
30b).  These differential responses suggest the N-terminal lipid binding domains, 
which are not highly conserved between mammalian PLD isoforms, may play a 
role in SERM mechanism of inhibition.  Early SLV binding studies with raoxifene 
further support differences in the small molecule effects on the catalytic versus 
the PXPH domains (figure 30c).  Using the SERMs as tools, differences in the 
mammalian isoforms and the multifaceted functional contributions of both the 
PXPH and catalytic domains could be explored. 
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Figure 30.  Preliminary mechanistic studies performed with the SERM class of PLD 
inhibitors. BSI was used to determine whether three representative small molecules 
from this class of compounds directly inhibited PLD1.d311.  BSI-derived Kd were 
compared to IC50 values from biochemical concentration response curves (A).  
Biochemical concentration response curves were performed for tamoxifen and  4-OH 
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tamoxifen with purified recombinant enzyme (B). Preliminary SLV experiments were 
performed with raloxifene to compare the impact of the compound on protein-lipid 
binding for the PXPH and catalytic domains of the protein (C). 
 
Other interesting small molecule mechanistic findings include differences 
in the composition of lipids that co-purify with PLD, or differences in gel filtration 
elution profiles dependent on small molecule present.  These findings might 
contribute to further enzymological and mechanistic understanding of the protein-
small molecule interaction (i.e. dodecyl maltoside detergents trigger monomeric 
and dimeric protein states, tungstate displaces phosphatidylinositolphosphate, 
VU-series compounds result in protein bleeding off the size exclusion column).  
This knowledge might also be used in conjunction with self-interaction 
chromatography (SIC) to identify protein buffer components that facilitate protein 
self-interactions ideal for protein cyrstalization.  SIC measures the second virial 
coefficient (B22) which describes all possible interactions between two protein 
molecules in a dilute solution. Proteins aggregate to form crystals in a narrow 
range of B22 values, which can be determined using SIC.  Preliminary SIC 
results, obtained in collaboration with Larry DeLucas, identified reagents that 
shifted the B22 from an initial value of -100 (severely aggregated) to zero (just 
outside the crystallization slot).  Overall yield and separation off gel filtration 
chromatography was significantly improved in the presence of these additives.  
Small molecule inhibitors might be ideal components to improve the B22 and 
facilitate protein crystallization.   
Overall, the dissertation studies described herein have added to the tools 
with which we have to biochemically study mammalian PLD and has enhanced 
 162 
 
our understanding of its enzymology.  Completion of these studies leaves us with 
a novel class of potent and isoform-selective small molecules that specifically 
target mammalian PLD, for which we have determined the mechanism of action 
and region of the protein that encompasses the high affinity small molecule 
binding site.  In characterizing these novel compounds we have optimized and 
validated the use of BSI for measuring both protein-small molecule and protein-
lipid binding affinities.  This technique in combination with the VU-series PLD 
inhibitors significantly expands our biochemical capabilities and provides 
excellent opportunities for further characterizing mammalian PLD enzymology.  
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